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Abstract 
A total of 6 steroidal ligands have been synthesised from simple starting materials using 
Sonogashira coupling reactions. The ligands are based on testosterone substituted in the 
l7a-position with ethnynyl-pyridine, ethnynyl-quinoline or ethnynyl-isoquinoline. A 
range of platinum(II) complexes have been synthesised using these ligands of the type 
trans- and cis- [Pt(NH3)2(L)(CI] [N031 , where L is the steroidal ligand, alongside control 
complexes containing simple aromatic amines for comparison. The addition of the steroid 
imparted a substantional ability of the steroidal platinum(II) complexes to alter the 
structure of B-DNA. Furthermore, the steroid imparted cytotoxicity onto the complexes, 
which were very much more active that the steroidal ligand alone or platinum(II) 
complexes containing only an aromatic amine. Moreover, forcing the steroidal skeleton 
closer to DNA using 3-substituted pyridine rings and cis-gcometries caused greater DNA 
unwinding, which is likely to relate to direct interactions between the DNA helix and the 
steroidal skeleton. 
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5'-TMP Y-thyminemonophosphate 
A Adenosine 
Amu Atomic mass unit 
AT Adenine and thiamine DNA base pair 
Wavelength 
v Frequency 
C Cytosine 
CC-ET-3-Py cis-[Pt(NH3)(ET-3-Py)(Cl)][NO31 
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Chapter One - Platinum(II) Metallodrugs 
1.1. Prologue 
The anticancer drug cisplatin is a DNA damaging agent based on the metal platinum; it is 
licenced for clinical use throughout the Western world and represents an important line of 
treatment in a number of cancers. 111 As a cure its only substantial success is treatment of 
germ-cell testicular cancer. [21 The mortality resulting from other cancers is merely 
delayed, whilst a large number of tumour types are insensitive to treatment regimes from 
the very beginning. [31 
One of many problems in the treatment regimes of cisplatin is a lack of tissue specificity; 
there is no differentiation between normal and malignant cells. The work contained in this 
thesis outlines an attempt to overcome this problem (and others). Chapter One introduces 
the concept of chemotherapy which may be defined as 'the use of chemicals for the 
treatment of cancer'. One of the most important chemotherapy drugs, cisplatin, is 
highlighted with emphasis on its discovery and ability to bind the DNA. The biological 
consequences of DNA binding and subsequent changes to cellular mechanisms are 
reviewed, together with biological consequences of new, post-cisplatin drugs based on 
platinum. 
1.2. Introduction 
Malignant disease is a major cause of human mortality across the world. Currently, 
malignant disease is responsible for 25 % of worldwide human mortality, equating to 
>150,000 deaths in the UK per year. [4,51 Breast, colorectal, lung and prostate represent 
50% of diagnosed cases, the remainder comprising over 200 different types of disease. [6-81 
Current 5-year survival rates are 30% for men and 43% for women but variations between 
tumour types are well established. For example 5-year survival rates for testicular cancer 
are 95 %[2,9,101 but only 3% for lung cancers. [41 
Chemotherapy began in the 1940's (selected agents are shown in Table 1.1) with the 
int roduction of alkylating compounds such as melphalan and cyclophosphamide. Around 
the same time other groups of drugs, the antimetabolites and anti-tumour antibiotics found 
use in the clinic. Both groups of compounds interfere with the correct functioning of DNA 
via direct or indirect mechanisms involving physical interaction between the agent and 
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DNA. Later hormone treatments such as tamoxifen helped treat breast cancers but these 
do not act at a DNA level. 
The platinum(II) complex cis-diamminedichloroplatinum(II) (cisplatin) was licenced in the 
early 1970s and possesses useful therapeutic valve in ovarian, head and neck and lung 
turnours"'. It forms metal-ligand bonds to nitrogen containing bases on DNA as a pre- 
requisite for cytotoxicity. Further developments led to carboplatin, a less toxic complex 
with very similar results to cisplatin. 
Table 1.1. Selected chemotherapy agents. 
Class of Mechanism of action Examples' 
chemotherapy 
Alkylating agents Covalently bind to DNA (a) Melphalan"" 
Cq N(CH2CH2CI)2 obstructing replication. (b) Cyclophosphamide 
112,131 
N, 
P, ý 
0 
Cyclophosphamide 
Antimetabolites (a) Impedes DNA (a) Flurouracill 14-171 
synthesis by inhibiting (b) Methotrexate 
118-211 
or hampering (c) Thioguanine 
118,22-241 
thymidylate synthesis (d) Mercaptopurine jig, 22,2 S. 261 
S and becoming 
HN N fraudulent nucleoside. 
H2N7 W' N (b) Interfering with SH H 
Thioguanine thymidylate synthesis. N 'N 
(c) Used as aNN H 
fraudulent nucleoside 6-mercaptop urine 
in DNA synthesis. 
(d) Acts as a fraudulent 
nucleoside. 
Antibiotics (a) Causes break-up of (a) Bleomycin 
[27-3 21 
DNA backbone via (b) Mitomycin 
1281 
metal dependent (c) Dactinomycin 
oxidative cleavage of (Actinomycin 
D)1331 
deoxyribose. (d) Doxorubicm 
134.351 
(b) Acts as an 
alkylating agent. 
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NH2 
0 
0 
0 H2N 0 
,'H 
NH 
0 'H 
Mitomycin C 
Hormone-based 
(c) Impedes DNA 
synthesis by 
interfering with the 
topoisomerase 11 
pathway. 
(d) Intercalates with 
DNA between guanine 
residues. Inhibits 
DNA transcription. 
(a) Interferes with the 
correct functioning of 
the androgen receptor. 
(b) Selective estrogen 
receptor modulator 
(SERM) and blocks 
uptake of estrogen by 
the estrogen receptor. 
Tamoxifen 
Platinum-basedl 1,45- 
511 
H3N, --Pl pt. 
cl H3q 
All form covalent 
bonds to DNA 
inhibiting cellular 
process involving 
DNA. 
(a) Cisplatin 
(b) Carboplatin 
(c) Nedaplatin 
(d) Oxaliplatin 
cisplatin 
0 
H3N, -9, Pt 
H3N' '(» 
:0 
0 
carboplatin 
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(a) Anti-androgens and 
inhibitors [36-401 
(b) Tamoxifen [41441 
Platinum-based chemotherapeutics have moved beyond the classical cisplatin structure to 
encompass new ligands: 1,2-diaminocyclohexane in oxaliplatin, multinuclear complexes 
(e. g., BBR3464) and orally active Pt(IV) complexes (e. g., JM-216). Some of these 
structures are shown in Figure 1.1 and will be discussed later. 
H2 H2 7 4+ 
H3N, NN NH2 pi, HP, HN A lpt NH3 cl 
ýiNH3"'ýý 
'NH3 
"'-ý'\ýN 
N H2 H2 
BBR3464 
OAc 
H3Wýt,. \Cl 
H2N" 'Cl 
C5 
OAc JM-216 
Figure 1.1. The molecular structures of selected chemotherapy agents. 
1.3. The discovery of cisplatin 
The first recorded synthesis of cisplatin by Peyrone in 1844 led to cis- 
diamminedichloroplatinum(II) being known as Peryone's Chloride 1521 and its biological 
activity was discovered in 1965. It was observed that cell division of Escherichia coli (E. 
coli) was inhibited and filamentous growth occurred when an electric current was applied 
across bacteria growing in culture [531 caused by the formation of Pt(II) and Pt(IV) 
complexeS[53,541 in the growth media (Figure 1.2). Cis-diammincdichloroplatinum(li) was 
identified as a very potent antiturnour agent whilst the trans isomer was not. 1551 
cl 
Cl/t, ýtAH3 Cll,. pt%kNH3 Cl/,. pt, %NH3 
Cl" 'NH3 Cl' 'NH3 H3N' 'Cl 
cl 
abc 
3 Figure 1.2. Molecular structures of platinum complexes discovered by Rosenberg et al. 15 I 
a) trans-diamminetctrachloro(IV); b) cis-diamminctctmchloroplatinum(II); c) trans. 
diamminedichloroplatinum(II). 
The initial trials of cisplatin were almost abandoned due to kidney toxicity 
(nephrotoxiCity)156-581, later treated with pre-hydration therapy [591 and diuretics. 1601 Other 
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common side effects relate to hearing damage (ototoXiCity), 
E6 'I nerve damage (peripheral 
neuropathy) '[62-681 hypomagnesemia 
[691 
and hypocalcemia[701 and procedures to aliviate 
these include using sulphur containing dithiocarbamates 
[711 
to reduce cytotoxicity by a 
reduction in cisplatin-protein binding levels. In addition to side-effects, resistance to 
cisplatin, aquired and intrinsic, is a major obstacle to the clinical efficacy of cisplatin. 
Turnours, are, or become resistant to cisplatin (and often to a wide range of chemotherapy). 
Patients initially respond to treatment but the majority of turnours progress to a refractory 
state. 
1.4. The biological targets of cisplatin 
Intravenous administration of cisplatin prevents substantial levels of hydrolysis due to 
chloride concentration (approx. 100 mM). In the blood, cisplatin binds to plasma 
proteins, [72-741 some allowing a small proportion of platinum to be bioavailable. [75,761 
Cisplatin binds to many other biological targets such as enzymes [771 including actin [781 , 
proteinases [791 and also albumin, [79,801 some of which may be extra- and/or inter-cellular. 
Binding to sulphur containing molecules is believed to be responsible for cisplatin 
deactivation[811 although sulphur-platinum 
platinum for future reactions. [82-851 
conjugates may represent a reservoir of 
Passage through cell membrane enables cisplatin to interact with lipids and interspersed 
proteins, [86,871 however uptake is linear and not saturable up to millimolar 
concentrations, [88-921 a result suggesting passive diffusion into cells. However, very 
recently, three copper transporters were found to regulate the sensitivity of a number of 
cell lines to cisplatin and similar analogue. The proteins CTRI, 193,961 ATP7A [97.981 and 
ATP713198'1031 regulate uptake, accumulation and efflux, respectively. For - 30 years a 
diffusion mechanism has been accepted as likely and it now appears both passive and 
active transport of platinum(II) drugs can occur across cell membranes. 
Once inside the cell, the widely accepted view is that hydrolysis products of cisplatin, 
caused by low intracellular chloride concentration (3 - 30 mM), bind preferentially to 
DNA. This viewpoint is backed up by a large range of studies finding: - 
1. DNA damaging agents such as UV radiation produce the same effects (e. g. cell 
death) as cisplatin in bacteria and are known inhibitors of DNA synthesis. 11041 
2. More platinum is bound to DNA, per mole, than RNA and proteins in cells treated 
with cisPlatin. 11051 
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3. DNA synthesis is selectively inhibited compared to the synthesis of RNA and 
proteins [106,1071 and the trans-isomer does not have this cffcct. 
11"I 
4. Cultured cells deficient in DNA repair mechanisms exhibit greater sensitivity to 
cisplatin compared 
prokaryotic 
[112-1191 
cells. 
or [Pt(dien)CI]CI. 11 
141 
1.4.1. Cisplatin-DNA adducts 
to the wild type in cukaryotiellos-1111 and 
Such correlations are not found with tmnsplatin[113-115,1181 
The complex structures that DNA can adopt are discussed in depth in Chapter 4.1 Iowevcr 
to understand binding of cisplatin and analogues it is necessary first to apprcciate the 
structure of B-DNA. DNA possesses a rich source of sites for binding metals ions and/or 
complexes. 1120-1221 Briefly it consists of two strands consisting of alternating substituted 
versions of the 4 nuclcobascs, guanine (G), adenine (A), cytosinc (C) and thymine (T), 
shown in Figure 1.3, joined together with a sugar ring-phosphate backbone. Between each 
base is a sugar ring and a phosphate group as shown in Figure 1.4. Each base is capable of 
hydrogen bonding to another (G bonds to C and A bonds tol). 
NH2 0 NH2 
> NNH 
Ný N 
NN N0 NY NN H2 HHHH 
AGcT 
Figure 1.3. The 4 nucleobases of DNA. 
base base 
II 
phosphate- sugar -phosphate -sugar- phosphate 
Figure 1.4. The bonding arrangement between sugar, phosphate and nucleobase moieties 
in a single strand of DNA. 
Hydrogen bonding between the bases on strand I and strand 2 bind the two strands 
together. This bonding arrangement forms a helix and the bases stack one above the other 
in the helical structure, shown in Figure 1.5. 
32 
Sugar 
phosphate 
backbone 
Guanine 40-06 Cyrosine 
Thymine 
Adenine 
AOF Nitrogenous 
base 
Base pair 
Figure 1.5. The structure of DNA showing the helix and base pair stacking. 
Ultraviolet spectrophotometry studies suggest an interaction between nucleobases and 
cisplatin rather than the phosphate backbone. [123 1 Furthermore, interaction is specific to 
DNA rich in GC pairs, [116,124-1261 or areas containing tracts of (dG)n. [127-1301 It is known the 
N7 atom of G is often the site of attack by alkylating agents to which cisplatin is often 
compared. 1 1311 
The nomenclature used to represent DNA in the following sections is exemplified by the 
DNA sequence d(GpApTpC). The letter d denotes deoxyribose, the sugar ring between 
phosphate groups that the nucleobases are covalently bonded too. It is used in front of the 
sequence to remove the necessity to continuously quote dB, where B represents a 
nucleobase. The p represents the phosphate group linking sugar-base groups together. 
Thus d(GpApTpC) is a shorthand for dGpdApdTpdC which is a short length of DNA with 
the bases in order GATC linked by phosphor-deoxyribose groups. When platinum is 
bound to a length of DNA the site of binding is indicated by a letter and superscript 
number in parentheses after the base, i. e. N7. Thus cis- 
[Pt(NH3)2{d(ATG(N7)pG(N7)pTpC)] represents a platinum atom with two cis ammonia 
groups bound to 2 adjacent guanines using the N7 atoms in the sequence 
d(ApTpGpGpTpC). 
It is now known that 90% of platinum atoms bound to DNA do so by forming metal-ligand 
bonds to adjacent N7 atoms of guanine and / or adenine residues on the same strand of 
DNA. 1 132,1331 Before the binding site of cisplatin was established studies found cisplatin or 
[Pt(en)2CI2] bound to G, C, A in model nucleobases such as 5'-GMP (Figure 1.6). In the 
case of thymine, often little or no binding was observed, ' 126,134-1371 indicating thymine is 
substantially un-reactive towards cisplatin. 
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Guanine 
-NH <I 
Phosphate group 0N 
:ý 
ýýNH2 
If 
-0-P-0--l 
0- r-v 
--V H'--' OH OH 
Deoxyribose sugar ring 
Figure 1.6. Guanosine-S'-monophosphate (5'-GMP) 
Studies found Pt(II) binding sites to be the N7 atom of G113S, 
138-1411 
, the N' atom and N7 
atom of AIDS, 
136,139] 
and the N3 atom of C(135,137,1391 and bi-functional adducts of the type 
cis-[Pt(NH3)2(G(N 
7 )G(N7))], cis-[Pt(NH3)2{A(N7 )A(N))], cis-[Pt"13)2(G(N7)A(N))] 
and cis-[Pt(NH3)2{G(N 
7 )A(N'))] are reportedly formed. 1 
1391 Interestingly no bi-functional 
adducts with C are formed even when cytidine was attached to aG moiety to which Pt(H) 
wasbound 
[1421 
and no adducts of the type cis-[Pt(NH3)2(A(N')A(N'))] arc observed. 
From the early 1980's research turned to determining the actual adducts formed on DNA. 
Identification and characterisation of cisplatin-DNA and transplatin-DNA adducts was 
successfully carried out using enzyme digests of platinated DNA followed by 
chromatographic separation. 
[132,133,143-1451 The major cisplatin-DNA adducts (totalling 85 
%- 90 % of all adducts) were those bonded to the N7 atoms of adjacent guanine and 
adenine residues on the same strand of DNA. 
1 132,133) These adducts, cis- 
[Pt(NH3)2(d(GpG))] (cis-GG) comprising 60 - 65% of all adducts and cis- 
[Pt(NH3)2(d(ApG))] (cis-AG) which formed approximately 20 % arc labelled 1,2- 
intrastrand adducts. Only the cis-AG adduct is formed and no cis-GA, a fact which may be 
explained by geometry. 
[1461 The abundance of the cis-[Pt(NI13)2(d(GpG))] indicates a 
preference in cis-GG adduct formation. Additional work using tritium (31 1) labelled 
cisplatin and Pt(en)C12 (Figure 1.7) confirmed the previous results 
[1431 that both complexes 
form the same adducts. 
91 
HNI, R't-Cl i <,, ýNH 
Figure 1.7. The molecular structure of Pt(en)C12 
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Two other adducts were identified; mono-functional cisplatin binding to guanine and cis- 
[Pt(NH3)2{d(GMP)2)], resulting from linking of guanines on the same strand and separated 
by at least one nucleobase. The latter 1,3-intrastrand adduct represents around 6% of the 
total number of adducts. 11451 A further adduct, an interstrand. adduct, formed by binding to 
G residues on opposing DNA was identified, although it had been discovered previously 
using DNA1105,123,143,147,148] and in Mammalian cell culture [1491 and forms -I% of all 
adducts. A very similar range of adducts is reported in hamster ovary cells, E1501 the 
leukaemia cell line L121011511 (using antibodies that recognise specific adducts)11 521 and in 
isolated DNA, cell culture and white blood cells of patients undergoing treatment for a 
range of tumours with cisplatin. 1153-1571 It is noteworthy that adducts formed on native 
DNA in vitro and extracted from patients in vivo are comparable. Finally, small 
proportions of intermolecular adducts are observed including glutathione-Pt-DNAE8 11 and 
protein-Pt-DNAE'58,1591 cross-links. The structure of the reduced form of glutathione is 
shown in Figure 1.8. Glutathione is a common molecule present within cells. 
0 CH2SH 
HOOC COOH 
NH2 0 
Glutathione (reduced form) 
Figure 1.8. The molecular structure of the reduced form of glutathione. 
A surnmary of adducts found on DNA caused by cisplatin are shown in Figure 1.9. 
so 
Pt 
G 
3' 
Mono-functional 
so 
59 
tG 
Pt 
G 
3' 
Inter-strand 
Protei 
t 
p 
3' 
1,2-intrastrand 
Figure 1.9. The type of adducts formed when cisplatin is bound to DNA. 
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Inter-molecular 1,3-Intra-stran; 
IAZ The effect of cisplatin adducts on DNA structure 
There are many parameters that are used to describe DNA structure. Three of these 
parameters relevant to the effect of Pt(II) complexes on DNA are unwinding, bending and 
melting. In B-DNA there are 10 base pairs per I turn of the helix, giving a helical twist of 
36' and DNA unwinding may be defined as the degree to which the helical twist has 
changed from 36'. DNA bending is the angle produced when the helical axis is bent at a 
given point. DNA melting is the temperature at which enough interstrand hydrogen bonds 
have been broken so that DNA exists as single stranded and doubled stranded in a 50: 50 
ratio. 
Some early crystal structures contained a cis-[Pt(NI13)2 12'. moiety linked to the small 
fragments d(pGpG), ' 160,161 1 as shown in Figure 1.10. Fach structure shows evidence of 
large distortions to the bases away from the structure they occupy in free DNA including a 
complete disruption of base stacking. 
orm 
Ds 
_NI3,1 (RIR 
mi 
lito 
V M21 
C4, R ýjX CI'm 
-A 
4. r'le- "m 
Fm C; i 
CLI 
(-) cm 
or 
""-% cl -I 
cs It 
-(r C2'l 
CT C31 
II 
mg 
Figure 1.10. The crystal structure of a cis-[ Pt(NI13)2 Jd(pGpG)) 111601 
The effect of the cis-GG adduct on the thermal stability of DNA is to reduce it between 8 
and looC. 1123,162- 1641 and the evidence to date suggests a 1,2-intrastrand GG adduct can be 
found in the major groove causing significant bending of the helix whilst maintaining 
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hydrogen bonding (Table 1.2). Comparing the adducts formed using the small fragment 
d(GpA(N 7 )pG(N 7) and a cis-GG cross-link, similar changes to the DNA structure are 
observed. 1146,1651 Immunohistochemically, cis-GG and cis-AG are also very similarl 1661 
although recognition is less specific for the cis-AG adduct Cf cis-GG. At the molecular 
level the adducts are dissimilar as shown by reactivity towards chemical probes. [1671 
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Table 1.2. The Effect on DNA structure of various cisplatin-DNA adducts 
Adduct Oligonucleotide Unwinding Bending Techniques(s) 
Angle Angle 
1,2- d(CpCptJ"'pCp'l'p(i"pG*p'l'p 32-40' X-Ray"" 
intrastrand CP'I'PCPC)- 
cis-GG d(GpGpApGpApCpCpApG 
pApGpG) 
d(CpCpUi3rpCp,,, P(i*P(I*P, I, p 78' 
CPI'PCPC)- 
d(GpGpApGpApCpCpAp(i 
pApGpG) 
d(CpTpCpTpCpG*p(i*p'l'pC 9011 N%IRI"ll 
pTpC)- 
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The binding of cis-[Pt(NH3)2]2+ to the N7 of guanine residues forming a 1,3-intrastrand 
adduct causes the central cytidine residue to become extra-helical and no longer take part 
in stacking interactions, [1891 a result confirmed using longer duplexes [180-182,1901 and 
chemical probes. 11911 The thymine residue did not participate in the stacking arrangement 
(Figure 1.11) and the loss of 2 hydrogen bonds, in part, may explain the destabilisation of 
the duplex with a 26'C reduction in melting temperature (I YC Cf 39'C in the unplainated 
duplex). Van Garderen and van Houte [1831 report no extra-helical thymine residue, 
however a re-interpretation by Teuben et d 1821 leads to a similar structure proposed by 
many other studies. A 1,3-intrastrand adduct causes larger and perhaps more significantly, 
different structural changes to the DNA helix cf. 1,2-intrastrand adducts. 
Figure 1.11. The distortion to DNA structure caused by a 1,3-intrastrand adduct [1821 
Interstrand adducts are found to stabilises the DNA by 9'C and with the exception of 
Malinge et all 1881 , report the hydrogen bonds joining the GC pairs disrupted and the 
cytidine residue no longer takes part in stacking interactions in the helix and is exposed to 
the solvent (Figure 1.12). The interstrand adduct results in considerable structural 
aberrations and despite it only representing -1 % of the total number of adducts on DNA, 
such large changes may cause serious problems to the correct functioning of DNA. 
Whilst exact magnitudes of bending and unwinding angles may not fully agree it is clear 
there exists considerable differences between the structures of intrastrand and interstrand 
adducts. Such DNA damage is unlikely to go unnoticed by the biological machinery and it 
is likely that interstrand and intrastrand adducts cause different biological responses. 
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Figure 1.12. The distorted structure of DNA containing an interstrand adduct caused by 
cisplatin. 11841 
1.4.3. Transplatin-DNA Adducts 
Similar experiments used to identify cisplatin-DNA adducts find transplatin-I)NA digests 
consisting of transJ Pt(N H3)2 {d(GM P)) fd(AMP)ý 1, trans-[ Pt(N 113)2 ((dGM P)2 ýI and trans- 
[Pt(NH3)2fd(GMP)Ifd(CMP))] forming 10 %, 40 % and 50 % respectively, 11921 
representing intrastrand and interstrand adducts. Of' particular note is that the trans 
stereochernistry prevents the formation of 1,2-intrastrand cross-links due to steric 
constraints [128,193 1. Also of note is the relatively high amount, approximately 85 %, of 
monofunctional adducts remaining after 2 hours. 11941 Cisplatin produces 15% 
monofunctional adducts after 2 hours reducing to 4% in an hour. 1 1451 Transplatin also 
forms protein-Pt-DNA and interstrand adducts1158,1591. Like cisplatin. transplatin retains 
similar preferences and prefers to binds to the N7 of guanine residues. The major 
interstrand adduct, the interstrand trans-GC corresponds to 10 - 20 % of the total number 
and the work of Eastman 11921 suggests the 30 - 40 % of dG - Pt - dC adducts are intrastrand 
in nature. The 1,3-intrastrand trans-CNG adduct has been formedl'95"991 and small 
oligonucleotide studies suggest transplatin adducts are metastable 1200,2011 which, in large 
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oligonucleotides, result in re-arrangement to 1,4-intrastrand adducts [195-1971 , although this 
may be related to the annealing processes used 12021 and is not seen in all cases. [2031 In 
contrast, Boudvillian et aIE2021 reports only interstrand and monofunctional adducts when 
reacting transplatin with native DNA and Brabec et al[2041 report the interstrand trans-GC 
adduct is preferentially formed. Similar to some 1,3-intrastrand cisplatin-DNA adducts in 
1,3-intrastrand transplatin-DNA adducts the central bases is extra-helical (Figure 1.12). 1198, 
1991 It appears the actual proportions of adducts caused by transplatin on double-stranded 
DNA are not fully quantified and comparison to cisplatin is difficult. 
1.4.4. The effect of transplatin adducts on DNA structure 
The effect of transplatin adducts on the structure of DNA are substantially less known than 
cisplatin. Gel electrophoresis has shown a 1,3-intrastrand trans-GTG adduct caused a 26' 
bend (towards the major groove) and 45" unwinding on DNA. [2021 ]Later work by Brabec et 
al [2051 agreed reporting bending towards the major groove of 26 - 27' using gel mobility 
assays, chemical probes and molecular mechanics. The structure of the ma or interstrand 
adduct trans-GC has been solved using NMR techniques revealing a -20' bend towards the 
0 [2061 minor groove with no discernable unwinding, although gel electrophoresis suggest 12 . 
Such a bend is very much smaller than those reports for cisplatin interstrand adducts. 
Like cisplatin interstrand adducts, transplatin interstrand adducts increase the melting point 
of a 20 bp oligonucleotide by _5oC. 
[207,2081 Such thermal stabilisation originates from 
entropic effects, i. e. the two strands cannot be totally separated. The overall stability of the 
duplex is much reduced as structural perturbations caused by the adduct result in enthalpic 
effects, reducing the overall DNA stability; however base pairing is reportedly 
maintained, [2051 unlike in cisplatin interstrand adducts. The differences between cisplatin 
and transplatin adducts in terms of DNA structure may, in part, be responsible for the 
differing cytotoxicities observed. Since transplatin is highly toxic, important studies such 
as those identifying adducts formed in vivo are not available but comparisons with 
cisplatin suggestions in vitro adducts formed by transplatin are similar to those that would 
be found in vivo. 
1.4.5. The mechanism(s) of adductformation 
In a significant experiment, during the first 2 hours of treating cells with radiolabelled 
cisplatin none was found bound to genomic DNA. 11061 The authors suggested cisplatin is 
not the active agent and is converted into an activated species and that -2 hours is required 
before sufficient concentration(s) of active agent is achieved. Several authors have 
reported partial hydrolysis is required for cisplatin (and its analogues) to bind to DNA. 1123, 
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209,210] and kinetic analyses show the initial binding of cisplatin (and transplatin) is 
kinetically controlled by the rate of hydrolysis [125,21 11. From these reports it is reasonable 
to suggest hydrolysis products arc almost certainly active metabolites towards DNA in 
aqueous solution and that cisplatin is not. 
It is possible to follow the reaction between CiS-[Pt"13)2CI(II20)1+ and DNA using 195pt 
NMR12 121 and cisplatin initially forms mono-functional adducts closing to bi-functional 
adducts with no evidence of aquated products observed. The step-wisc formation of bi- 
functional adducts is illustrated in Figure 1.13, although this evidence does not agree with 
that of Eastman and Barry, [1941 who found a much slower rate of conversion betwcen 
monofanctional. and bifunctional adducts. 
NHý NH3 NH3 NFý DNA I 2hr 3hr 
_Cl 
2tr 
NHi-r-u NH-ýP ---"'NH3--ý_Cl N"r It-OH2 3 %ý 0.1hr B, cl OH2 
B 
B'B B-B 
Figure 1.13. The step-wise platination of DNA by cisplatin via a mono-aqua moiety. B 
represents nucleobases from the double helix of DNA. The half life is given for each step. 
Using more biologically relevant DNA concentration than used in 1951't cxpcrimcnts, 
Johnson et al[2111 found cis- [Pt(NH3)2CI(H20)1+ and cis- [Pt(NI 13)2(1120)212+ were 
significant in relation to DNA binding and trans- [Pt(NI 13)(1120)C I]+ for transplatin. Both 
cisplatin and transplatin form hydroxo-complexes where a bound water molecule looses a 
proton to form, for example, the neutral species cis- [Pt(NI 13hCI(01 1)] and cis. 
[Pt(NH3)2(OH)(H20)1+ and these being as reactive towards DNA as the diaqua. Kozelka et 
al [2131 suggest that the active species towards DNA is the couple cis-[Pt(N1Ij)2(0I1)(1I20)1+ 
/ cis-[Pt(NH3)2(H20)212-" rather than cis-[Pt(NI13)2CI(II20)1+- Ilie relevance of these to the 
intracellular environment in vitro and in vivo remains to be proven and is doubtful given in 
human ovarian 2008 and C13 cell lines a substantial reduction in intracellular chloride 
concentration by substitution with nitrate has no effect on the cytotoxicity or the 
platination of cellular DNA J21 41 A previous study found cells treated with 34 - 2400 fold 
increased levels of aquated species had a 1.9 fold increase in levels of platination of 
DNA. [2151 The two studies suggest the composition of aquated species in the cytoplasm are 
not relevant to those found in vicinity of DNA. Individually, results rcgarding adduct 
formation are clear but taken as a whole package of evidence they do not agrcc on scvcral 
points: the relative important of cisplatin metabolites and if chloride concentration is 
relevant in vivo. Biological studies on cells are likely more relevant given that dilute 
44 
solutions of DNA resemble very little the tightly coiled and packed structure of genomic 
DNA but more experiments are needed before more definite conclusions may be reached. 
1.5. The consequences of cisplatin on DNA function 
1.5.1. In vivo distribution of cisplatin adducts 
Once a certain level of platination of DNA has occurred a cell will die and this is thought 
(in bacterial cells) to occur around 1.8-7.5 nmoles Pt /g DNAE109,2161 , corresponding to a 
single bound platinum atom per 80,000 - 550,000 nucleotides. Oshita and Eastman 
[217] 
report growth inhibition occurring when a single platinum binding event per 250,000 
nucleotides occurs in the leukaemia cell line HL-60, representing -48,000 adducts per cell. 
Using previously established adduct distributions the 48,000 adducts may be split between 
29,000 cis-GG, 14,000 cis-AG, 4,000 cis-GNG and interstrand GG, 500 mono-functional 
and DNA-protein or -thiol cross-links. Assessing the relative potency of each adduct(s) is 
a great challenge and to this date the efficacy of each adduct is uncertain. 
1.5. Z The effect of cisplatin adducts on DNAfunction 
The primary functions of DNA involve its replication and transcription. Replication is 
required for cell division and transcription for correct production of messenger RNA for 
protein synthesis. These two processes occur at different times in the cycle of a cell. The 
cell cycle consists of 4 phases, namely gap phase I (GI), synthesis phase (S), gap phase 2 
(G2) and mitosis. Transcription occurs in the G2 phase and replication occurs in the 
synthesis (S) phase and investigation of these two phases give indications of the ability of 
cisplatin, or any platinum drug, to interfere with these processes. 
1.5.3. The effect of cisplatin adducts on DNA replication 
DNA replication involves unravelling DNA from its chromatin structure, separation of 
strands, synthesis of new strands of DNA using the old strands as templates using a vast 
array of co-factors proteins and DNA polymerases including polymerase T7 (shown in 
Figure 1.14). Harder et a112181 reported inhibition of several polymerases, although up to 7 
fold higher levels of platination of transplatin arc required compared to cisplatin. [2191 
Inhibition (using polymerase I) occurs chiefly at (dG),, sites (n ý: 2) in cisplatin treated 
DNA [220,2211 and d(GpNpG) sites for transplatin abeit with lower specificity and indicates 
the possibility of 1,3-intrastrand adducts on viral DNA. [2201 Villani et a/12221 report the 
prokaryotic DNA polymerase I and eukaryotic polymerase a were blocked at (dG). sites, 
d(GpG), d(ApG) and d(GpApG) sites indicating cis-GG, cis-AG and cis-GAG adduct can 
block DNA replication and Hoffmann et al [2231 found inhibition of DNA synthesis in the 
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order than the cis-GG > cis-AG, although small levels (>5 %) of replication still occurred 
in both cases. Monofunctional adducts did not prevent replication and were bypassed in 
the majority of cases. Replicative bypass occurred for in all adducts studied by Comess el 
J2241 including, cis-GG (2-6 % bypass), cis-AG (2-19 %) and cis-(; ('(i (4-27 ', o bypass) 
and the 1,4-intrastrand trans-CGCG (39-90 % bypass. Despite being blocked, inhibition of 
DNA synthesis does not account fully for the antiturnour properties of cisplatin and several 
studies using 1,1210 leukemia cells report inhibition ofDNA synthesis does not correlate 
with cytotoxicity. [225-227 1 Another mechanism must be reslx)nsible (at least in part) for 
cisplatin cytotoxicity. 
MDL 
Figure 1.14. The crystal structure of T7 polymerase / DNA complex. (2221 
1.5.4. The effect of cisplatin adducts of DNA transcription 
The results reported by Sorenson and F. astman 1225,2201 suggest inhibition of' DNA 
transcription due to cisplatin adducts rather than replication possesses an important role. A 
slow progression of the cells through the S phase of the cell cycle before growth arrest in 
G2 in low concentrations of cisplatin before growth restarting may be interpreted as cells 
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repairing DNA damage in the S phase before attempting transcription resulting in arrest in 
G2 which, at higher concentrations of cisplatin, becomes permanent and cells die. Several 
studieSI229,2301 in simplified transcription systems found cis-GG, cis-AG, cis-GTG, trans- 
GTG, cisplatin interstrand crosslinks and monofunctional adducts [Pt(dien)CI]CI provided 
blocks to DNA transcription, although trans-GTG and monofunctional adducts were 
primarily bypassed. Conditions perhaps possessing greater biological relevance were used 
by Cullinane et al [2311 Who found cis-GTG adduct inhibited RNA polymerase activity by 
80% whilst the 1,2-intrastrand cis-GG adduct was bypassed in He-La and GM8437A 
cellular extracts, an unexpected result given previous reports. Later reports in model 
systems found cis-GG and cis-GTG adducts blocked transcription by RNA polymerase 
11[2321 and T7 RNA polymerase J2331 It appears the source of RNA polymerases (which 
often differ between experiments) may be a factor in determining the propensity of adducts 
to inhibit transcription. As such the results, while interesting and informative, are difficult 
to envisage occurring in vivo with substational levels of confidence, even perhaps when 
using cellular extracts. 
Whilst the action of individual adducts is important, the effect of large numbers of adducts 
was ascertained by Mello et al[2341 in perhaps the nearest experiment conditions in vitro to 
real biological conditions. Up to Mold higher levels of transcription of the plasmid occurs 
in cell treated with transplatin compared to cisplatin and 4-fold more transplatin adducts 
were required for similar levels of transcription blockage caused by cisplatin. Only 0- 
16% of cisplatin adducts and 60 - 76% of transplatin adducts are bypassed. To date this 
represents the most relevant and as such, the most persuasive piece of research on cisplatin 
and transplatin adducts and DNA transcription. 
1.6. Cisplatin and gene expression 
The fact cisplatin interferes with DNA transcription suggests differences in the expression 
of genes may result. This may occur as a direct result of inhibiting transcription of genes 
encoding essential proteins or binding and interfering with the correct functioning of 
transcription factors (proteins involved in transcription) and has been reviewed in depth 
recently. [235-2391 
1.7. Cisplatin and apoptosis 
The evasion of apoptosis is a peculiarity of most if not all cancers. [2401 Apoptosis is a 
mechanism by which internal cellular signals caused by one or more factors instruct a cell 
to die. [2411 Apoptosis is characterised, although not exclusively, by cell shrinkage, 
chromatin condensation and subsequent endonuclease cleavage in 180 base pair 
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multimers. (2421 Apoptosis is a consequence of the mechanism (DNA binding) of 
cisplatin [2431 , although other, non-DNA 
binding events leading to apoptosis should not be 
ruled out. [2441 
1.8. The recognition and processing of cisplatin-DNA adducts 
It is established DNA binding is an essential first step in the cytotoxicity of cisplatin and 
apoptosis is the last. [2451 The biological events between the two cnd-points have attracted 
considerable interest in attempting to fully explain the mechanism of action of cisplatin 
and are likely to require recognition of DNA damage by cellular proteins to activate 
mechanisms mediating the cellular response. The DNA damaged caused by cisplatin is 
recognised by a wide range of often unrelated proteins that may to split into two groups; 
those preferentially binding to cisplatin-damagcd DNA and those whose binding sitc(s) is 
similar to cisplain-damaged DNA. [2461 Some of the protein groups that rccognisc cisplatin- 
DNA adducts are listed below: [247-2501 
1. Nucleotide excision repair (NER) 
2. Recombinant repair (RR) 
3. Mismatch repair (MMR) 
4. High mobility group (HMG) 
5. Trans-lesion synthesis (TLS) 
6. DNA-dependent protein kinases (DNA-PK) 
In this section how cells respond to DNA adducts will be elucidated, i. e. attempt repair and 
how such repairs may be modulated by proteins specifically recognising DNA adducts. 
1.8.1. Nucletide excision repair, recombinant repair and trans-lesionsyntliesispatlilvays 
The primary mechanism for the repair of cisplatin adducts is thought to occur by NER1251- 
2521 and involves an incision at either end of the damaged DNA, removal of the adduct and 
ligation to form and bond the new section of strand to the exisiting helix. 1253-2551 Two other 
pathways, the RR and TLS modulate cisplatin cytotoxicity in yeast and lung tumour cells 
in vitro [2561 and strains of S. cerevisiae lacking the RR and TLS path%%2ys arc 
hypersensitive to cisplatin, [257,2581 suggesting a significant role of the RR and TLS 
pathways in addition to the NER mechanism in repairing cisplatin-DNA adducts. Infact 
intrastrand cross-links are found to be repaired by NER, RR and TLS pathways, whereas 
repairing interstrand cross-links results in a double strand breaks in DNA12591 indicating the 
RR mechanism although it requiries functioning NER. The RR pathway repairs DNA 
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whilst TLS allows DNA polymerase to bypass the adduct creating mutated DNA and 
possible genetic damage. 
1.8.2. Interaction between HMG proteins and the NER pathway 
High mobility group proteins comprise a large array of polypeptides intrinsically entwined 
in the integral functioning of DNA related activities including, amongst others, DNA 
repair, 12601 transcription and gene regulation [2611 and chromatin structure. [262,263 1 HMG-box 
proteins HMGI and HMG2 (now referred to as HMGBI and HMGB2) bind to cisplatin 
(but not transplatin) damaged DNA. [264,2651 In the same year Pil and Lippard [2661 identified 
recombinant rat HMGBI binds specifically to 1,2-intrastrand cis-GG and cis-AG adducts 
and not transplatin adducts or 1,3-intrastrand cis-GTG adducts. The affinity of HMGBI 
for cisplatin-damaged DNA correlates with the amount of damaged DNA'2671 and crystal 
structure of the A domain of HMGBI bound to a 1,2-intrastrand cis-GG adduct has given 
much additional information (Figure 1.15). [2681 
vol F) i 
Figure 1.15. The crystal structure of domain A of HMGB I bound to a 1,2-intrastrand cis- 
GG adduct, [2681 drawn using protein explorer 12691 
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Ile cis-GG adduct has been found refmctory to rcpaiý2701 and using wholc ccll cxtmctsl2711 
1,3-intrastrand adducts are repaired 15 - 20 fold more than 1,2-intrastrand adducts. 
Specific binding of IIMG proteins to cis-AG or cis-GG adducts inhibited excision rcpair of 
DNA 12721 in line with other reports. 1269,273.2741 Unfortunatcly in vit-o data regarding the 
protective ability of IlMG proteins remains absent but the existing rcports make a strong 
case for 1,2-intrastrand adducts being shielded from repair by members of the I INIG-box 
protein family. 
1.8.3. MMR Patio way 
The mismatch repair (MMR) mechanism recogniscs and corrects mismatched nuclcotidcs 
in newly synthesised DNA and consists of more than 13 individual proteins which tak-c 
part in the recognition and repair of DNA and if required signal opoptosis. t2751 TIc NINIR 
protein hMSH2 specifically recogniscs cis-GG adducts and shows affinity for other 
cisplatin adducts but not those of transplatin or [Pt(dicn)CI ICI. 12761 Another NINIR protein, 
hMutSa displays a similar affinity profilc, binding to cis-GG adducts but not 1,3- 
intrastrand trans-GTG addUCt. 12771 A decrease in the capacity the MNIR path%%2y can lead 
to cisplatin resistance. [278-2801 and given that MMR is thought to partially mediate apoptosis; 
as a response to DNA damage, [281,2921 the MMR is likely, to an unkno%%m extent, determine 
a cell's response to the cisplatin adducts it rccogniscs. This links directly cisplatin-DNA 
adducts to apoptosis via the MMR mechanism and is unusual, most routes arc circuitous 
protein recognition of adducts simply activates many downstream signalling factors, 
effecting apoptosis. [283,2841 Errors in the MMR proteins hMutSa and hNtutLcL arc proposed 
to lead to increased levels of TLS, preventing MMR recognition of DNA damage 12831 and 
very likely allowing genetic mistakes to pcrsist on DNA. 
Kartalou and Essigman 12861 propose 2 possible pathways that explaining the events 
occurring from the formation of cisplatin adducts to cell death involving the MMR 
pathway. Pathway A involves recognition of adducts by MMR proteins but the NIMR is 
unable to effect the correct repair causing accumulation of DNA strand breaks that arc 
recognised by apoptotic signalling mechanisms. Pathway B describes the recognition of 
adducts by MMR proteins acting as DNA-damage sensors activating apoptosis. More 
reseach in this area is required to attain a full picture of the role of the NIMR in mediating 
cisplatin toxicity. Should the MMR proteins be found acting as 'apoptotic sensors' it will 
signal another area in which research should investigate further. 
so 
1.9. Mechanisms of resistance to cisplatin 
Several mechanisms have been proposed to account for resistance and have been reviewed 
in depth recently: 
[49,248,287-2901 
a) Decreased uptake / increased efflux of cisPlatin from the cell. 
b) Increased levels of sulphur containing proteins/compounds that bind to 
1291.2921 platinum and render inactive (such as glutathione). 
c) Enhanced DNA repair by the NER mechanism. [2931 
d) Loss of MMR activity (reduced recognition of DNA damage). [2941 
e) Defective elements of the apoptosis mechanism. [2951 
f) Altered expression of significant genes, e. g., p53, bcl-2. [296,297] 
g) Altered expression of important proteins. [298,2991 
The identification of mechanisms of resistance to cisplatin in cells allows chemists to 
selectively design compounds targeting single or multiple mechanims involved in cisplatin 
resistance. These new complexes, in addition to those overcoming clinical ineffectiveness 
may be called the 'next generation' platinum complexes. 
1.10. Next generation platinum complexes 
Post-cisplatin complexes have been synthesised in an attempt to overcome the problems 
associated with cisplatin treatment. In designing these compounds chemists have taken 
into account structure-activity relationships of Pt(II) complexes. 
1.10.1. Structure - activity relationships 
Structure-activity relationships (SAR) regarding cisplatin are by definition empirical. 
RosenbergI53,551 found only the cis isomers and not trans isomers were active and Cleare 
and Hoeschele [3001 using systematic ligand replacement in platinum(II) complexes and 
Sarcoma 180 mice and suggested that for antiturnour activity a platinum(II) complex 
should possess: 
a) Electrical neutrality. 
b) A pair of cis leaving groups (necessary but not sufficient for activity). 
c) The leaving groups should 'fall within a window of reactivity'. Too reactive 
and the complexes are toxic. To inert and the complexes are inactive. 
d) Non-leaving groups should be trans to leaving groups and consist of inert amine 
type systems. 
51 
In apparent contradiction to earlier findings, Braddock et al. 13011 concluded no systematic 
pattern of structure activity relations exists when investigating a range of platinum(II) and 
platinum(IV) complexes. However, the SAR of Clcarc and 11ocschc1c has guided research 
from the early 1970's onwards with thousands of cisplatin analogues being produced. 
Some notable successes have been achieved and now two other platinum(11) complexes, 
carboplatin and oxaliplatin are used in the clinical setting. The SAR described by Clcarc 
and Hoeschelc have been 'broken' a substational number of times and such rules may be 
considered somewhat redundant and whether these rules really informed research or 
narrowed its view is a valid debate. 
1.10. Z Carboplatin 
Carboplatin (Figure 1.16) was developed by a collaboration of Johnson Nlatthcy and the 
Institute for Cancer Research, UK and was dcsigned to rcducc the scvcre toxicity 
encountered with cisplatin in the clinical setting by using a less labile leaving group. As a 
result, carboplatin possesses a much reduced toxicity profile compared to cisplatin 
although myleosupression (suppression of bone marrow production of rcd and white blood 
cells) is increased [3021 and determines the maximum dose tolcratcd by the patient. It is 
active in the same turnours as cisplatin and unfortunatcly rctains a similar resistance prof ilc 
as cisplatin despite having different proportion of DNA adducts. 11921 
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Figure 1.16. The molecular structure of carboplatin 
1.10.3. Oxaliplatin 
Oxaliplatin, (trans-R, R)1,2-diamminocyclohcxancoxalatoplatinum(II) is shown in Figure 
1.17. It has a different spectrum of activity compared to cisplatin and carboplatin and is 
active in cisplatin-rcfractory turnours (tumours that no longer respond to cisplatin 
treatment). 13031 Oxaliplatin acts in synergy with other chemotherapy drugs (cisplatin, 
carboplatin and others) in colorectal and ovarian cancer, two types of maliganant disease 
commonly resistant to cisplatin. [3041 
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Figure 1.17. The molecular structure of oxaliplatin. 
Oxaliplatin DNA-adducts are 60 - 65 % cis-GG, 25 -4 0% cis-AG, 5- 10 % cis-GNG and 
1305"3071 
a few percent interstrand adducts (similar to cisplatin). Oxaliplatin adducts are 
differentially recognised by cellular repair proteins belonging to the MMR mechanism 
differently to cisplatin (but the same in the RR and TLS pathways). [481 Such differential 
recognition (due perhaps to the non-leaving group) is likely to form part of the explanation 
13083 for its activity in cisplatin-resistant turnours. Oxaliplatin has recently been granted 
approval for clinical use in the USA in treatment of metastatic carcinoma of the colon and 
rectum. [309] 
1.10.4. Multi-nuclear platinum comple-ves 
If the activity of platinum drugs is based on the recognition and processing of DNA 
adducts then complexes producing different adducts may be recognised and processed 
differently. This may lead to complexes with broader anti-cancer activity and lacking 
cross-resistance with currently licensed drugs. This idea has lead to the development of 
dinuclear and trinuclear complexes (Figure 1.18). 
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Figure 1.18. The chemical structures of dinulcear BBR3005 and trinuclear BBR3464. 
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Farrell and co-workers investigate "non-classical" structures and arc of the opinion that 
"future discovery of clinically useful platinum agents is likely to arisc from 'non-classical' 
structures". [3021 The structures are very different from cisplatin and arc not consistant with 
the SAR suggested by Clcare and IloeschclC. 13001 Ilic aim u-as to producc complexes 
possessing 'activity in cisplatin-resistant cells and a broader profilc of antiturnour 
activity'. [3 101 A large range of dinuclear and trinuclcar complexes have bccn synthcsiscd 
and assessed for biological activity and this work has been recently reviewed . 
13 111 T11C 
complexes display activity in vitro and in vivo comparable to cisplatin and often at 10 fold 
less concentrations in cisplatin-rcsistant tumours. 13101 Tle, complex BBR3464 binds to 
DNA and the profile is significantly different from cisplatin with 20% of DNA adducts, 
being interstrand (cisplatin -I-3 %) and capable of spanning 6-8 base pairs. 13121 Ile 
study also found antibodies recognising cisplatin adducts did not rccognisc adducts formed 
by BBR3464 suggesting structural features that would not be rccognised by those proteins 
binding specifically to cisplatin adducts. 
The 1,2-, 1,3- and 1,5-intrastrand adducts caused by BBR3464 on DNA arc repaired by the 
NER pathway more efficiently than 1,2-intrastrand cisplatin adducts; and arc not rccogniscd 
by the 1IMG domain proteins. [3131 Further work identified the effect of intcrstrand adducts 
of BBR3464 on the structure of DNA and found 1,2-, 1,4- and 1,6-interstrand adducts and 
are not recognised by HMGB1 or IIBGB2. [3141 Significantly 1,4-intcrstrand adducts arc 
not repaired by NER and may remain on DNA for an unknown length of time. BBR3464 
also exhibits increased levels of intracellular accumulation compared to cisplatin. 13151 -1-hiS 
is perhaps surprising as neutrality is a requirement of the early SAR for cisplatin. It now 
appears increased charge may correlate with enhanced uptake as the +8 complex is uptakcn 
faster than the +6 J3161 The complex (Figure 1.19) is unusual as it possesses no chlorides 
and is likely to bind electrostatically. It is possible it represent a future class of platinum 
based anti-canccr drugs possessing only the ability to bind electrostatically to DNA. 
H2 H2 
7 8+ 
H3N(H2C)6H2N. N,, H3N, N, ý, 
HP. NH3 
Pf (CH2)6 Ft (CH2)6-ý_ Pk 
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N2 
Figure 1.19. The latest trinuclear complex from Farrell and co-%vorkcrs. 
54 
1.10.5. Sterically hinderedplatinum complexes (ZD0473) 
ZD0473, shown in Figure 1.20, was specifically designed by Johnson Matthey and the 
Cancer Research Campaign, UK to inhibit detoxification by sulphur containing cellular 
components and be active in cisplatin resistant turnours. 
HA 
cl-pit 
NH3 
ZD0473 
Figure 1.20. The chemical structure of ZD0473 
Inhibiting detoxification is via creation of axial steric crowding (caused by 2-methyl 
group) hindering substitution of chloride groups. As may be expected, slower rates of 
hydrolysis are reported [3171 and reduced rates of detoxification by sulphur containing 
biomolecules without significant loss of DNA binding ability and retention of cytotoxicity 
are observed. [3181 In ovarian and colon cancer cell lines resistant to oxaliplatinE3191 and 
cisplatin (320,3211 ZD0473 is not cross-resistant. As of November 2005, ZD0473, now 
known commercially as picoplatin received orphan drug designation by the U. S. Food and 
Drug Administration. [3221 
1.10.6. Trans-activation and other non-classicalplatinum complexes 
The current status of platinum complexes possessing trans stereochernistry has been 
reviewed in detail recently where more detailed information is present. [323-3251 The intial. 
SAR suggest trans complexes are inactive, although only 7 complexes of the formula trans- 
[Pt(L)2CI21 where L is NH3, MeNH2 or MeEt2 were tested. More recently the group of 
Farrell discovered 'activation' of the trans geometry by replacing the ammonia, groups of 
transplatin by pyridine or 4-methylpyridine; these complexes exhibit greater activity than 
cis counterparts. [3261 Replacement of a single amine group of transplatin by a planar 
aromatic ligand to yield the formula trans- [PtC12(quinoline)(NH3)] or an additional 
substitution by DMSO such as trans- [PtC12(quinoline)(DMSO)] resulted in biologically 
active trans complexs. [327,328] These complexes are shown in Figure 1.21. An inversion of 
cytoxicity was observed as the trans-complexes were more cytotoxic in L 12 10 tumour cells 
than the cis counterparts. 
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Figure 1.21. The trans-complexcs developed by Farrell and co-%vorkcrs. 
Other active trans complexes such as those with the formula trans- 
Pt[C12(amine)(isopropylamine)] [3291, trans-Pt[C12(4-mcthylpyridine)(pipcrizinc)]13301 and 
trans-Pt[C12(iminoether)21 133 11 as shown in Figure 1.22 as A, B and C rcspcclivcly, arc also 
active. It may be suggested rather than transplatin cpitomising the tmns geometry by its 
lack of cytotoxicity it is infact the cxception to the rulc and that trans complcxcs arc 
generally active. 
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Figure 1.22. Active tmns complcxcs 
Charged complexes based on the structure in Figure 1.23, where L was a range of 
substituted pyridine, purine and pyrimidine ligands are found to be CytotoXiC. 1332, In vivo 
testing in mice found 12 out of 32 complexes more active in S180a tumours in mice than 
cisplatin and the origin of the cytotoxic was reported due to the formation of 
monofunctional adducts. 13331 
LP /, f, Pt 
H3N' NH3 
Figure 1.23. Cytotoxic; complexes based on [Pt(NI13)2(L)Cl][X] 
Such trans complexes, neutral and also charged represent a very important line of 
investigation in the search for new complexes for use in the clinic. 
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1.11. Epilogue 
Chapter One has introduced the concept of chemotherapy: the use of chemicals in the 
treatment of cancer. Platinum(II) complexes, the best example of which is cisplatin act via 
binding to DNA and disrupting cellular pathways. There are several modes whereby 
cisplatin binds to DNA of which 1,2-intrastrand adducts form the majority. Each adduct 
type is not equivalent in terms of causing structural changes to the DNA helical structure 
each is differentially recognised by cellular proteins. It is this differential recognition that 
is likely to result in the degree of biological response of the cell. 
Platinum(II) drugs, via DNA binding, are effective in treating a limited range of tumours 
and such treatments have many problems including high levels of toxicity, lack of tissue 
specificity and eventually cells become resistant. 
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Chapter Two -Targeting cancer with steroidal conjugates 
2.1. Prologue 
The attempt to overcome the lack of tissue specificity in current anticancer drugs such as 
cisplatin involves the use of a transport mechanism common to many tissues in the body 
but found to be enhanced in malignant tissue; the localisation of steroids into the DNA 
containing nucleus of cells by steroid receptors. 
Through attaching a steroid based on testosterone to a platinum centre known to be 
cytotoxic, [334,335] it may be possible to transport a steroidal platinum complex direct into 
the cell nucleus. A large number of turnour types tend to express high levels of steroidal 
receptors; for example -80 % of breast tumours overexpress the androgen receptor which 
binds many substrates based on testosterone. [336-3381 The hypothesis on which this work is 
based is that using the steroidal transport system, steroidal platinum complexes might be 
selectively localised in the nucleus of turnour cells leaving normal tissue less affected. 
In this chapter combinations of steroids with anticancer compounds are discussed and the 
role of steroids in malignant disease evaluated. The design of such agents is also reviewed. 
Finally the epilogue unites these themes together. 
2.2. Approaches for targeting of cancer with steroids and mimics 
Conjugating a suitable cytotoxic moiety and active bio-ligand may cause improved 
transport of a compound into targeted cells and / or a synergistic effect. This has been 
attempted many times in pursuit of targeting DNA binding drugs such as cisplatin to the 
nucleus of cells, using a number of different delivery vectors tethered to platinum(II) and 
platinum(IV) complexes. Examples include attaching platinum(II) to DNA intercalators 
such as doxorubicin, [339,340] anthraquinones, [341-3431 ethidiurn bromide [3441 and acridine 
derivatives, [345-3481 anticipating increased localisation of the drug in the vicinity of genomic 
DNA. Others groups have attached sucrose [3491 and antitrypanosomatid [3501 drugs but 
overall the attempts have produced mixed results and no clinical progress. Other groups 
have targeted sex steroid receptors by linking steroids to cytotoxic agents and it is this 
aspect of targeting that will be concentrated on. 
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ZZI. Steroid conjugates with alkylating agents 
Early efforts with 3-substituted steroids (Figure 2.1) exhibitcd no binding affinity for their 
respective receptor (progestcrone receptor) or therapeutic activity. 1351-3531 
steroid 
6 
alkylating agent 
cl 
0 
Figurell. The structure of 3p-hydroxy-5-cholcstcnc p-[N, N-bis- 
(chloroethyl)amino]phenylacetatc. 
Later work by Leclercq produced compounds with strong binding affinity for the estrogen 
receptor but bereft of cytotoxicity [3541 and one is shown in Figure 2.2. 
0 
H3CO2S*-O-'-'s,,,, 10 
HO 
Figure 2.2. A mesylate derivative of the estrogen cstronc. 
The group of Leclercq turned to synthetic estrogens as vehicles for cytotoxic agents using 
hexestrol- and dicthylstilbestrol-linked to alkylating agents. 11cxestrol (flex) and 
diethylstilbestrol (DES), whose structures are shown in Figure 2.3, have affinity for the 
estrogen receptor. Substituted Ilex and DES compounds in many cases showed acccptable 
receptor binding but exhibited proliferative effects in the breast cancer cell line MCF-7.1"" 
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Figure 2.3. The chemical structures of Hex and DES. 
ZZZ Targeting steroid receptors with metal centres 
More recently, structures with affinity for the estrogen receptor conjugated to a metal 
centres by many different groups have been synthesised and are reviewed below. The 
research possesses two distinct aims; the first as complexes useful for imaging agents and 
the second as complexes for targeted chemotherapy. Both aims require complexes to be 
selectively uptaken by estrogen receptors in tumour cells. 
For use as imaging agents the group of Katzenellenbogen have used Rhenium(V) and 
Technetium(V) complexes as mimics for steroids based on androgens, oestrogens and 
progesterones. The radiopharmaceutical 99Technetium may be used in medical imaging 
technologies and in these systems part of the steroid is replaced with a chelated metal as 
shown in Figure 2.4. 
OH 
0 H 
5-dihydrotestosterone 
0, H 
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steroid mimic 
Figure 2.4. Design of a metal complex mimic of the steroid 5-dihydrotestosterone. 
In addition to androgens 
[359,360] (the family of male steroids based on testosterone), metal 
complex mimics of the steriods estradiol[361,3621 and progesterone 
(3631 have been reported. 
This type of design has resulted in unstable complexes and poor affinity for the respective 
receptors. 
Another approach is appending a chelating ligand. to a steroid skeleton capable of binding 
selected metals. Good binding affinities of complexes using steroid skeletons substitued, 
with a rhenium or technetium chelating system with the bound metal been reported 
targeting the estrogen 
(364-3761 
, progesterone 
[377-3791 
and androgen receptors. 
[3801 The group 
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of Jaouen has been very active in this area using steroidal estrogens and non-steroidal 
estrogens, such as tamoxifen, that are capable of binding metals. This creates 
radiopharmaccuticals with potential usage as imaging agents or due to cytotoxic properties, 
for chemotherapy. 
These include those based on ruthenium 
[381-3841 
and iron 
[385-3921 
primarily as cytotoxicity 
agents and rhenium. / technetium 
[384,3934001 
and metal (Co, Mo, Cr, Os) carbonyls primarily 
as radiopharmaceuticals for imaging. 
[384,4014 171 A steroid-linker conjugate is also reported 
to bind the metals Pt, Pd, Ni, Zn and Re 
[4 18). The structure-activity rules for some steroidal 
metal complexes have been reviewed recently. 
[4191 
ZZ3. Targeting steroid receptors with steroid-platinum conjugates 
Whilst much of the research into steroidal metal complexes has focussed on radioimaging, 
the possibility of using a steroid as a means of transporting a cytotoxic metal, such a 
platinum(II) was reported in 1986. The complex uses a 2-amino estradiol, shown in Figure 
2.5, as a steroidal ligand capable of binding to platinum. Once bound to platinum(II) the 
complex exhibits moderate relative binding affinity (RBA) of 8.5% toward the estrogen 
100V receptor in MCF-7 cells compared to estradiol (by definition RBA = 0). 14201 
OH 
0, 
H2N: 
ýl 
Figure 2.5. A 2-amino substituted oestrogen ligand capable of coordinating platinum. 
Georgiadis and Haroutounian [4211 report mixed results binding platinum to ocstrogen, 
progesteronc and testosterone skeletons. Only one complex achieved activity comparable 
to cisplatin in vivo, depicted in Figure 2.6 with an LD50 (the concentration which kills 50% 
of mice) of 35 mg / kg compared to 15-20 mg / kg for cisplatin. 
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H2NJ Pit-cl 
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Figure 2.6. A platinum complex based on progesterone designed to bind to the 
progesterone receptor. 
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The use of 3-substituted estrone and estradiol steroid skeletons resulted in binding 
affinities of 0.98 % and 0.57 % for the complexes A and B in Figure 2.7 . 
14221 Despite such 
poor RBA values, the cytotoxicity of the estrone derivative was comparable to cisplatin in 
the MCF-7 cell line. 
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Figure 2.7. The estrogen-derivatised platinum complexes, A based on estrone and B based 
on estradiol. 
Attempts to append a platinum group from the 17 position of estradiol resulted in low 
binding affinities. [3931 These complexes exhibited RBA values of 0.2 % (left) and 0.05 % 
(right) in Figure 2.8. Cytotoxic testing in vitro was not conducted on the basis of these 
RBA values. 
7ý\ / N\/ N- 
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Figure 2.8. Platinum(II) complex with 17 substituted estrogens as ligands. 
Very recently, during the course of this thesis, modification at the 16 position of estradiol 
has resulted in a set of complexes displaying high affinity for the estrogen receptor. The 
structure, based on a 2-aminopyridine chelating group joined via an alkyl chain to the 16 
position of estradiol is shown in Figure 2.9. 
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Figure 2.9. Steroidal platinum complexes based on oestrogen showing high affinity for the 
ER. 
Complex B in Figure 2.9 was found to possess a high affinity for the alpha form of the 
estrogen receptor and has 20 - 32 (- 0.5 jtM) fold greater cytoxicity than cisplatin and 
tamoxifen in MCF-7 cells. Complex A in Figure 2.9 exhibits 2-3 fold higher toxicity in 
MCF-7 (5.9 gM) cells compared to cisplatin and tamoxifen. [3341 The high level of receptor 
binding by complex B may relate to the observed levels of cytotoxicity but further work is 
required to prove this hypothesis. Additional work led to the development of the structure 
shown in Figure 2.10. The addition of a CH2011 group in the 16 position of the steroid is 
shown by molecular modelling to facilitate extra hydrogen bonding interactions bctwccn 
the steroid and receptor possibly increasing receptor binding affinity which is greater than 
J3351 estradiol. 
OH 
OH 
oý 
CI-Plt-N 
H ci 
Figure 2.10. A steroidal platinum complex based on oestrogen and targeting the estrogcn 
reccptor. 
The complex in Figure 2.10 is active against a range of breast cancer lines and the activity 
is best when n--8 and m=2 and exceeds that of cisplatin; 1423] in vivo testing is planned. 
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The group of Sch6nenberger designed complexes based on synthetic non-steroidal 
oestrogens and antioestrogens. In a derivatised hexestrol (Figure 2.11) cytotoxicity 
reportedly begins at concentrations of the order 100 pM in the MCF-7 cells. [4241 However, 
when tested in rat mammary turnours rich in oestrogen receptors the complex is better 
tolerated than cisplatin and displays higher efficacy. Moreover levels of platinum in the 
tumour compared to blood plasma were 10.6 fold high compared to cisplatin. A further 
study on the breast cancer cell lines MCF-7 (ER+) and MDA-MB231 (ER-) showed the 
complex possessed a poor RBA (0.35 %) and no selectivity for ER+ cells was observed. 
HO 71 ý 'Z OH 
H2N, 
\ ýNH2 1 Pt/ ci 
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Figure 2.11. A nonsteroidal platinum complex designed to target the oestrogen receptor. 
The antioestrogen 5-hydroxy-2-(4-hydroxylphenol)-3-methylindole was linked (via a 
variable length chain) to a cisplatin-analogue using the indole nitrogen shown in Figure 
2.12 (left) in an attempt to target the oestrogen receptor. Selective cytoxicity was observed 
in oestrogen positive tumours compared to estrogen negative turnours. [4244261 The complex 
was more cytotoxic than an equimolar dose of the free ligand. 
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Figure 2.12. Antiestrogen-platinum conjugates displaying cytotoxicity, selective to ER+ 
tumours. 
The complex in Figure 2.12 (right) also shows affinity for the estrogen receptor (RBA= 32 
OAN 
, uj and reduces the growth in ER+ mammary turnours in vitro and is more potent in 
vivo. 
[4271 
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An attempt to conjugate an oxaliplatin analogue to the estrogen receptor ligand tamoxifen 
was attempted by the group of Jaouen. The complex, pictured in Figure 2.13, have RBA 
values of 6.4 % (R = OH) and 0.5 % (R = 11) and possessed inhibitory effects on MCF-7 
cells at concentration of I_ 10 ItM. 14281 The cytoxicity of the complex %%-as higher than 
oxaliplatin. This was attributed to the anti-proliferative properties of the organic ligands 
and the platinum components produced no measurable effect. 
Figure 2.13. A tamoxifen-oxaliplatin conjugate. 
Approaches to using steroids have taken many different routes and the lack of in vivo 
testing is particulary noteworthy as extending results from in vitro testing to a truly 
biological cnviromcnt is fraught with difficulty. Despite this since mid-1980 when 
platinum was conjugated to steroid skeletons, this design has provided complexes with 
excellent affinity for their respective receptor. Such 'steroidal reagents" may be viewed as 
the most promising and a review of such complexes follows. 
2.3. Steroidal reagents 
Steroidal reagents may be defined as "multifunctional compounds based on steroids where 
one function is non-steroidal in nature". The ability of the steroidal platinum compound to 
be transported via steroid receptors, in this case the AR, relies on suitably altering the 
steroidal skeleton and incorporating a binding site for platinum. Unfortunately research 
into the differential binding affinities for modified testosterones toward androgen receptor 
is extremely limited. However, structure-function relationships exist between modified 
oestrogen and the ER and limited data regarding progestcrone and its receptor. 
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The structure of testosterone is very similar to that of oestrogen with the major difference 
being in the steroid A-ring, phenolic in oestrogen and an a, p-unsaturated ketone in 
testosterone. Full structural and numerical notations are shown in Figure 2.14. 
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testosterone oestradiol 
Figure 2.14. The full structural notation of testosterone and oestadiol; by convention the 
angular methyl groups 18 and 19 define the upper side or 0-face of the molecule. The 
oPposite face or lower side is the a-face. 
Structure activity relationships between oestradiol and the ER were reviewed in 1997 14191 
and report the importance of the phenolic-OH, aromatic A-ring and 17p-hydroxyl in 
substrate binding. Substitution in the 3 and 17 positions by a methyl ester reduces the 
RBA to 0.06 %14291 and 7 %14301 in rat ER at 040C indicates the importance of the 3- and 
170-hydroxyl functional groups. From crystal structure evidence presented later regarding 
the androgen receptor, weak hydrogen bonding interactions are found between amino acid 
residues and 3-keto and 17p-hydroxyl functionalities. It is likely modification of 3-keto 
and 170-hydroxyl groups in testosterone will be detrimental to the RBA of modified 
testosterones. Anstead et aIE4191 suggests positions on the skeleton tolerating small 
substituents and those that tolerate larger groups. Small hydrophobic groups are tolerated 
in the 4,120,14a and 16a positions whilst larger groups are tolerated at 7a, I 10 and 17a 
(Figure 2.15) 
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Figure 2.15. Modifications to the oestradiol skeleton that are tolerated by the oestrogen 
receptor 
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The A ring of oestradiol has been modified in attempting to create organomctallic 
chromium carbonyl complexes. Although not related to testostcronc, as it does not possess 
an aromatic A-ring, modifications indicate steric bulk in tolerated reasonably well below 
the a-face and not tolerated on the 0 face. [4031 It may be suggested l7a and 7a positions 
represent a promising position in which to append a platinum moiety. Large substituents 
are tolerated at these positions in addition to the a-face accommodating stcric bulk, 
characteristics likely attributed to an appcndcd platinum group. Since testostcrone has no 
hetroatoms able to coordinate platinum, a suitable group must be appended to the 
testosterone skeleton. This logically leads to a3 compartment design to a steroidal 
platinum agent; a steroidal domain (for receptor binding), a platinum domain (for DNA 
binding) and a linker domain aoining steroidal and platinum domains together). Out of the 
three positions reported to accommodate bulky substituents: 7a, l7a and IIP, 
modifications to the 7a and 17a position will be considered in terms of the RBA value of 
respective receptors (little data on IIP modification exists). It is approximated that an 
RBA of >I % is required to observe selective uptake is receptor positive tissucs. 143 11 
Z3.1.7a substitution 
Skaddan et al [3691 successfully targeted the oestrogen receptor substituting at the 7a 
position of oestradiol with metal binding sites at the end of an alkyl chain. Ile relative 
binding affinities of the compounds ranged from 845 % and are shown in Table 2.1. 
Rhenium is used as a surrogate for 99'Technitium, actually used in radioimaging but 
expensive to produce and presenting difficulties in handling. 
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Table 2.1. The relative binding affinity of a selection of modified oestrogens for the 
oestrogen receptor. 
7-alpha substituent RBA (25'C) 
21 % X=S 
S 
Yle, 
x 20% X=O ý, --j 
45% X=NMe 
OCCO 15% 
%I, CO Br 
/ 
Re,, 
\ s 
0 8% X=O 
Re 24% X=NH 
OC' I co 
ý" S)ý) N=C-Re -N 
S,,,, > 
15% 
0 
N 
H 
Re 
oc- 
cip 
0 
N 
Re 
oc- 
cip 
23% 
20% 
Skaddan et a113761 report further 7a-substituted oestrogens resulting in RBA values for the 
oestrogen receptor between 20-45%. The authors describe the use of 99'Tc in place of 
rheniurn in the four complexes in Table 2.2 and the tissue distribution profile. Low levels 
of uptake were observed in rats for all four 99'Tc complexes and the authors report, despite 
good RBA values, the observed uptake was not receptor mediated. 
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Table 2.2. The structures and RBA of several rhenium complexes for the oestrogen 
receptor. 
7ct-substituent RBA (25T) 
Ei") 45% 
O: Re-N 
s 11 1 
""> 
0 24% 
Re 
oc- 
C, 
&0 
0 23 % 
Re 
oc- 
C, 
&0 
0 20% 
H 
Re 
oc- 
cip 
Two further 7a-substituted oestradiol complexes with rhenium and 9"Tc were synthesised 
by Luyt et al [3721 with compounds A and B, in Figure 2.16 below, exhibiting R13A values 
of 18 % and 1.9 % respectively. No tissue selective uptake was observed indicating that 
good affinity for respective receptors alone is not enough for selective tissue uptake. What 
other indicators hold prognostic value remains a valid question. 
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Figure 2.16.7a-substituted oestradiol compounds complexed to rheniurn. 
Rhenium complexes of testosterone, modified at the 7a-position are reported by WOst et 
al[3801 who synthesised 2 complexes, shown in Figure 2.17 below. Unfortunately no RBA 
values have been reported. These are the only 7a-substituted testosterones to the author's 
knowledge. 
OH 
0 
S''S 
OH 
0 
s" 
Figure 2.17. Rhenium. complexes with 7a-modified testosterone as a ligand 
Modification of the 7a-position of the steroid skeleton with an alkyl chain and chelating 
group has shown itself to be an excellent method in forming steroidal metal complexes 
with good affinity for the target receptor. Several problems exist when substituting at this 
position. Such modification is synthetically time consuming and often requires >8 steps to 
achieve the final product and despite good RBA values no selective uptake in target tissue 
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(breast for example) has been noted. One possible cause of this is the lipoophi ficity of 
steroidal metal compounds. The compounds tend to have a greater lipophilicity that 
oestradiol. Relatively high lipophilicity is thought responsible tor non-specitic tissue 
uptake. 
23.2 1 7a substitution 
Salman el a11432,433 1 reports on the affinity of' 3) 1 COMPOLInds, ba. scd on 17a-SUbs-11tuted 
oestradiol, for the oestrogen receptor derived from rats. Some of the highest RBA's were 
reported for rigid groups such as ethynyl spacers and the lowest for less rigid motif's. RBA 
of selected substituents are given in Table 2.3. 
Table 2.3. The RBA of selected compounds, modified at the 17u-position, for the 
oestrogen receptor. 
17ct-Group R13A (%) 
lllý 4.9 
4.7 
<o. 1 
<0. I 
, -, 
N 
0ýý I 
, -, 
N 
0.2 
<o. 1 
32 
-0 
5.8 
7.1 
H2C -- -0 
0.4 
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The data suggests good RBA values are achieved by rigid substituted groups, such as 
alkyne groups originating at the 17-carbon of oestradiol and this too may be the case for 
testosterone. Since the reports by Salman et al [432,433] much work has focused on 
modification of steroids at the 17-carbon in the a position. For possible use in medicinal 
imaging Luyt et al[3721 modified oestradiol at the 17-carbon with a ligand chelating Re and 
94m Tc with two different spacers. The RBA toward the oestrogen receptor were 0.25 % 
and 0.14 % for complex A and B, in Figure 2.18 respectively. 
H 
(ýýo 
Figure 2.18. The Re complexes synthesised by Luyt et a113721. 
A large number of ligand and complexes based on modified steroidal skeletons have been 
reported by the group of Jaouen at carbon 17. Vessieres et al modified the ligand in Figure 
2.19 which possesses RBA's of 389 % and 251 % for the progesterone and glucocorticoid 
receptors, respectively. Substrates for the glucocorticoid receptor are adrenal hormones 
often involved in metabolism of carbohydrate, protein and fat. 
1 
Figure 2.19. The chemical structure of mifepristone or RU 486. 
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Synthesis of organometallic mifepristones results in dramatically reduced affinity for the 
oestrogenreceptor. Coordination Of C02(C0)4 and Mo(cyclopentadiene)2(CO)4 to the 
ethnynyl and benzene groups result in R13A values failing from 389 % to 10-201/6 for the 
PR and from 251 % to 8-29% for the GR. Whilst the drops are substantial the actual RBA 
values of 8-29% are higher than the I% thought enough for selecti%-e tissue uptake. 14 ; 11 
Further investigations by Amouri el al 13841 showed 17a-substitutions ot'(wstradiol by rigid 
allyl groups allows retention of a acceptable affinity for the oestrogen receptor. The 
coordination of Cr(CO)3 had little effect on the R13A of the steroidal chromium complex 
(Table 2.4) 
Table 2.4. Rigid substituents at the 17a-position and the RBA for the oestrogen receptor 
17ct-substituent R13A (25"(', lamb cytosol) 
OH 
-tR 
HO 
25% 
oc- (, r, Co 
Co 
27% 
24% 
oc- ur- Co 
Co 
Use of rigidity in 17a-modified oestradiols has resulted in further compounds with good 
RBA for the oestrogen receptor. Top el a, 1399 I report the use of 17a-cyclop-entadiene for 
cooridination of Mo and Re proving modification by ethnynyl based groups at the 17a- 
position can result in good affinity for the respective receptors, shown in Table 2. S. 
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Table 2.5. The RBA of selected modified oestradiols. 
17a-substituent RBA (25'C, lamb uterus) 
OH 
HO 
15% 
oc-MIO-co 
Co 
16% 
OC-R, e-Co 
Co 
Binding a metal direct to the 17cc-ethnynyl group can result in similar binding affinities to 
those observed using ethnynyl-pyridine and ethnynyl-cyclopentadiene as metal 
cooridination sites. For example M02(CP)2(CO)4 bound to 17a-ethnynylestradiol, shown 
in Table 2.6 has a binding affinity of 16 %. This RBA value is significantly reduced from 
the RBA of 17cc-ethnynylestradiol itself (70%). 
Table 2.6. The RBA of selected modified oestrogens 
17a-substituent ([M I) RBA (25'C, lamb uterus) 
OH 
IM] 
HO 
OH H 
HO 
70% 
[M]ýCOACO)6 
[MIýMOACP)AM4 
[M]ýOSACO)10 
5% 
16% 
0.5% 
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There are examples of poorer RBA using 17a-modified oestmdiol and Osclla et d3111 
reports on 3% affinity for the oestrogen receptor of the complex shown in Figure 2.20 
despite the rigid linker used. Even poorer aft'inity for the oestrogcn receptor is reported by 
Cassino et a ý3931, again using a rigid cthnynyl group at the 17a-position and somewhat less 
rigid moieties for binding platinum(II), shown in Figure 2.21. In this case the RBA -, %-as 
determined for the two different types of the oestrogen receptor labelled a and P. 1"he 
uncoordinated ligands achieved RBA of : 50.15 % and between 0.04-0.16 % for the 
platinum(II) complexes. The poor binding was attributed to protonation of the amino 
group, likely detrimental to binding, considering the hydrophobic nature of the LBD of the 
oestrogen receptor. The use of an - -C=C-CI12' group caused flexibility and relatively close 
proximity of the platinum(II) centre to the oestrogcn skeleton. Unlike other steroidal metal 
complexes with higher RBA for the respective receptor, whose metal group is further away 
from the steroid skeleton. 
\I Co 
H N 
Co y 
0 
Figure 2.20. An organometallic oestrogen-based colbalt complex with an RBA to%%2rds 
the oestrogcn receptor of 3 %. 
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\ / 
Figure 2.21. Steroidal platinum(II) complexes based on oestradiol using bidentate nitrogen 
donors and malonato leaving group. 
The use of an rigid ethnynyl group followed by a less rigid thioether was used by Wust et 
al. [3641 to attach rhenium to an estradiol skeleton as shown in Table 2.7. No in vitro testing 
was conducted on this compound. 
The studies of interaction of the oestrogen receptor with substrates allows an idea to be 
formed of those modifications to the steroid skeleton in testosterone based systems that 
result in substrates having, to first approximations, an excellent chance of possessing a 
high enough RBA to be potentially therapeutically useful. 
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Table 2.7. The RBA of a group of 17a-substituted estradiols 
17a-substituent RBA (25"C, lamb utenis) 
OH R 
HO 
2.3% 
S- -S 
V-j 7.4% n -2 
14.1 %n3 
gs--3 ýI 3.6% n1 e S' '0 7.4% n=2 
10.5% n=3 
0.6% 
R 
s-, 2.1 % 
Re Br 
OC' 1\ 
oc CO 
2.4. Androgens, the androgen receptor and malignant disease 
The terms 'androgen' encompasses the male sex hormones or steroids in vertebrates that 
control or maintain masculine characteristics. The production facilities of androgens are 
the testes and ovaries (women produce smaller amounts of androgens) producing gonadol 
androgens, the adrenal cortex adjacent to the kidney producing adrenal androgens and 
localised production in selective tissues. Testosterone is the major androgenic steriod 
circulating in plasma and is synthesised using two possible pathways shown in Figure 
2.22. [4341 Approx 60 % of circulating testosterone is bound to the sex hormone binding 
globulin (SIlBG), 40 % is bound to serum albumin and 1-2 % is circulating freely. 14; il The 
bio-available androgens are found localised in specific tissues including breast, ovarian and 
prostate. ""' The main function of the androgen receptor is to allows a relatively simple 
molecule, such a testosterone, once bound to the AR, to control many different 
biochemical pathways simultaneously resulting in a wide variety biological effects. 
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Cholesterol 
HOj 
p OH 0, 
\)V-: o 
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HOJ 
Pregnenolone 
Progesterone AD 
A 
OH 
Testosterone 
Figure 2.22. The pathways from cholesterol in the biosynthesis of testosterone. 
24.1. The structure of the androgen receptor 
The androgen receptor primarily binds testosterone and its metabolite (via the 5a-rcductasc 
enzyme), dihydrotestostcrone. Prior to establishing the structure of the AR, the structural 
details of two of its substrates are required and are shown in Figure 2.23. T and DHT are 
based on the steroid skeleton comprising the A, B, C and D rings 
Beta Face 
OH 
H 
H 
0 
je H 
Testosterone (T) 
= _OH 
0 
SHH 
OH 
HO HO 
DHEA 
1 
OH 
OH 
5-alpha-dihydrotestosterone (DHT) 
Z _OH 
0 
£eH 
Alpha Face 
Steroid Skeleton 
Ring System 
Figure 2.23. The molecular structures of testosterone and dihydrotestosterone showing the 
two faces of the molecule and the steroid ring system. 
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The androgen receptor is a ligand dependent nuclear transcription regulator whose gene of 
8 exons is located on the long arm of the X chromosome (Xq 11-12) and encodes a protein 
(the AR) approximately 920 amino acids long [4371 depending on the number of 
polyglutamine / polyglycine repeats. [4391 Similar to other members of the nuclear receptor 
family it consists of 3 domains, the NI-12-terminal domain, DNA binding domain (DBD) 
containing a hinge region and ligand-binding domain (LBD) J439,4401 The N112-tcrrninal 
domain contains a region known as an activation function (AF-1) which activates the 
receptor for transcription. The DBD is a 68-amino acid highly conserved region and 
consists of two zinc fingers (loops of amino acids joined by a sulphur-sulphur bridge 
between cysteine residues) that recognise and bind to DNA. 144 11 Also in the DBD is a 
hinge region which signals the requirement for nuclear localisation of the receptor- 
substrate complex for DNA binding. (442,4431 The structure of the unliganded retinoid X 
receptor LBD (RXR-LBD), shown in Figure 2.24 is comprised of 12 alpha helixes and 4 
strands. [4441 The LDB contain an activation function, AF-2 and is transcription inactive in 
the unbound state. Although no structure of unliganded AR LBD exists, the LBD of 
nuclear receptors is remarkably similar and RXR-LBD is considered a prototype for all 
receptor LBDs. [4451 Also in Figure 2.24 is the crystal structure of the AR LBD bound with 
the synthetic androgen metribolone (4461 (structure in Figure 2.25) and is similar to the 
crystal structure of the rat AR LBD bound with DHT. 14471 
80 
r 
LBD of human AR 
binding metribolone 
Figure 2.24. The crystal structures of the retinoid X receptor LBD and the AR LBD. [445 
4461 Structures have been drawn using Protein Explorer. [2691 
17 
Figure 2.25. The chemical structure of metribolone highlighting the 3 and 17 positions. 
In the absence of ligand, helix-12 (red) in Figure 2.24 (left), containing the inactive AF-2 
region is found directed away from the LBD and helix-I I partially fills the LBD. Upon 
binding helix-12 folds back over the LBD, trapping the androgen. Helix- II is now parallel 
to helix- 10 and formed a single helix with segmentation between helix- 10 and helix- II 
(yellow). These and other structural changes form the ligand binding pocket in the LBD 
(shown in Figure 2.26) and aids protein interactions with co-activators of transcription. [4481 
The LBP of the human AR is hydrophobic in character. Of the 19 residues interacting with 
metribolone, 12 are hydrophobic and the remaining 7 polar/charged residues are mostly 
concentrated around the 3 and 17 positions and involved in electrostatic interactions 
81 
Unliganded LBD 
retinoid X receptor 
between ligand and LBD, shown in the crystal structure bLlo%%' (Figure 2.26 and 2.27) with 
rat AR (identical amino acid sequence to human AR) and bound DI IT. 
Figure 2.26. The ligand binding pocket (LPB) of the 1.131) domain of the human AR 
receptor and bound metribolone. 1446 
1 Grey represents hydrophobic residues and purple 
those residues that are polar/charged in nature. 12691 
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Arg-752 
Gln-711 
Thr-877 
-, n-705 
Figure 2.27. The electrostatic interactions between 3-ketone and 17-hydroxyl of DHT and 
the LBD of the AR. [446] 
The 3-ketone group is interacting with Gly-711 (3.36 A distance) and Arg-752 (2.89 A) 
and a water molecule (3.46 A) whilst the 17-hydroxyl is interacting with Asn-705 (2.80 A) 
and Thr-877 (3.36 A) in Figure 2.2. Whilst the exact free energies are not known for the 
binding of androgens to the AR binding of estradiol to the estrogen receptor a, with a 
similar LBD to the AR is known. The free energy contributed by the 3 and 17 
functionalities of estradiol, shown in Figure 2.28 are approximately 1.9 kcal mol-1 and 0.6 
kcal Mol-1.14191 
OH 
HO 
Figure 2.28. The molecular structure of estradiol. 
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2.4.2 The mechanism of ligand activation of the androgen receptor 
Without substrate, the AR is cytoplasmic bound by heat shock proteins such as heat shock 
protein 90 (HSP-90) and other chaperoneS14491. The mechanism ofactivation of' the AR 
and formation of transcription complexes have been reviewed in depth recently 14-04S31 am 
depicted in Figure 2.29. Briefly, newly synthesised AR is phosphorylated and stabilised 
via binding of heat shock proteins (I ISP-90, -70, -56 and -54) and is primarliv located in 
the cytoplasm. The conformation of ligand-free AR prevents DNA binding. Ligand 
binding occurs in the activation function 2 region (AF-2)) of the C-terminus domain 
facilitating closing of the hinge region around the binding site and the release of heat sh(xk 
proteins and the AR is phosphorylated. The confOrmation changes induced by ligand 
binding expose new surfaces binding a variety of co-regulators (co-activators and co- 
repressors) and the AR translocates to the nucleus and form a dimmer complex. The AR- 
AR homodimer binds to the DNA recruiting a variety of cell specific and ubiquitous co- 
factors, allowing activation of the transcription machinery to stimulate or inhibit gene(s) 
transcription. This induces the synthesis of a variety of gene products dependent not only 
on AR-ARE interactions but the levels of co-activators; and co-repressors. These gene 
products are likely to initiate or involve other biological pathways associated %vith the 
proliferation and maintenance of malignant disease. 
14 
4ýýM 
01> hosphorylation permits ligand binding ý :, ý, 
0 newly synthesi sed II Ok Da AR %ndr"Im) -1-f. KtOr 
. 112kDa AR bind 
-Flinge region of I 
-inhibition of Zn 
-Co-factor bind 
-I l2kI)a AR binds steroid 
-Flinge region of N-terminal domain closes 
-inhibition of Zn fingers by N-terminal domain ccascs 
-Co-factor bind 49 DNA 
41 
-Receptors dimerise 
-DNA binding DNA 
41 
49 
Figure 2.29. A schematic of the steps from AR synthesis to DNA binding. 
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Z4.3. Malignant disease, androgens and the androgen receptor 
To the authors best knowledge no steroidal metal complexes have targeted the androgen 
receptor (AR) with the aim of localising cytotoxic drugs although it has been for 
radiopharmaceuticals. [3801 This is a surprising fact given that most cancers may be 
described as AR+ including -80 % of breaStE336-3383,74-90 % of ovarian 1454-4571 and 
virtually all prostate. [458"4601 The androgen receptor represents the predominant receptor 
expressed of the three sex steroid receptors in many turnours and the receptor pathways are 
often not independent, interactions and synergistic effects have been noted. [4611 
Many cancers depend specifically on androgens of which testosterone (T) and 
dihydrotestosterone (DHT) are the most abundant. However, only in prostate cancer are 
endocrine-bascd treatments inhibiting the actions of androgens employed, as shown in 
Figure 3.30. The treatments are known as androgen ablation (from Latin ablatus meaning 
to carry away) and involve blocking the action of androgens via the AR. 14621 Initial tumour 
response rates vary between 80-90% but almost all progress to androgen refractory states 
resulting in mortality occurs. Androgen ablation remains the mainstay treatment for cancer 
of the prostate although combination therapies involving carboplatin are under 
investigation. [4631 
The AR and its substrates are intrinsically linked with the fonnation of prostate cancer 
from normal tissue and mutations and over-expression of the AR are possible 
candidates. [4641 Several mechanisms are proposed for the transition and propagation of 
refractory tumours and this subject has been reviewed in general recently. [465-4711 Proposed 
pathways for the development of refractory tumours include: 
1. AR levels amplified. 
2. Overexpression of co-factors involved in AR pathway. 
3. Relaxing of ligand specificity (by gene mutation) allows promiscuous activation of 
the AR by non-androgens. 
4. The AR signalling pathway is bypassed and no longer required for cell survival. 
5. Susceptibility to prostate cancer is hereditary. 
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Figure 3.30. Targets used in endocrine therapy in prostate cancer. I Mcnising hormone- 
releasing hormone (LI I-RI 1) is released from the hypothalamus acting on the pituitary 
gland (PG) which releases lutenising hormone (1,11) and adrenocorticotropin hormone 
(ACTFI). Double lines represent current and possible endocrine treatments Interfering or 
inhibiting the connecting pathways and activation ofthe AR 
Despite progression to refractory disease the AR continues to be expressed in substantially 
all prostate turnours and none of the above pathays reduce the applicability of using the AR 
as a transporter of cytotoxic drugs. This fact makes the androgen receptor in prostate 
malignancies a target for steroidal platinum complexes. 
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The role of androgens in relation to breast cancer has been reviewed recently by Liao and 
Dickson [4721 who suggest several mechanisms (the issue has been reviewed additionally [473, 
4741) of carcinogenesis/cartinornatosis in breast tissue: 
1. Androgens cause growth stimulation in breast epithelia (membrane tissue covering 
breast tissue) and breast cancer by biotransformation to oestrogens via aromatase 
enzymes. [475,476] This results in an excess of oestrogen resulting in growth 
stimulation of breast tissue. 
2. Low levels of adrenal androgens stimulate breast cancer cell proliferation via 
binding to the ER in low oestrogens levels situations, i. e. postmenopausal women. 
The treatment of breast turnours, generally involves endocrine treatments blocking the 
oestrogen receptor [4771 such as tarnoxifen or preventing oestrogen biosynthesis such as 
aromatase inhibitors. [4781 Platinum-based chemotherapy is generally not used due to 
toxicity [4791 except in metastatic maligancies. [4801 The AR remains a viable target in breast 
tissue. 
Ovarian epithelium tissue, the membrane like tissue coving the ovaries is reported to 
respond to androgen treatment in primary cell cultures from patientS14811 which are the 
origin of 90% of ovarian cancers. [4821 The study demonstrated that treatment with 
androgens lead to decreased cell death or increased proliferation in 7 out of 9 cell cultures. 
The role of androgens, in addition to oestrogens, are reportedly involved and are risk 
factors for developing ovarian cancer [4824841 with possible synergistic effects occurring 
between oestrogens and androgens. E4851 Endocrine treatments are not used in ovarian 
cancers but many ovarian cancers are treated by surgical removal of malignant tissue 
followed by carboplatin but most patients eventually relapse. [486,4871 Here too the AR may 
be used as a transporter of cytotoxic complexes. 
2.5. Eplilogue 
In cancer chemotherapy few drugs specifically target turnours over normal tissue. 
Platinum drugs such as cisplatin and newly licensed metal-based cancer therapeutic arsenic 
trioxide may hardly be called targeted. One of the problems with cisplatin is a lack of 
tissue specificity. If a cytotoxic drug is designed to specifically target malignant tissue the 
possibility of overcoming poor tissue specificity of platinum(II) drugs may be addressed. 
Since the primary target of chemotherapy is DNA, using an existing cellular mechanism to 
transport a cytotoxic platinum(II) complex directly to DNA is very appealing. Achieving 
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targeted metal therapeutics requires hijacking an active transport mechanism present in 
higher levels in tumour tissue compared to normal tissue. Such a methodology permits 
many different types and configurations of moieties to be transported using the same 
vector and the most active selected in prc-clinical trials. 
Using the steroid transport system to localise platinum(II) complexes in the vicinity of 
DNA may result in drugs that target both specific tissue and arc also rccognised 
differentially by cellular proteins overcoming several type of resistance mechanisms 
observed in cells treated with platinum(II) drugs. 
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Chapter Three - Synthesis and characterisation of 
steroidal ligands and platinum(II) complexes 
3.1. Introduction 
3.1.1. Platinum - an introduction 
Platinum, from the Spanish plata meaning 'silver plate' was discovered in 160' century 
Columbia and belongs to the family of noble metals that includes palladium. The 
chemistry of platinum was subject to intense study after its arrival in Europe in the 1740's 
and the I" organometallic derivative of platinum known as Zeise's Salt, in Figure 3.1, 
K[Pt(C2H4)CI31-1120 was reported in the 1820s. [4884901 
cl 
C141t 
cl 
Figure 3.1. The structure of Zeisse's Salt 
Platinum exhibits a large range of oxidation states. It exhibits every oxidation state from 
fon-nal negative oxidation states in carbonyl anion clusters ([Pt3(CO)3*t-CO)3]n 2ý to the 
VI state in PtF6. [4911 The most common oxidation states are II and IV and the 11 (d8) state is 
by far the commonest. The 11 state is heavily studied, partly due to the ease of forming 
complexes with a large range of ligands whose donor atoms come from most groups of the 
periodic table and a number of reviews have been published E492-1011. The most interesting 
oxidation states, from a chemotherapeutic viewpoint, are Pt(II) and Pt(IV) as both have 
proven anti-tumour properties. 
The +11 state exhibits varied coordination numbers from 4 to 6 but 4 coordination 
represents the vast majority of d8 complexes (cordination numbers of 5E502-5061 or 6 [507-509] 
are known but rare) and exhibits square planar geometry. The square planar structure 
arises as the most stable configuration for d8 low spin metals. The approximate relative 
energies of the 5d orbitals in several crystal fields are shown in Figure 3.2. In the square 
planar ligand field the 8d electrons of Pt(II) occupy stabilised orbitals, leaving the high 
energy dxý_Y, orbital unfilled. These relative energy levels are only approximate and from 
spectral studies of [ptC4]2. the d., orbital lies below that of dXY and dxz and often depends 
on the nature of the ligands for a given metal in a square planar configuration. 15101 
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t 
Figure 3.2. The approximate relative energies of d-orbitals in differing crystal ficld 
environments. 
The most important Pt(II) complex from a medical viewpoint is cisplatin, first reported 
synthcsised by Peyrone in 1844. [521 Its structure was correctly assigncd by Alfrcd NVcmer 
who in 1893 proposed structures for the a (cis) and 0 (trans) forms of 
diamminedichloroplatinum(II). IsllI In 1913 for 'his work on the linkagc of atoms on 
molecules... ' he was awarded the Nobel Prize for Chemistry. 
3.1. Z The molecular desigu of steroidalplatinum complexes 
The conjugation of steroids and platinum(II) logically follows a design containing 3 
distinct moieties. The first is a steroid, in this case testostcronc, as to the author's 
knowledge, this has not been attempted for targeted cytotoxic drugs. Tbc second is a 
platinum centre and one with only a single leaving group and/or a DMSO ligand satisfics a 
requirement to be non-conventional. The third is a suitable linking group and a mono- 
functional aromatic amine such as pyridine or quinoline. Figurc 3.3 shows the three 
moieties or domains. 
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Tetrahedral Free Octahedral Square- Square Trigonal 
ion planar Pyramid bipyramid 
The design of a steroidal metal complex will contain the following features: 
1. Attachment of planar aromatic amine to testosterone skeleton should allow good 
receptor binding. 
2. The groups coordinated to platinum(II) must allow covalent DNA binding. 
3. The synthesis should be relatively facile. 
4. The platinum centre should be positively charged to enhance water solubility (very 
important due to the hydrophobic steroid). 
5. The platinum domain should be 'non-classical' in terms of the ligand. arrangement, 
e. g. monofunctional and containg ligand such as DMSO. 
OH 
N 
xlpt. 
'x X 
0 
jj 
steroid domain linker domain platinum(II) domair 
Figure 3.3. The design of steroidal platinum complexes. 
Features 4 and 5, regarding the platinum centre are very important; since 1969 much 
synthesis has focussed on the structure activity rules proposed in the early 1970's and it's 
essencial that new complexes move away from those rigid rules if truly novel-acting 
complexes are to be developed. The ethnynyl-pyridyl or ethynyl-quinyl group will be used 
to link to testosterone and is capable of coordinating platinum(II), leaving three vacant 
coordination sites on Pt(II), giving rise to the possibility of a very large number of different 
combinations of ligands and geometries unlike bidentate ligands. Figure 3.4 shows the 5 
combinations of geometries and ligands which will be made. The labels given to each type 
of coordination sphere, i. e. trans-cationic = TC will be used from now on. 
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\---/ cl NH3 
trans-neutral (TN) trans-cationic (TC) 
\\N-Pit-DMSO 
\-/ L 
DMSO complexes 
Figure 3.4. The geometry of 5 different types platinum(II) complexes. The steroid-linkcr 
ligand is replaced by pyridine for clarity. 
Trans- and cis-cationic (TC and CC) and those containing DMSO are non-convcntional. 
All are positively charged to aid water solubility and reduce the high lipophilicity often 
associated with steroidal metal complexes. The design results in complexes similar to that 
shown in Figure 3.5, using a 4-ethynynl-pyridine to link the steroid and platinum moieties 
together. The molecular design primarily focuses on using testostcronc to deliver a 
platinum complex with the ability to bind to DNA and overcome the problem of decreased 
uptake found is some cisplatin resistant cells. The complex is also designed to have less 
systemic toxicity through two methods; firstly, the compound is more targeted so less is 
required for treatment and secondly, using less complex for treatment will result in less 
toxicity. The complex is designed to overcome other mechanisms of resistance. %Vhcre 
the platinum centre and steroidal group are close together, when using 2 and 3 ethynyl- 
pyridine linker domains for example, it is entirely likely that decreased levels of 
inactivation by sulphur containing bio-molccules may occur due to stcric crowding. 
Finally the design is a large departure from 'classical' platinum drugs and as such, cross- 
resistance with cisplatin and carboplatin is not expected to occur. 
HA + rl 
PF 
N' % 11 NH3 
Figure 3.5. An example of a steroidal metal complex. 
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3.1.3. Synthetic routes to organic ligands 
The route chosen to produce modified testosterone is via Sonogashira coupling due to the 
commercial availability of inexpensive bromo-pyridines, quinolines, isoquinolines and 
17a-ethynyltestosterone in addition to the relative ease of separation of the desired 
products. 
A Sonogashira coupling is a palladium catalysed reaction between an acetylinic group (i. e. 
17a-ethnynyltestosterone) and a halogenated groupI5121 (i. e. 2-bromopyridine), an example 
of which is shown in Figure 3.6. A copper(I) salt is used to reduce Pd(II) to catalytically 
active Pd(O) in situ and requires inert conditions as copper(l) salts catalyse homo-coupling 
of the acetylinic groups in a Glaser coupling. [5131 To remove the acetylinic proton the 
reaction was originally conducted in an organic base. 
Pd(O) 
Me OH Me OH or PQ I) + Cu(I)l cat. 
Me 
111ý"H + X-Py 
-HX 
Me N 
0"X= 
Br, 1, OTf 0 ET-2-Py 
Figure 3.6. The Sonogashira coupling between ethisterone and 2-bromopyridine. 
The proposed catalytic cycle of the Sonogashira reaction is presented in Figure 3.7 and in 
addition to the product, a protonated base is the major by-product of the reaction. 
[Pd(PPh, ), Cl, l 
--Testosterone 
Reductante. g. Cul 
N PPh3 
Cl-Pq 
PPh3] Br--o , \I / x, ) 
I PPh3 N C3\ 
PC 
PPh3 
NNN 
d --PPh3 
Testosterone PPh 
L- Br 3 
BaseH*Br H--------Testosterone 
Figure 3.7. The proposed catalytic cycle for the palladium catalysed Sonogashira, cross- 
coupling reaction. [512,514-5161 
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The catalytic cycles involves reduction of Pd(II) to Pd(O) by Cu(I) and insersion into a Ar- 
Br bond and the formation of a Pd-C bond after the dcprotonation of cthistcrone by a base, 
i. e. triethylamine. The protonated base precipitates out from solution and a 1,2-inscrtion 
reaction at the Pd centre completes the reaction to form the desired product. - 
Another route to steroid-linker ligands involves a nucicophilic attack of a lithiated 
ethnynyl-pyridinc nuclcophile create a new stcrcoccntrc at the 17-carbon, sho%%n in Figure 
3.8. This nuclcophilic attack possesses facial selectivity but diastcroisomcrs inevitably 
occur, requiring addition purification steps and is unlikely to be attempted. 
0 Li OH, = .. 11 ma-C, +N 
OJ5 
of 
OJS13M"ajor Product 
. 6. 
Figure 3.8. The nucleophilic attack by a lithiated species, possessing facial 
steroselectivity, creating a 17ce-pyridylethynyl-substituted tcstostcronc. 
3.1.4. Synthetic routes to steroidal metal complexes 
The five different co-ordination spheres will require 4 different synthetic routes. Trans. 
cationic (TC) and cis-cationic (CC) complexes arc synthesiscd using the same synthetic 
method, removal of a chloride ion from transplatin (for TC complexes) or cisplatin (for CC 
complexes) by a silver nitrate and binding of the solvent (DMF) to the vacant ligand site 
forming the complex [trans-Pt(NI13)2(DMF)Clj+. [332,3331 The labile DMF ligand is 
substituted by the organic ligand to form the complex, shown in Figure 3.9. 
DMF + HP, prýql + AgN03 
HP, pjýpl 
H3N' 'Cl Ligand H3N' 'Ligand 
+ AgCl 
+ N63 
Figure 3.9. Synthetic route to TC complexes. 
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Trans-neutral complexes will be synthesised using the main synthetic route to this type of 
complexes; substitution of two chlorides forming 'solvento species' before substitution by 
steroidal ligands (Figure 3.10). Treatment with hydrochloric acid, due to the trans-effect 
results in a trans geometry. 
H 
H20 
HH 
2+ 
Apt, ýql + 2AgNO3 
A tý 20 
H3N' 'Cl H3N' H20 
2L 
HP, pt, ýýl 
CIH H 
2+ 
-14 
AprýL 
Cl" 'L H3N' 'L 
Figure 3.10. Synthesis of trans-neutral complexes. 
Synthesis of complexes (cis-neutral) with the molecular formula cis-Pt(NHAL)(Cl)2 may 
follow two routes. The first route is via the reactive intermediate [Pt(NH3)(CI)31' and 
treating this with an amine ligand, L, to form cis-Pt(NH3)(L)(Cl)2- Syntheses by Abrams 
and co-workers have produced several different salts of [Pt(NH3)(CI)31' for use in a range 
of solvents in addition to water (Figure 3.1 1). 15171 
yl Et4NCI 
H3N-Plt-Cl m- [Et4N][Pt(NH3)CI31 [Nal[Pt(NH3)CI31 
NH3 DMA I OOOC *"ýPh4NCI 
L 
[Ph4N][Pt(NH3)CI31 L 
cis-Pt(NH3)(L)CI2 
IL 
\L 
cis-Pt(NH3)(L)CI2 
[K][Pt(NH3)CI31 
Figure 3.11. The routes to platinum complexes with the molecular formula cis- 
Pt(NH3)(L)(CI)2- 
Regarding complexes containing DMSO, the substitution of a DMSO ligand from cis- 
Pt(DMSO)2CI2 by amines has been known for over 30 years. E5 181 Farrell and co-workers 
investigated amine and DMSO containing complexes thoroughly during the 1980's and 
assigned the reaction products as trans and reported several crystal structures. [519-5221 
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Farrell also proposed a mechanism for the reaction between an anitrogcn containing ligand 
and cis-Pt(DMSO)2CI2 shown in Figure 3.12.15191 
YMSO 
Cl-Plt-DMSO 
No' 
cl 
DMSO 
Cl- 19-DMSO + cr 
N 
DMSO 
C14t-Cl + DMSO I 
N 0: "- 1 
Figure 3.12. The proposed mechanism for the reaction of a ligand with cis-Pt(DNISO)2CI2 
using pyridine as an example. 
Once the last complex (Figure 3.12) has been formed, removal of chloride using silver 
nitrate, addition of a planar amine such as pyridine and subscqucnt purification should 
yield a complex of the formula Pt(L)(Pyridine)(DMSO)Cl+. 
3.2. Results and discussion 
Whilst all characterisation data is referrcd to in this section, much is to be found in the 
appendices and these are referred to, for example, Figure A. 2.3., meaning Figure 2.3 in 
Appendix 2) 
3. ZI. The synthesis of Ra-subsituted testosterones 
The only problem encountered using the Sonogashira reaction was the requirement for 
inert conditions. Failure to observe strict inertness resulted in varying dcgrces of Glaser 
coupling, visible in the 1H NMR spectrum as a deviation of 1: 1 ratio bctwccn steroidal and 
pyridine hydrogens and in the mass spectrum (ESI-MS, +ve) at nVz = 623, corrcsponding 
to (Ethynyl-testosterone)2, 
3. ZZ The synthesis of figands L, - L6 
Using readily available commercial reagents six ligands were synthesiscd, (Figure 3.13) in 
good to high yield with the majority requiring only simple purification steps such as re- 
crystallsation. Only ET-3-Py and ET4-Py required flash column chromatography to 
separate out the desired product. The compound structure was confirmed using a range of 
spectroscopic techniques. In general the molecular formulae were confirmed using 
elemental analysis and the 111 NMR spectra used confirm the ratio of steroidal skeleton and 
aromatic group and 13 C DEPT NMR spectroscopy was used to establish that no changes to 
the steroidal skeleton occurred, Le. quaternary. Infrared spectroscopy confirmcd the 
presence of the major functional groups including an a, p-unsaturated carbonyl, hydroxyl 
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and aromatic ring. Vibrational bands relating to the ethnynyl group were not always 
present. 
OH Pd(PPh3)2C12 OH 
'Pr2NH 
Br Cul N 
0 oýd5 
ET-2-PY 
OH 
c\ p/. N 
0ýc 
ýý 
ET-3-Q 
OH 2z 
/. 
N 
O£c 
ET-4-IQ 
OH Z 
N 
0 
j5 
Z 
ET-6-0 
OH 
ET-3-Py 
0 
OH 
O£c 
ET-4-Py 
Figure 3.13. The molecular structures of ligand L, - L6 
The 6 ligands (Figure 3.13) are identified by shortened acronyms. A pyridine with 17a- 
substitured testosterone at the 2 position full nomenclature name is 
(8R, 9S, IOR, 13S, 14S, 17S)-17-Hydroxy-10,13-dimethyl-17-pyridin-2-ylethynyl- 
1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3 -one 
although here the steroid skeleton will be referred to as testosterone and the ligand as 17a- 
pyridin-2-ylethynyl-testosterone or ET-2-Py. This nomenclature is repeated for all the 
ligands and subsequent complexes. 
97 
3.221. LigandLI: ]7a-pyridin-2-ylethynyl-lestosterone (ET-2-Py) 
6' 
N 5- 
2U'Zý 1 0ý 4- 4 
12 
ý-`21 3' 
1 
3- 20 
8 ,e 15 
C261131NOz 
The Sonogashira, cross-coupling reaction between cthistcrone and 2-bromopyridine 
afforded the product 17a-pyridin-2-ylethynyl-tcstostcrone in excclicnt yield and rcquiring 
only simple purification. The product was soluble in chloroform, dichloromethane, 
methanol, DMF and DMSO, partially soluble in acetonitrile, barcly soluble in diethyl cthcr 
and insoluble in water. Purification of the crude product involved two steps: a) washing 
with water to remove diisopropylamine and copper salts; b) rccrystallisation to remove 
palladium complexes (determined by their orange / yellow colour) together with small 
amounts of ethisterone and product that remain dissolved. The product began to crystallise 
almost immediately after the cooling period was initiated and this was complete in 24 
hours. 
The white solid was analysed by elemental analysis and mass spectroscopy whose results 
are consistent with the proposed structure. The mass spectrum (Appendix A. 1.1) 
corresponds to C26H31NO2 + II+ and has the correct isotope distribution pattern. 
The 1H NMR spectrum (Figure 3.14) shows a steroidal skeleton and pyridine ring in a 1: 1 
ratio with a loss of acetylene resoance ca. 2.55 ppm indicating a reaction at that centre. 
The a, p-unsaturated carbonyl proton (H4) and methyl resonances appear with little shifting 
compared to ethisterone as would be expected due to the distance from the pyridine ring. 
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Figure 3.14. lH NMR spectrum of ET-2-Py in CDC13- 
The assignment of the pyridine resonances may be made from inspection of the coupling 
constants and was confirmed by a COSY spectrum (Figure A. 1.2). The COSY spectrum 
clearly shows 3J and 4j coupling allowing assignments in conjunction with the ID 'H- 
NMR spectrum. Cross coupling of H6' with a triplet at 7.63 ppm. shows this is 1-15'. 
Coupling of 1-15' to a doublet at 7.40 pprn and coupling of this doublet with a ddd signal at 
7.21 ppm allows the assignment of 1-13' and 115' respectively. 
The 13 C DEPT NMR spectrum (Figure 3.15) contains 26 signals, with the correct amounts 
ofC/CH2andCH/CH3 groups. The pyridine carbons, C2, C4, C18 and C19 are assigned 
in association with a 'H- 13 C HMQC spectrum (Figures A. 1.3 and A. M. ). The signal of 
highest chemical shift at 200 ppm is assigned to the ketone carbon, C3. The signal around 
171 ppm is assigned to C5 which is P to an a, p-unsaturated carbonyl and the 143 ppm. 
resonance is assigned to C2'. The close signals at 123.8 ppm and 122.9 pprn may be 
assigned to C4 and C5' respectively using the cross coupling peak locations in the HMQC 
spectrum. The three resonances at 93.0 ppm, 85.3 ppm and 79.8 ppm may be assigned 
either of the three quaternary carbons C17, C20 and C21. The three remaining signals of 
CH type carbons at 53.2 ppm, 50.1 ppm and 38.8 ppm may be assigned to either of three 
carbons C8, C9 and C14. 
99 
The IR spectra (Figure A. 1.5) show bands of the most characteristic functional groups. 
The steroid skeleton is represented in the spectrum with uO-11, uC-11, uC-=C and uC=O 
stretches. The weak band at 2219 cm" and strong band at 1665 cm" arc assigned to a 
uC=-C and an a, p-unsaturated ketone uC=O stretch, respectively. The pyridine ring 
exhibits several bands, aromatic i)C-11 stretches between 3150 cm" and 3180 cm"' and i)C- 
H out of plane ("oop") at 765 cm". The 765 cm" band is indicative of a 2-substitutcd 
pyridine ring. The yield is 76 %. The combined spectroscopy data is in agreement with 
the structure of ET-2-Py. 
Exnansion (123-127oom) C6' 
PPM 
c1q, 
Figure 3.15. The 13C spectrum of ET-2-Py with selected assigmnents. 
3.2.2.2. Ligand L2: ]7a-pyridin-3-ylethynyl-lestosterone (ET-3-Py) 
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The coupling of 3-bromopyridine and 17a-ethynynltestosterone afforded the product 17a- 
pyridin-3-ylethynyl-testosterone in good yield. The product was soluble in chloroform, 
dichloromethane, methanol, acetonitrile, DMF and DMSO, partially soluble in diethylether 
and insoluble in water. Purification was primarily by flash column chromatography 
although washing a chloroform solution of crude product with water removed proportions 
of protonated base and copper salts. Column chromatography separated the product from 
the remaining impurities using silica gel. 
The molecular formula of ET-3-Py was confirmed by elemental analysis and the parent ion 
peak in ESI-MS at nilz = 390 may be attributed to protonated ET-3-Py (Figure A. 1.6. ). 
The 1H NMR spectrum (Figure 3.16) reveals resonances assigned to a 3-substituted 
pyridine ring and steroidal skeleton in a 1: 1 ratio. There is no evidence of an acetylene 
proton ca. 2.54 ppm, observed in ethisterone, indicating the reaction took place completely. 
The assignment of the pyridine resonances may be made from inspection of the coupling 
constant of the 7.73 ppm resonance and the cross-peaks in the COSY spectrum of ET-3-Py 
(Figure 3.17). The origin of broadness of the 3 aromatic protons is unknown. 
Expansion (7.10-9.00 ppm) IVIM 
1-14! 
11 
2, -ý-N 
Iz 
6' IVL-19 3QI OH " 4ý,, 5' 
18 
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14 16 HT H6' 
8 15 
7 
6AA 
IIIIIIIIIIIIIIIIII 
PPM 
8.50 8.00 7.50 
steroid protons 
no 
pp 
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Figure 3.16. The 1H NMR spectrum of ET-3-Py in CDC13- 
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Inspection of the COSY spectrum, cross-peaks may be observed between the doublet at 
7.73 ppm and singlet at 8.53 and multiplet (overlapping with ClIC13) at 7.27 ppm. This 
permits assignment of H5' and H6'. 'Me remaining signal at 8.72 ppm may be assigned to 
HT which shows no evidence of coupling to any other proton and being a to the pyridine 
nitrogen is expected at higher chemical shift than some other pyridine protons. 
(M 0 to 
'01 eILD 
CD 
PPM 
8.50 8.00 7.50 
Figure 3.17. The COSY spectrum of ET-3-Py in CDC13. 
7.50 
8. W 
8.50 
The IR spectrum (Figure A. 1.7) shows the fundamental vibrations characteristic of 
functional groups in ET-3-Py. The steroid is represented by VO-11, VC-11, VC=O stretches 
whilst the pyridine vC=C stretch as shoulders to the vC=O vibration and vC-1 I out of plane 
bend at lower wavenumbers. The yield is 68 %. The spectroscopic data confirm the 
structure of ET-3-Py. 
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3.2.23. LigandL3: 17a-pyridin-4-ylethynyl-testosterone (ET-4-Py) 
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C26H31NO2 
The reaction between 4-bromopyridine and ethisterone using 
bis(triphenylphosphine)dichloropalladium(II) as a catalyst in the presence of copper iodide 
and diisopropylamine produced the desired product ET-4-Py in reasonable yield. 
Purification required several steps: a) removal of diisopropylamine by washing with 
chloroform and reduction in vacuo; b) removal of diisopropylarnine salt by selective 
precipitation and washing; c) flash column on silica to separate the ET-4-Py from 
palladium salts. The product is a white fluffy solid very soluble in DMSO, DMF, 
chloroform, dichloromethane, methanol and acetonitrile, partially soluble in diethylether 
and insoluble in water. 
Elemental analysis confirmed the chemical formula and mass spectroscopy confirmed the 
parent ion is 390.3, corresponding to protonated ET-4-Py with the correct isotope 
distribution (Figure A. 1.8). The 1H NMR (Figure 3.18) indicates the presence of a 
steroidal skeleton and 4-substitited pyridine ring in a 1: 1 ratio. No evidence is present of 
acetylinic protons such as that seen in ethisterone indicating the reaction took place 
completely. The integrations of all protons in the 1H NMR spectrum accounts for all 
steroidal and pyridine protons except for 17P hydroxyl group. The assignment of pyridyl 
protons assumes hydrogens closer to the nitrogen atom are at higher chemical shifts than 
those at greater distance. The broadness of the pyridine signals indicates the ring is 
spinning on the NMR timescale. H4 may be assigned due to its chemical shift and Mel 8 
and Me 19 from comparison with estradiol which posses an identical D ring but no Me 19 in 
its structure. 
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Figure 3.18. The 'if NMR of ET4-Py in CD30D. 
The infrared spectrum (Figure A. 1.9) shows several bands characteristic of functional 
groups in the proposed structure. Bands due to the steroid skeleton v0-11, vC-11 and vC=O 
stretching modes are present in the spectrum. The weak band at 2220 cm'l may be 
assigned to vC=C stretch whilst the band at 824 cm*l is vC-11 bending. The position of the 
824 cm" agrees with that expected from a4 substituted pyridinc ring. The yield is 68 %. 
The spectroscopic data is fully in agreement with the production of E-T4-Py. 
3.2 2.4. Ligand L4: I 7a-quinolin-3-ylethynyl-lestosterone (ET-3-Q) 
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C301133NO2 
The cross-coupling of ethisterone and 3-bromoquinoline afforded ET-3-Q in 80 % yield, 
using simple purification methods. The final re-crystallisation from acetonitrile resulted in 
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the formation of a bright white crystalline solid. The ligand was very soluble in DMF, 
DMSO, chloroform, dichloromethane and THF, partially soluble in methanol, ethanol and 
acetonitrile and insoluble in diethylether and water. Purification of the crude product 
involved separating ET-3-Q from the copper, palladium and diisopropylammoniurn salts 
(Br' or I). The first and latter were removed by treating the crude product with water and 
palladium salts by slow crystallisation from acetonitrile. The black precipitate observed in 
the re-crystallisation steps may possibly be decomposed palladium salts which were 
filtered off. 
The 1H NMR spectrum (Figure 3.19) and ESI-MS spectrum and elemental analysis 
indicate a successful reaction. Signals originating from a steroid skeleton (H4, Mel8 and 
Mel9) and substituted quinoline are present in the 1H NMR spectrum in a 1: 1 ratio. No 
acetylene proton from ethisterone is apparent indicating the reaction took place at this 
centre. The assignment of the quinoline resonances may be completed by combined 
analysis of the ID and 2D 1H NMR (Figure A. 1.10) spectra. The highest resonance at 
8.99 ppm results from HT, on account of its coupling constant and proximity to the 
nitrogen atom; 114' is assigned from its coupling constant. Other assignments are best 
guesses from the resonance structure of quinoline. A NOE differential or NOESY NMR 
spectrum is required for a complete assignment. All steroid protons are accounted for 
including the broad resonance at 3.81 ppm which may be assigned to the 17a-hydroxyl 
group as well as H4 (5.72 ppm) and the steroidal methyls C19 and C18. The steroidal 
skeleton hydrogens arc, in some cases, well resolved and coupling patterns of individual 
hydrogens may be distinguished. 
The carbon spectra may be assigned from ID and 2D NMR spectra. The 13C DEPT NMR 
(Figure 3.20) contains all resonances except that only two resonances are seen of C8, C9 
and C14 in the 30-50 ppm region. The quinoline signals may be assigned using 13 C-1H 
HMQC spectrum (Figure A. 1.11). The signal at 200 pprn may be assigned to C3. The 
resonance around 170 pprn was assigned to the quaternary carbon C5 due to it's P 
proximity an a, p-unsaturated ketone. Since CIO' is a to a nitrogen its resonance will be 
higher that CY whose position is P and both are assigned accordingly. 
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Figure 3.19. The lH NMR spectrum of ET-3-Q in CDC13. 
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Figure 3.20. The 13 C DEPT NMR spectrum of ET-3-Q in CDC13. 
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The IR spectroscopy (Figure A. 1.12) shows several bands characteristic of the functional 
groups of ET-3-Q. The vO-H stretch at 3210 cm-1 is assigned to the 17p-hydroxyl group of 
the steroidal skeleton. Bands around 2800-2950 cm" and at 1668 cm-1 result from vC-H 
and vC=O stretches. Often vC=-C stretching modes are too weak a band to observe but in 
the case of ET-3-Q weak band at 2215 cm71 may be assigned to this vibrational mode. The 
yield is 80 %. The combined data prove ET-3-Q was successfully synthesized in high 
yield. 
3.2.2.5. Ligand L, 5: I 7a-isoquinolin-4-ylethynyl-testosterone (ET-4-IQ) 
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C30H33NO2 
The Sonogashira palladium cross-coupling of ethisterone and 4-bromoisoquinoline 
successfully formed the desired product in high yield and only simple purification 
techniques, yield a slightly off white crystalline solid. The molecular formula of 
C30H33NO2 was confirmed by elemental analysis and the appearance of 441 "Vz ion in ESI- 
MS corresponds to this formula. 1H and COSY NMR techniques confirm the expected 
substitution pattern of the isoquinoline group of 2 singlets, 2 doublets and 2 triplets. The 
signal at 9.14 ppm (Figure 3.2 1) may be assigned to HT by comparison to the ligand, ET- 
3-Py, and H8' by its proximity to the nitrogen atom; following on from this assignment 
H5', H6', HT and HI 0' may be assigned. However, an NOE differential spectrum would 
confirm the assignment of HT and H 10' and is required for a full assignment. 
The loss of the acetylene proton at ca. 2.55 ppm in the 1H NMR demonstrates the reaction 
took place completely. The a, O-unsaturated ketone proton (H4) is evident at 5.72 ppm and 
broad 170-hydroxyl resonance at 4.72 ppm. The 13 C DEPT NMR (Figure 3.22) shows a 
carbonyl resonance at 199.45 pprn in addition to it's infrared stretching mode at 1645 cm*1 
(Figure A. 1.6). The quinoline resonances in addition to C4, Mel8 and Mel9 have been 
assigned using 13C-1H HMQC techniques (Figures A. 1.14 and A. 1.15) although C5' and 
C6' peaks are too close together to accurately assign. Higher field (0-60 ppin) resonances 
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from CH and CH3 groups from the steroid skeleton are present with one exception. 'I'lie 
methyl. carbons C 18 and C 19 are present but only two signals remain for the chiral carbons 
C8, C9 and C14. This may be due to the relative insensitivity of 13 C NMR. 
7' 
6' 81 
0 91 10, 
H 
18 
ý-12-1ý- 
PN 21 2' 
19 
11 20 
ý 0, ( 15 28 
cP S, 46,, 
17 
isoquinoline 
chloroform 
Expansion, (7.50-9.20 ppm) 
HIO 
H4 
OH 
Lri y L-ri Y 'rly 
99 5D 
%0 10000 
00 00 CD 00 
9.0 8.0 7.0 6.0 
PPM 
too 
5.0 4.0 3.0 
Figure3.21. The 111NMR spectrum of ET4-IQ in CDC13. 
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The infrared spectrum (Figure A. 1.16) contains all the fundemental bands characteristic of 
the functional groups present in ET-4-IQ with the expection of E-T4-IQ with the exception 
of the vC- =C stretch around 2215 cm7 1. Given that vC=C stretches are weak and often not 
observed the lack of a vibrational mode is unsurprising. The vC=O stretch position at 1645 
cm*1 is consistant with a a, p-unsaturated carbon. The yield is 89 %. The above data is 
conclusive evidence for the successful synthesis and purification of ET-44Q. 
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Figure 3.22. The 13 C NMR spectrum of ET-4-IQ in CDC13- 
3.2.2.6 LigandL6: ]7a-quinolin-6-ylethynyl-testosterone (ET-6-Q) 
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C3oH33NO2 
The reaction between 6-bromoquinoline and ethisterone using the Sonogashira coupling 
reaction afforded the desired product in good yield and requiring only simple purification 
techniques. The product was soluble in chloroform dichloromethane, methanol, DMF and 
DMSO, partially soluble in acetonitrile, barely soluble in diethylether and insoluble in 
water. Purification involved 2 steps: a) the removal of copper salts and protonated 
diisopropylamine with water; b) recrystallisation to remove palladium salts. The product 
required 72hrs to fully crystallise. 
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Elemental analysis confirmed the chemical formula of the compound and the parent ion 
peak at nzlz = 440 in the ESI-MS corresponds to the mass of protonatcd ET-6-Q (Figure 
A. 1.17). The 1H NMR spectrum (Figure 3.23) shows two large sets of protons, aromatic 
and aliphatic in a 1: 1 ratio in addition to a peak at 5.65 ppm which may be assigned to 114. 
The aliphatic region may not be assigned using the current data beyond that of Mel 8 and 
Me19 and confirming the correct number of hydrogen atoms (26). 'Me 17a-hydroxyl 
proton is not observed, probably due to proton exchange. The aromatic resonances, from 
quinoline, may be assigned in part from examination of the coupling constants and 
confirmed by a COSY spectrum (Figure A. 1.18). 112' may be assigned from its position at 
the highest chemical shift due to it's proximity to the nitrogen atom and the 3j(I 1_1 1) and 4J01- 
to coupling forming a double of doublets. 116' may be assigned from 
4J(11-1, 
) coupling from 
H8'. H3' is assigned from the coupling pattern (doublet of doublets). The splitting pattern 
expected from H9' is a doublet with no 4JOI-10 coupling observed, hcnce assignment of the 
7.97 ppm resonance. The assignment of 114' and 118' is confirmed by cross-coupling 
peaks in the COSY spectrum. 
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Figurc 3.23. The 111 NMR spcctrum of ET-6-Q in CD30D 
The IR spectrum (Figure A. 1.19) of the product exhibits several bands characteristic of the 
fundamental vibration of several functional groups. Bands due to t)0-11, X-11 and vC=O 
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stretches may be observed at 3156,2938 and 1673 cm" respectively. No band due the 
vC=-C stretch mode is seen although these are often too weak to observe. The yield is 60 
%. The combined spectroscopy is in agreement with the structure of ET-6-Q. 
3. Z3. The synthesis of steroidalplatinum(II) complexes: trans-cationic (TQ 
Trans-cationic complexes ftorn herein are described as TC-X where X is the steroidal 
ligand, i. e. ET-6-Q or a simple ligand such as pyridine (TC-Py) or quinoline (TC-Q). 
Attempts to form TC complexes with quinoline ligands often resulted in mixtures of trans- 
[Pt(NH3)2(L)Cl]+ and [Pt(NH3)2(L)2]2+ in ratios of sometimes 8: 1 respectively. The 
[Pt(NH3)2(L)21 ion may be observed using mass spectroscopy (ESI, +ve) and 1H NMR 
spectroscopy. In some cases in mass spectroscopy the [M-H]+ is observed and in others 
the M2+ ion is observed where M= [Pt(NH3)2(L)21. The use of decolourising charcoal in 
these situations aided isolation of the desired product. However, in the case of TC-IQ 
isolation of the desired product did not result in success. The complexes were 
characterised using a range of spectroscopic techniques (1H NMR and mass spectroscopy 
are examples) and elemental analysis. Evidence for platinum bonded to the hetrocyclic 
nitrogen atom is presented using NMR evidence, including platinum satellites, downfield 
shifts of aromatic resonances and in some cases 195Pt NMR spectroscopy. 
22.3.1. Trans-[Pt(NH3)2(Py)CIJ[NO3]: TC-Py 
4' 
3' 5' 
2' 
H3N-Plt-NH3 
cl 
[C5HjjCIN3Pt][NO31 
The desired product was formed relatively easily between the reaction of trans- 
[Pt(NH3)2(DMF)Cl]' and pyridine. Purification consisted of several re-crystallisations to 
achieve the desired purity level of the product. The mass spectrum shows a peak at nz1z = 
343 whose isotope distribution pattern matches that of [Pt(NH3)(PY)Cll+ (Figure A. 2.1). 
Elemental analysis is consistant with proposed formula of [CsHIICIN3Pt][NO3]. The 1H 
NMR spectrum (Figure 3.24) may be assigned by inspection of the integration and 
coupling constants. Platinum satellites either side of the signal assigned to HT/ H6' are 
clearly visible and provide excellent evidence for a Pt-N bond. The chemical shifts move 
downfield compared to pyridine (Figure A. 2.2); Downfield shifts of 0.28,0.22 and 0.14 
ppm are observed for the hydrogen atoms, H2'/H6', H4' and H3'H5', respectively. The 
III 
195Pt NMR chemical shift is in the region expected for the complexes of the type 
[Pt(L)3CII+ where L= nitrogen containing ligand. The yield is 20 % and the data presented 
is in agreement with the proposed structure of TC-Py. 
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Figure 3.24. The aromatic region of the 11I NMR spectrum of TC-Py in CD30D. 
3.2.3.2. Trans-[Pt(NI13)2(Quinoline)Cl][NOil: TC-Q 
4' 5 6' 3T 
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H3N-ýit-NH3 
cl 
[C91113N3Pt][NO31 
The reaction of transplatin and quinoline via the intermediate tmns-[Pt(N[13)2(DMF)Cl]" 
produced crude trans- [Pt(NH3)2(Quin)Cl]+ in high yield which due to purification by 
selective precipitation and re-crystallisation was substantially rcduccd by > 50 %. The 
complex was very soluble in DMSO and DMF, soluble in water, partially soluble in 
methanol and insoluble in diethylether and chloroform. 
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The mass spectrum (Figure A. 2.3) is consistant with the chemical formula 
[Pt(NH3)2(DMF)Cl]+ and elemental analysis confirmed the proposed chemical formula of 
[C9Hl3N3Pt][NO31. The 1H NMR spectrum (Figure 3.25) may be assigned from the 
coupling constants and comparison with unbound quinoline. A full assignment requires 
NOE differential or NOESY NMR techniques and assignment are based on the unbound 
ligand. All the chemical shifts move downfield between 0.3 (117') and 1.68 (H9') 
compared to quinoline. Although no platinum satellites are observed around 112' due to 
the poor solubility of TC-Q in CD30D the downfield shifts of the hydrogen resonances is 
evidence for platinum binding to the quinoline nitrogen atom. The binding requires 
donation of electron density from the nitrogen atom to platinum, making the nitrogen 
increasingly electropositive and itself withdrawing electron density from the aromatic rings 
causing the dowfield shift. The chemical shift in 195 Pt NMR is characteristic of the ligand 
arrangement [PtL3CI]' where L is a nitrogen containing ligand. 
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Figure 3.25. The 1H NMR spectrum of TC-Q in CD30D. 
The IR spectrum (Figure A. 2.4) shows fundamental bands characteristic of the functional 
groups present within TC-Q. Bands assigned to vN-H stretch are observed at 3266 cnf 1 
whilst the strong broad band centred around 1330 cnf 1 may be assigned to uN-0 stretch 
and vN-H defonnations overlapping and is evidence for the nitrate counter ion. The yield 
is 15 % and the spectroscopic data presented above is consistent with the proposed 
structure of TC-Q. 
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3.23.3. Trans-[Pt(NH3)2(ET-3-Py)CII17VO31: TC-ET-3-Py 
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TC-ET-3-Py was formed by reacting trans-[Pt(NI13)2(DMF)Clj+ with one equivalent of 
ET-3-PY in DMF and purified using decolourising charcoal and repeated rccrystallisations; 
from methanol. The products was a white fluffy solid, soluble in DMSO, DMF, less so in 
methanol and water and insoluble in diethylether and chloroform. 
Elemental analysis confirmed the chemical formula as that expected and the mass spectrum 
(ESI, +ve) found a single peak at tWz = 654 corresponding to the platinum complex 
[Pt(NH3)2(ET-3-Py)Cl]+. The aromatic region of 111 NMR spectrum (Figure 3.26) may be 
assigned by inspection of the coupling constants and confirmed by a COSY spectruin 
(Figure A. 2.5). The resonance of highest chemical shift may be assigned to 112' due to the 
small coupling constant (1.8 Hz) and 116' by its splitting pattern, a doublet of doublets (3j 
and 4j coupling). Finally H5' is assigned by the coupling constants, doublet of doublets (3j 
coupling) leaving the remaining signal assigned to 114'. Of particular note is the baseline 
broadness around the signals assigned to 112' and 116' and is very suggestive of platinum 
satellies (and hence platinum binding to the pyridine nitrogen) although no distinct 
satellites may be observed. The other signals are assigned by the chemical shift and on the 
case of Me 19 by comparison with estradiol, a steroid with an identical D ring but no Me 19. 
The steroidal skeleton may not be fully assigned but the correct integration is observed. 
Additional evidence of the ligand bound to platinum comes from the downficid shifts 
observed when compared to the free ligand (Figure A. 2.6). Shifts of 0.42,0.23,0.17 and 
0.36 ppm are observed for 112', 114', H5' and 116' respectively and these are of lesser 
magnitude with increasing distance from the pyridine nitrogen. 
The IR spectrum (Figure A. 2.7) displays many bands including those at 2943,1645 and 
1330 cm" and may be assigned to vC-11 str, vC=O str and W-11 dcf/uN-0 str respectively. 
The spectroscopy confirms the expected structure of the desircd product and the yield is 28 
%. 
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Figure 3.26. The lH NMR spectrum of TC-ET-3-Py in CD30D. 
3.2.3.4. Trans-[Pt(NH3)2(ET-4-Py)CII[NO31: TC-ET-4-Py 
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[C26H37CIN302Pt][NO31 
The reaction between transplatin and ET-4-Py via a reactive intermediate resulted, after 
purification, in a bright white solid that was very soluble in DMSO and DMF, less so in 
methanol and water and insoluble in diethylether. Purification was by repeated 
recrystallisations. 
Elemental analysis confirmed the proposed chemical formula and mass spectrometry (ESI, 
+ve) where the parent peak of nz1z = 654 corresponds to [Pt(NH3)2(ET-4-Py)Cl]+ (Figure 
A. 2.8). In the 11-1 NMR spectrum (Figure 3.27) the chemical shifts of the pyridinc proton 
NIOOH 
NleOH 
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pairs H2'/H6' and H3'/H5' are shifted downfield by 0.28 and 0.12 ppm, respectively, 
compared to the free ligand (Figure A. 2.9). 
The downfield shift in TC-ET-4-Py Cf. ET4-Py may be rationalised by the withdrawal of 
electron density from the pyridine ring due to an increasingly electropositive nitrogen atom 
as a result of donating its non-bonding electron pair for covalent bonding to platinum. The 
closer proximity of H2'/H6' to the pyridine nitrogen atom accounts for its larger shift 
downfield compared to H3'/H5' after binding to platinum(II). 
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Figure 3.27. The 1H NMR spectrum of TC-ET4-Py in CD30D. 
The infrared spectrum (Figure A. 2.10) shows several vibrational modes characteristic of 
the functional groups present in TC-ET-4-Py. The ligand ET4-Py is represented in the 
spectrum by bands assigned to vO-H, vC-11, vC=-C and vC=O stretches. The N113 groups 
of the complex show characteristic absorptions around 3210 and 1300 cm7l corresponding 
to uN-H stretch and i)N-H deformation respectively. The UN-0 stretch expected from the 
nitrate salt likely contributes to the broad band around 1300-1400cnf 1 in addition to the 
other bands mentioned. The band at 825 cm" may be assigned to vC-11 out of plane 
deformation and is characteristic of a 2-substituted pyridine ring. The spectroscopic 
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evidence presented here is in agreement with the proposed structure of TC-ET-4-Py and 
the yield is 22 %. 
3.2.3.5. Trans-[Pt(7VH3)2(ET-3-Q)CII[NO31: TC-ET-3-Q 
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[C3oH39CIN302Pt1[NO31 
The reaction between trans-[Pt(NH3)(DMF)Cl]+ and ET-3-Q yielded the desired product in 
low yield. The purification involved filtration of DMF insoluble silver chloride and 
selective precipitation / adsorption on charcoal in isolating the main product from DMF 
and unreacted transplatin, trans-[Pt(NH3)(DMF)Clj+ and the disubstituted complex 
[Pt(NH3)2(ET-3-Q)2]2+. 
Elemental analysis confirmed the chemical formula and ESI-MS parent ion peak at nilz 
704.2 corresponds to the ion [Pt(NH3)2(ET-3-Q)Cl]+ (Figure A. 2.1 1) whose experimental 
isotope distribution pattern matches that predicted for [Pt(NH3)2(ET-3-Q)Cl]+ (Figure 
A. 2.12). The 1H NMR spectrum (Figure 3.28) is that of the bound ligand ET-3-Q and 
assignment are as for the free ligand. The spectrum may be assigned by observation of the 
coupling constants, COSY spectrum (Figure A. 2.13) and comparison with ET-3-Q. There 
is no clear evidence of platinum satelites either side of the H2' signal but small signals can 
be differentiated from the baseline. No evidence of NH3 groups is present possibly due to 
proton exchange. Compared to the 1H NMR spectrum of the free ligand, in the spectrum 
of TC-ET-3-Q the aromatic proton resonances have shifted downfield and in general the 
closer the proton to the nitrogen atom, the greater the shift (Figure A. 2.14). The 
resonances of the protons H2', 114', W, H7' and H8' are shifted downfield by 0.68,0.29, 
0.15,0.18,0.03 ppm respectively. The signal from H9' is shifted 1.97 ppm downfield and 
such a large downfield shift may represent a direct interaction between H9' and platinum. 
The IR spectrum of TC-ET-3-Q (Figure A. 2.15) exhibits several broad bands from 
overlapping characteristic vibrational modes of groups within TC-ET-3-Q. Overlapping 
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vO-H, vC-H and W-H stretches are centred around 3256 caf 
1 and bands corresponding to 
vC=O is seen at 1645 cm-1 and vN-H deformation and vN-0 stretch from the NH3 ligand 
and N03' counter-ion overlap around 1332 ctn". The combined spectroscopic data is in 
agreement with the structure of TC-ET-3-Q and the yield is 28 
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Figure 3.28. The 'if NMR spectrum of TC-ET-3-Q in CD30D. 
3.2.3.6. Trans-[PI(7VH3)2(ET-4-IQ)CII[NOi]: TC-ET-4-IQ 
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[C30H39CIN302Pt][NO31 
The reaction between trans-[Pt(NI13)2(DMF)Clj+ and ET4-IQ produced two main 
products, trans-[Pt(Nfl3)2(ET-4-IQ)Cl]+ and [Pt(NI13)2(ET4-IQ)2]2*, presumably trans, in 
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an approximate 8: 1 ratio by 1H NMR (Figure A. 2.16). The complex [Pt(NH3)2(ET-4-IQ)2] 
was observed as the monocation, presumably loosing H' (Figure A. 2.17). The ratio was 
not dependent on the ratio of starting materials: up to an 5 fold excess of ET-4-IQ over 
transplatin nor if ET-4-IQ was added slowly to the solution containing trans- 
[Pt(NI13)2(DMF)Cl]+. Purification of the crude mixture was achieved in several steps: a) 
selective precipitation of steroidal platinum complexes to separate from un-reacted starting 
materials; b) selection adsorbtion onto charcoal of disubstituted complexes compared to 
monosubstituted, presumably due to charge differences; c) selective dissolving in methanol 
(the complex crystals are more soluble than ET-4-IQ). The product was soluble in DMF, 
DMSO and methanol, less so in water and insoluble in diethylether and chloroform. 
The use of charcoal had two effects on the relative proportions of the reaction products. 
Whilst ET-44Q, trans-[Pt(NH3)2(ET-4-IQ)Cl]+ and [Pt(NH3)2(ET-4-IQ)2]2+ adsorbed onto 
the charcoal, ET-4-IQ adsorbed more slowly than trans- [Pt(NH3)2(ET-4-IQ)Cl]+ which in 
turn adsorbed slower than [Pt(NH3)2(ET-4'IQ)2]2+. The effect of removing [Pt(NH3)2(ET- 
4'IQ)212+ lead to increased relative amounts of ET-4-IQ compared to trans- [Pt(NH3)2(ET- 
4-IQ)Cl]+ which were later separated. The final product was analysed by mass 
spectroscopy whose nVz = 704.2 corresponds to the platinum complex [Pt(NH3)2(ET-4- 
IQ)Cl]+ (Figures A. 2.18 and A. 2.19) with comparable experimental and theoretical isotope 
distribution pattern. Elemental analysis matches the proposed chemical formula. 
The 1H NMR spectrum (Figure 3.29) may be assigned by the coupling constants and 
comparison with the spectrum of ET-44Q. The assignment are as for ET-4-IQ but require 
NOE differential or NOESY NMR spectroscopy to fully assign. The NH3 groups are not 
visible possibly due to hydrogen exchange. Broadening of the signals assigned to H2' and 
H10' may be attributed to platinum satellites although no discernable peaks are visible 
either side of the main peak. Other NMR evidence for the ligand bound to platinum is the 
chemical shifts of the aromatic protons of TC-ET-4-IQ are shifted downfield compared to 
ET-4-IQ (Figure A. 2.20). The downfield shifts are 0.85,0.45,0.39,0.26,0.30,0.30 ppm 
for H2', H 10', H8', H5', H7' and H6' respectively. 
The infrared spectrum of TC-ET-4-IQ (Figure A. 2.21) shows bands characteristic of the 
functional groups present in the TC-ET-4-IQ. The broad bands around 3200 cm71 may be 
assigned to vO-H, vC-H and vN-H stretching modes overlapping. The broad band at 1657 
cin" likely originates from the vC=O stretching vibrational modes overlapping other 
bands, whilst the large broad band around 1350 cin" may be assigned to vN-H 
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deformations and vN-0 stretch from the N113 ligand and [N031" counter-ion respectively. 
The yield is 25 % and the spectroscopic evidence presented confirins the proposed 
structure for TC-ET-4-IQ. 
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Figure 3.29. The 1H NMR spectrum of TC-ET-4-IQ in CD30D. 
3.2.3.7. Trans-[Pt(NH3)2(ET-6-Q)Cl][NOjj: TC-ET-6-Q 
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[C30H39CIN302Pt][NO31 
The reaction between trans- [Pt(NI13)2(DMF)Cl]+ and ET-6-Q yielded the desired product 
after purification by selective precipitation to remove residual DMF, E-T-6-Q and 
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transplatin. The product was a white fluffy solid, soluble in DMF and DMSO, less so in 
methanol and water and insoluble in chloroform and water. 
The chemical formula of the product was confirmed by elemental analysis to be 
[C3oH3qCIN302Pt1[NO31. The parent ion peak at ntlz = 704.2 corresponds to the platinum 
complex [Pt(NH3)2(ET-6-Q)Cl]+ and the theoretical and experimental isotope distribution 
patterns match (A. 2.22). The 1H NMR (Figure 3.30) is essentially that of the ligand ET-6- 
Q, the NH3 groups are not observed possibly due to proton exchange. All hydrogen atoms 
are accounted for with the exception of the 17p-hydroxyl hydrogen atom which isn't 
observed in the free ligand perhaps due to proton exchange. The quinoline resonances may 
be assigned by inspection of the coupling constants and comparison with the free ligand 
ET-6-Q. 
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Figure 3.30. The lH NMR spectrum of TC-ET-6-Q in CD30D. 
There are two differences between the 1H NMR spectrum and that of ET-6-Q. Whilst clear 
platinum satilites are not observed either side of the resonance assigned to HT, broadening 
of the baseline can clearly be seen indicating that platinum is bound to the nitrogen atom of 
the quinoline ring. As may be expected there is a downfield shift in all the aromatic 
hydrogen resonances with some greater than others (A. 2.23). Shifts of 0.59,0.12,0.30, 
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0.17,0.30 and 1.67 ppm. are observed for atoms 112', 113', 114', 116', 118' and 119, 
respectively. The magnitude of the shift decreases with decreasing distance away from the 
nitrogen atom. The large shift of 119' is perhaps due to direct interaction with the 
platinum(II) metal. 
The IR spectrum (A. 2.24) shows several bands characteristic of the functional groups 
present in TC-ET-6-Q. Around 3300 cm" several overlapping bands may be observed and 
assigned to X-H, vN-11 and vO-11 stretching vibrations. Aliphatic X-11 stretching modes 
from the steroidal skeleton are clearly observed between 2830 and 2974 cm*l as is the 
vC=O stretch at 1666 cm7l. The large broad band centrcd around 1325 cm" may be 
assigned to overlapping bands from vN-11 deformations of N113 ligands and W-O 
stretching from the nitrate counter ion. The above data is evidence for the proposed 
structure of TC-ET-6-Q and the yield was 38 %. 
3. Z4. The synthesis of steroidal platinum(H) complexes: cis-cationic (CQ 
In the case of CC complexes cisplatin was used as a starting material to result in cis 
complexes. Of particular note was the light sensitivity of some of the CC complexes and 
decomposition was accompanied by the complexes turning from white to grey / green. 
The complex CC-ET-3-Q decomposed whilst the crude product was being filtered as did 
CC-ET-4-Py. The other complexes were much more robust and required only storage in 
dark conditions. Without this the complexes shows signs of decomposition within one 
week. Light sensitivity is not new in platinum complexes; an aqueous solution of cisplatin 
will decompose within days if not stored in the dark. The complexes were analysed using 
a range of techniques including elemental analysis and NMR spectroscopy. 195Pt NMR 
spectroscopy was attempted on the complexes and despite the low sensitivity of the 
technique signals were observed in many of the complexes and commensurate with the 
formula [Pt(NI13)2(L)Cl]+ where L is a nitrogen containing ligand. 
3.24.1. CiS-[PI(NH3)2(PY)CII[NOJI: CC-PY 
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Synthesis of the crude complex was easily achieved and the pure complex after several 
rccrystallisation procedures. The complex was identified using several techniques 
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including elemental analysis, ESI-MS, IR and 1H and 195Pt NMR spectroscopy. Elemental 
analysis is consistant with the formula [C5H, ICIN3Pt][NO3] and the mass spectroscopy 
(ESI, +ve) spectrum shows a parent ion peak at nVz = 344 and isotope distribution 
matching [C5HIlCIN3Pt]+ (Figure A. 3.1). 
The 111 NMR spectrum (Figure 3.3 1) shows the aromatic hydrogen atoms of the pyridine 
ring in the product. Three signals are observed due to symmetry with H2/II6 having the 
highest chemical shift due to it position relative to nitrogen. The H2/H6 protons are split 
by H3/H5 into a doublet but the smaller signals at each side of the signal are due to 3JM-M 
coupling with a coupling constant of 21.6 Hz. The magnitude of the splitting observed is 
consistent with that expected from 195Pt. The chemical shifts of all 5 hydrogen atoms of 
the pyridine are shifted relative to free pyridine as shown in Figure A. 3.2. H2/H6, H4 and 
H3/H5 are shifted downfield by 0.32 ppm, 0.19 ppm. and 0.14 ppm respectively. This is 
consistent with bonding arrangements between platinum and pyridine where the nitrogen 
spý lone pair is donated to the platinum centre making the nitrogen more electropositive 
and withdrawing electron density from the aromatic ring system. The 195 Pt NMR 
resonance is in agreement with that expected of a complex of the type [Pt(NH3)2(L)Cl]+ 
where L is a nitrogen containing ligand. 
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Figure 3.3 1. The 1H NMR spectrum of CC-Py in CD30D. 
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The IR spectrum (Figure A. 3.3) shows several bands, many of which may be attributed to 
vN-H and vC-11 stretching and bending modes. The broad strong peak at around 1340 cm*1 
may be attributed to an overlapping vN-11 deformation mode and W-O stretching mode. 
The I't W-O stretching mode in nitrate ions exhibit a single band in the 13SO cm71-1380 
cm" region whilst the vN-11 deformation is between 1280 cm" and 1300 cm-1 in cisplatin 
and transplatin and the two appear overlapping. This gives evidence for the nitrate counter 
ion and NH3 groups present within the structure. Further evidence of a pyridine ring may 
be found due to vC-11 out of place deformations found at 760 crif 1 and 687 cm" and are 
those expected for a pyridine ring. The spectroscopic data is in agreement with the product 
being CC-Py and the yield is 23 %. 
3.2.4.2. CiS-[Pt(NH3)2(ET-3-Py)CIJ[NO3j: CC-ET-3-Py 
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[C261137CIN302Pt][NO31 
The substitution of a chloride in cisplatin by DMF aided by silver chloride and further 
substitution of DMF by ET-3-Py produced the desired product in low yield due the large 
number of purification steps required. Multiple re-crystallisations resulted in a bright 
white solid soluble in DMSO, DMF, partially soluble in water and methanol and insoluble 
in chloroform and diethylether. The chemical formula of the product matches that of 
C26H37CIN405Pt and the nz, 1z = 654 corresponds to the complex [Pt(NI13)2(ET-3-Py)ClJ"'. 
The 1H NMR (Figure 3.32) is essentially that of ET-3-Py and the correct integration ratio is 
observed between the pyridine ring and steroidal skeleton. 'Me methyl groups of the 
skeleton ring, Mel8 and Mel9 are assigned by comparison with estradiol, an oestrogen 
based steroid with an identical D ring to ethistcronc but without Mc19 on the A/B ring 
interface. In this case it appears the 170-hydroxyl hydrogen is seen. The remaining 
spectrum may be assigned by inspection of the coupling constants observed for the 
pyridine ring. The highest pprn resonance is assigned to 112' due to its position and 
coupling constant (1.8 11z), whilst 116' is assigned to the second highest resonance due to 
it's proximity to the nitrogen atom of the pyridinc ring and it being a doublet. The signal 
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around 7.4 ppm is assigned to 115' as a doublet of doublets is predicted from this hydrogen. 
The remaining signal is assigned to H4' and the coupling constant further confirms this. 
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Figure 3.32. The lH NMR spectrum of CC-ET-3-Py in CD30D. 
No discernable platinum satellites are observed in the 1H NMR spectrum due to the low 
concentration in CD30D. However the 195Pt NMR resonance is commensurable with a 
platinum complex of the formula [Pt(NH3)2(L)Cl]+ where L is a nitrogen containing ligand. 
The downfield shift of the aromatic hydrogens H2', H4', 115' and H6' resonances by 
approximately 0.23,0.14,0.06 and 0.20 pprn indicates the ET-3-Py is bound to platinum 
(Figure A. 3.4). The IR spectrum (Figure A. 3.5) contains viubrational bands assigned to 
vN-H (3281 cm7l), vC-H (2940 cm") and vC=O (1644 cm7 'stretching modes. The 
spectroscopy confirms the predicted structure of CC-ET-3-Py and the yield is 12 %. 
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3.24.3. CiS-[PtMI3)2(ET-4-IQ)CIjfNOjj: CC-ET-4-IQ 
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The reaction to produce the CC-ET4-IQ resulted in the formation of the desired product 
and also a complex where 2 ET-4-IQ ligands appear bound to platinum fort-ning a 
disubstituted species in an approximate ration of 8: 1 (Figure A. 3.6). Purification involved 
extensive stirring of a methanolic solution of the crude product with dccolourising charcoal 
to which the disubstituted appeared more attracted and hence removed from solution at a 
faster rate than the desired product. 'Mis charcoal treatment also had the cffect of 
removing DMF but increasing the relative proportions of the free ligand, ET4-IQ which 
was removed later via repeated rccrystallisations procedures. 
The desired product was isolated as a bright white solid, soluble in DMSO, DMF and 
methanol, less so in water and insoluble in diethylcther. Ile elemental composition 
matches that expected of the desired products and the mlz =704 matches the complex 
[Pt(NH3)2(ET-4-IQ)Cl]+ (Figure A. 3.7) with the correct isotope distribution pattern (Figure 
A. 3.8). The 11-1 NMR spectrum (Figure 3.33) is that of bound ET4-IQ and is assigned as 
the ligand. It may be assigned by inspection of the coupling constants, comparison %vith 
the free ligand ET-4-IQ and a COSY spectrum (Figure A. 3.9). The broadness baseline 
around the signals assigned to 112' and 1110' indicate that ET4-IQ is bound to platinum 
but no distinct satellites may be observed. 
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Figure 3.33. The lH NMR spectrum of CC-ET-4-IQ in CD30D. 
Evidence for the ligand bound to platinum comes from the 195 Pt NMR resonance, that is in 
line with that expected from a complex of the formula [Pt(NH3)2(L)Cl]+ where L is a 
nitrogen containing ligand. Further evidence is the downfield shifts of the resonances from 
the hydrogens of the isoquinoline ring system (Figure A. 3.10). Each hydrogen, 112', 115', 
W, H7', 118' and H 10' are shifted downfield by 0.75,0.3 3,0.3 6,0.29,0.3 6 and 0.3 3 ppm 
respectively and is commensurate with the effect of withdrawing electron density from the 
isoquinoline ring for binding to platinum. The IR spectrum (A. 3.1 1) shows several bands 
expected from the proposed structure, including t)C=O and vC-H stretching modes. The 
strong broad band around 1330 cm7l is likely arising from overlapping vN-H deformation 
and vN-0 stretching modes indicating the presence of the nitrate counter ion. The 
spectroscopy is in agreement with the structure propsed for CC-ET-4-IQ with a yield of 
27%. 
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3.2.4.4. Cis-[Pt(NH3)2(ET-6-Q)CIJ[NO3j: CC-ET-6-Q 
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The synthesis of CC-ET-6-Q proceeded smoothly. I lowcvcr, in common Nvith some other 
reactions it produced a disubstituted complex, [Pt(NIl3)2(ET-6-Q)2j2", as identified by 
mass spectroscopy (A. 3.12 and A3.13). Unusually for a steroidal platinum complex the 
ESI mass spectrum exhibits the 2+ charged ion, rather than the ion [M-11]* which is usually 
found, where M= [Pt(NH3)2(ET-6-Q)21. This impurity was removed in a similar way to 
the reactions synthesising TC-ET-4-IQ and CC-ET4-IQ, by using charcoal, to which the 
higher charged complexes adsorbed more quickly than those of less charge, i. e. the 2+ 
disubstituted complexes were selectively removed solution leaving only cis-[Pt(NI13)2(ET- 
6-Q)Cl]+ and residual free ligand (removed by rccrystallisation). The complex %iims soluble 
in DMSO and DMF, less so in methanol and water and insoluble in dicthylcther and 
chloroform. 
The mass spectrum produced a single peak at PVz = 704 corresponding to the complex 
[Pt(NH3)2(ET-6-Q)Cl]+ (Figure A. 3.14) with the correct isotope distribution (Figure 
A. 3.15) and elemental analysis confirmed the predicted molecular formula. The 111 NMR 
(Figure 3.34) may be assigned by analysing the coupling constants and comparison -with 
the unbound ligand. Similar to all complexes with quinoline the chemical shift of 119' is 
further downfield (by 1.63 ppm) than all the other signals compared to the free ligand 
(Figure A. 3.16. ). This may represent an interaction between 119' and the platinum atom. 
The other hydrogen atoms, 1-12', 113', 114', 116' and 118' are also shifted downfield by 0.42, 
0.04,0.23,0.09 and 0.19 pprn indicating that the ligand is bound to platinum. Noplatinum. 
satellites are observed due to the low concentration of the complex in methanol. 
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Figure 3.34. The lH NMR spectrum of CC-ET-6-Q in CD30D. 
The infrared spectrum (Figure A. 3.17) reveals several vibrational bands in agreement with 
the proposed structure of CC-ET-6-Q. Bands assigned to vN-H, vC-H and vC=O stretches 
may be observed at 3284,2939 and 1646 crn" respectively. A broad band is observed 
round 1330 cm-1 and may be assigned to overlapping vN-H dcf and vN-0 stretching modes 
indicating the presence of the nitrate counter-ion. The spectroscopy agrees with the 
proposed structure of CC-ET-6-Q and the yield is 24 
3. ZS. Geometry of cis-cationic and trans-cationic complexes 
There exists no direct evidence of the geometric arrangement in TC and CC complexes, Le. 
a structure solved by X-ray crystallography. The evidence presented does support the 
ligands bound to platinum(II), i. e. 2 NH3 groups, a steroidal ligand and a single chloride. 
From the reaction scheme used, it may be reasonably expected that the complexes products 
from transplatin are trans and those from cisplatin are cis. Given the ligands, only two 
geometric arrangements can be reasonably expected; whereby the NH3 groups are cis and 
where NH3 groups are trans. The only technique fully used that is sensitive to this 
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arrangement is 11-1 NMR spectroscopy. The chemical shifts of the hydrogen atoms of the 
pyridine, quinoline and isoquinoline rings are dependent, to an extent, on the bonding of 
aromatic rings to the platinum atom whose bonding is affected, primarily, by the ligand 
trans to the aromatic amine. It is also reasonable to postulate if the ligand trans is different, 
then the chemical shifts of the aromatic hydrogen atoms will also be different. Comparing 
the chemical shifts of the 8 complexes, cis and trans-cationic containing the ligands 
pyridine, ET-3-Py, ET-4-IQ and ET-6-Q reveals that in all cases the chemical shifts of 
aromatic hydrogen atoms are found at higher ppm values in the complexes labelled trans to 
those labelled cis (Figures A. 4.1 to AAA). This indicates there is less clectron density in 
the aromatic ring(s) in one set of complexes (labelled trans) than another set (labelled cis). 
This gives evidence that one set of complexes using cisplatin as a starting material has a 
different trans ligand than those using transplatin as a starting material and from this is it 
reasonable to suggest that one set of complexes is cis and another trans. 
3. Z6. The synthesis of steroidal platinnm(H) complexes: trans-neutral (TA9 
The poor solubility of steroid-linker ligands caused problems in attempts at this reaction 
scheme. For example, the use of 50: 50 water: cthanol to aid solubility of E-T4-Py resulted 
in an orange solution after 96 hours at 65T. The 111 NMR spectrum showed two sets of 
peaks, those of the free steroid and presumably those of trans-[Pt(NI13)2(ET4. py)2j 2" at 
lower field. The addition of concentrated IlCl with heat resulted in an orange solid after 
24 hours at 80T. The orange solid did not contain the steroidal ligand (by 'if NMR) and 
neither did the filtrate and presumably the steroidal ligand decomposed. Further reactions 
were attempted but without success; firstly in gaining acceptable yield of complexes with 
the formula trans- [Pt(NH3)2(ET-4-PY)212+ and secondly the use of hydrochloric appeared to 
decompose the organic material. Attempts to form tmns-Pt(NI13)(3-bromopyridine)CI2 
were successful but subsequent reactions attempting a Sonogashim coupling with 17a- 
ethnynyltestosterone (using K2CO3 as a base) failed even using molar percentage ratios of 
catalyst from 4-50%. All attempts to synthesisc trans-neutral complexes , vcrc not 
successful. 
3. Z 7. The synthesis of steroklalplatinum(II) complexes: cis-neutral (CA) 
The use of this reaction scheme did not result in the successful synthetic of complexes of 
the type cis-[Pt(NH3)(L)CI21 where L is a range of steroidal ligands. Even the 
dichloromethane soluble salt, [Ph4N][Pt(NI13)CI31 did not react with ligand LI-L3- 
Forming cis-[Pt(NI13)(PY)CI21 required 75'C for a 28 % yield so the difficulties with LI-L6 
are perhaps unsurprising. Using this reaction cis-[Pt(NI13)(3-bromopyridine)CI21 was 
synthesised successfully but this did not react with 17a-ethnynyltcstostcrone under 
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Sonogashira conditions, even with high catalyst loading (up to 50 molar percent) and using 
various solvents. 
3. Z8. The synthesis of steroidalplatinum(H) complexes containing DMSO as a ligand 
Unlike other reactions in this chapter forming trans geometries the complex trans-Pt(ET-2- 
Py)(DMSO)CI2 formed with ease, despite the sterically hindered ligand. The formation of 
the desired products was monitored using several techniques. In some cases elemental 
analysis confirmed the chemical formulae, whilst in all cases peaks at nilz values 
corresponding to protonated complexes were observed by mass spectrometry (ESI, +ve). 
1H NMR spectroscopy was used to further aid confirmation of the structure and chemical 
shifts relative to the free ligands and platinum satellites were used to confirm the DMSO is 
not only bound to platinum, but bound via the sulphur. Sulphur binding is also strongly 
suggested by an increase, to higher wavenumbers, of the IR band assigned to the 
fundamental vS=O stretching mode. [5231 Interestingly, the chemical shift of the DMSO 
methyl hydrogens, technically diastereotopic, appears dependent on the NMR solvent with 
a singlet in some solvents and a doublet in others. 195Pt NMR spectroscopy was also 
employed with ease due to excellent complex solubility and the chemical shift in all cases 
corresponded to that expected from a complex of the formula Pt(L)(DMSO)CI2 where L is 
a nitrogen containing ligand. 'H NMR spectroscopy suggests the stereochemistry is trans, 
due to the platinum satellites accompanying the DMSO methyl hydrogens signal. In the 
case of Pt(Quinoline)(DMSO)CI2 and Pt(ET-2-Py)(DMSO)CI2 an X-ray crystal structure is 
reported and in both cases the stereochemistry is trans. 
3.28.1. Trans-Pt(Py)(DMSO)CI2 
91 2' 3' 
/ 
S-Plt-N 4' 
Cl 6' 5' 
C7HIIC12NOPtS 
The reaction between cis-Pt(DMSO)2CI2 and 1 equivalent of pyridine in methanol resulted 
in a fine yellow powder requiring only washing to remove DMSO. The solid was soluble 
in DMSO and DMF, partially soluble in chloroform and methanol and insoluble in water 
and diethylether. 
Elemental analysis confirmed the predicted chemical formula Of C7HIIC12NOPtS and the 
195 Pt NMR signal is consistent with the formula type [Pt(DMSO)(L)CI21 where L is a 
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nitrogen containing ligand confirming the trans nature of the complex. Ile III NMR 
spectrum (Figure 3.35) may be assigned by observation of the coupling constants and 
integrations. Platinum satellites are visible either side of the resonances assigned to H21 
(8.79 ppm) and the DMSO methyl. hydrogens resonance (3.52 ppm). This provides 
evidence for platinum being bound to the nitrogen pyridine and via the sulphur as 3jM-1 1) 
coupling occurs in sulphur bound and 4jM_l 1) in oxygen bound DMSO. The shift to higher 
wavenumbers; of the 6=0 stretch at I ISO crTf 1 in the IR spcctrum (Figure A. S. 1) provides 
additional evidence for sulphur bound DMSO. 15231 Vibrational bands relating X-H 
stretching and vC-H deformations of the DMSO methyls and pyridine arc observed at 299S 
/ 2913 and 765 and 691 crn7l respectively. The spectroscopic evidence is in agreement 
with the proposed structure of trans-Pt(DMSO)(PY)CI2 and the yield is 95 
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Figure 3.35. The aromatic region in the 111 NMR spectrum of trans-Pt(DMSO)(Py)CI2- 
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3.2.8. Z Trans-Pt(Quin)(DMSO)CI2 
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The reaction between cis-bis(dimethylsulphoxide)dichloroplatinum(II) and quinoline 
produced a fine, bright yellow powder. The 195 Pt NMR spectra resonance is in agreement 
with the structure Pt(L)(DMSO)CI2 where L is a nitrogen containing ligand whilst the peak 
at nVz = 474 corresponds to protonated Pt(Quin)(DMSO)CI2. The 11-1 NMR (Figure 3.36) 
may be assigned by examination of the coupling constants; however, some assignments are 
best guesses given the resonance structure of quinoline and NOE differential and / or 
NOESY NMR spectroscopy is required to confirm the assignment. Clear platinum 
satellites are visible on either side of the signals at 9.01 and 3.45 ppm assigned to H2' and 
the DMSO methyl's respectively with respective 3j coupling constants of 15.2 and 8.8 Hz. 
In addition to downfield shifts of aromatic hydrogen resonances using 1H NMR 
spectroscopy compared to quinoline and movement to higher wavenumbers of the VS=O 
stretching fundamental vibration in the IR spectrum (Figure A. 5.2) this provides evidence 
of the both quinoline and DMSO bound to platinum. [5231 
A smaller set of quinoline peaks is observed downfield from those of trans- 
Pt(Quin)(DMSO)CI2 and may be assigned to either of the disubstitutcd complexes 
Pt(QUin)2CI2 or [Pt(QUin)2(DMSO)Cl]+, both observed in the mass spectrum as small 
peaks at nLIz = 567 ([Pt(QUin)2(DMSO)Cl]) and nVz = 525 [H(Pt(QUin)2CI2)1+- 
The infrared spectrum (Figure A. 5.2) shows signals that may be assigned to quinoline and 
DMSO ligands. In particular the vS=O, vC-S (asym) and vC-S (sym) stretching bands at 
1132 / 1124,739 and 698 cm-1 of the DMSO and vC-H 'oop' deformation bands at 811 
and 779 cm" of the quinoline are very evident. The overall spectroscopy is in agreement 
with the structure proposed and a yield of 98% is achieved. 
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Figure 3.36. The 111 NMR of trans-[Pt(Quin)(DMSO)Clzl in CDClj. 
3.28.3. Trans-Pt(ET-2-Py)(DMSO)CI2 
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Mixing of the complex cis-[Pt(DMSO)CI21 with ET-2-Py in methanol afforded the crude 
complex in quantitative yield. The main impurities in the crude product were identified, by 
NMR and ESI-MS as Pt(ET-2-PY)2CI2 and Pt(ET-2'PY)2(DMSO)(CI) in a ratiowith Pt(ET- 
2-PY)2CI2 of -2 : 98. The formation of side produces is not reduced with slower addition 
of ligand or excess of ligand (up to 5-fold). The compound could be purificd by flash 
column chromatography as the mono-substitutcd main product elutcd slightly faster than 
the di-substituted products and collecting the first half of the single yellow band did that 
not contain disubstituted products. 
H6'/Hlr 
H4! 
HT Hr 
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Pt(ET-2-Py)(DMSO)CI2 was partially soluble in methanol and insoluble in diethylether 
and water. The solid was highly soluble in DMSO, chloroform, dichloromethane, acetone, 
acetonitrile and ethyl acetate. Such unusual solubility, given a neutral platinum(II) 
complex and steroidal ligand, may be attributed to the coordinated DMSO. Insolubility in 
water and diethylether may be attributed to the neutrality of the complex and the steroidal 
ligand. The reaction is complete in 24 hours produces. 
Mass spectroscopy (ESI, +ve), 1H NMR spectroscopy and elemental analysis confirmed 
the identity of this complex. The 1H NMR spectrum (Figure 3.37) clearly shows 4 
pyridine hydrogen signals together with a singlet of the DMSO methyl hydrogens. The 
baseline around the resonances at 8.53 and 3.44 ppm is broadened due to 195pt coupling but 
no distinct satellites are observed. The broadening of the 3.44 ppm signal is explained by 
3j(Pt_10 cross coupling and is strong evidence of sulphur binding the Pt rather an oxygen. 
Oxygen bound implies a 4J(pt-10 coupling arrangement and baseline broadening is likely 
less pronounce. The 1.2 ppm downfield shift indicates a loss of electron density on the 
sulphur of the DMSO ligand compared to free DMSO and is consistent with electron 
donation from the sulphur to platinum(II). 
The assignment of the pyridine protons may be made ftorn inspection of the coupling 
constants and confirmed by a COSY spectrum (Figure A. 53). The resonance at 5.72 pm is 
assigned to H4 and those at 1.20 ppm and 0.97 ppm to the steroidal methyl groups from the 
chemical shifts and integrations. The 13 C NMR spectrum DEPT spectrum (Figure 3.38), 
run in deuterated acetone to gain a concentrated sample show the DMSO methyl carbons 
chemically non-equivalent similar to that of the methyl protons in 1H NMR spectrum. All 
carbons are accounted for in the spectrum and assignments are aided by 111- 13 C HMQC 
spectrum (Figure A. 5.4). The effect of platination on the Pyridine ring was assessed by the 
shift in the 1H NMR resonances. Every resonance of the pyridyl hydrogens is shifted. 
H31, H4' and H5' resonances shift downfield by 0.15,0.16 and 0.17 ppm respectively 
confirming binding induces deshielding of these protons (Figure A. 5.5). The H6' 
resonance is different and a small shift of 0.03ppm upfield suggesting a small shielding 
effect. 
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Figure 3.37. The 111 NMR spectrurn of trans-Pt(ET-2-Py)(DMSO)CI2 in CDC13- 
The infrared spectrum (Figure A. 5.6) is very informative regarding the functional groups 
and bonding arrangement in the complex. The steroidal ligand dominates the infrared 
spectrum with the vO-H, vC-H, vC=-C, and vC=O stretches. Ile vC=-C is clearly visible at 
2227 cm*l and the 3-keto vC=O stretch is at 1657 cm". The X-11 out-of-planc ('oop") 
deformation at 747 cm" is indicative of a 2-substitutcd pyridine ring and is likely to 
overlap somewhat with X-S asymmetric and symmetric stretching modes of the DMSO 
ligand. The bonding between Pt and sulphur of the DMSO are elucidated in the split vS=O 
band at 1147 cm*1 and 1127 cm-1 which is approx 100 cm7l higher than free DMSO (1042 
cm") and strongly suggests sulphur binding. 
15231 The ESI peak of nVz = 734.5 agrees with 
that expected from protonated trans-Pt(ET-2-Py)(DMSO)CI2- 
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The methyl groups of platinum bound DMSO exhibit a single band in the 1H NMR 
spectrum. This is not the case in non-chlorinated solvents where the band is split into a 
doublet as shown in Figure 3.39, with a splitting of 5.4 Hz, 5.7 Hz and 7.0 Hz for 
deuteratcd acetonitrile, methanol and acetone respectively. If the non-chlorinated solvents 
are removed in vacuo and replaced with CDC13 (far right spectrum) the signal is a singlet 
strongly suggesting this is a solvent effect of unknown origin. 
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Figure 3.39. The 'H NMR of DMSO methyl proton resonances in various solvents. 
The reaction requires <24 hrs for completion and may be monitored via NMR. The 'If 
NMR spectra of 2 hr and 6 hr aliquots of the reaction mixture are shown in Figures 3.40 
and 3.41. After 2 hours approximately 28% of the ET-2-Py is co-ordinatcd to platinum 
which increases to 93% after 6 hours. In the 111 NMR spectra at 2 hours and 6 hours there 
are 2 proton resonances around 3.45 ppm. The resonance at 3.44 pprn is the final product 
whilst the lower field resonance at 3.47 ppm, appears to be an intermediate in the reaction 
whose integration relative to the 3.45 pprn signal is equal to that of 3.47 pprn after 2 hours, 
lower after 6 hours and is not observed in the final product. In the aromatic region there 
still appears to be only one environment for the pyridine ring protons. 11is is also found in 
13 C NMR, where the DMSO methyl carbon resonances, confirming using cross coupling 
peaks from IIMQC spectra are split into 2 signals (around O. Ipprn difference) in those 
solvents where doubles are observed around 3.45 ppm in 111 NMR spectra and singlets 
where singlets are observed in 1H NMR spectra. 
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Figure 3.40. The 'H NMR spectrum of an aliquot of the reaction between cis- 
Pt(DMSO)2CI2 and ET-2-Py after 2 hours at 25'C in CDC13- 
Purification entailed separation of the major product from impurities totalling approx 2% 
(by NMR). Several species and fragments were identified by mass spectrometry (ESI, 
+ve) including Pt(ET-2-Py)(DMSO)CI22 Pt(ET-2-PY)2(CI)2 and Pt(ET-2-Py)(DMSO)(CI) 
and were all observed as monocations (Figure 3.42 and Table 3.1). The peak at nilz = 
1123 may be a 5-coordinate Pt complex, Pt(DMSO)(ET-2-PY)2C, 2 in a protonated form; 
given the relatively slow kinetics of platinum chemistry, such a 5-coordinate intermediate 
may exist at a high enough concentration to be sensitive to ESI-MS. 
139 
H4'(8) 
Final product 
Intermediate DIVISO Me's 
DIVISO Me's 
I 
H6'(B) 
HT(B) 
H5'(B) 
I= 10 
H6'(F) 3.450 3.400 H4 
j 
'(F) HT(F) H5'(F) 
PPPPPPPP 
10 10 CD 10 G 'D I. ^ P. 1ý 
8.50 8.00 7 So 
Figure 3.41. The reaction between cis- I't(I)MSo)2('I-, and ET-2-11', 1 monitored bN 111 N' NIR 
after 6 hours at 25'C in COC13. Approximately 7% of ET-2-Py remains untx)und to 
platinum. 
Table 3.1. Selected assignments from the reaction of cis-Pt(I)MSo)2(CI)2 and ET-2-Py in 
methanol at 250C 
Peak Label Obsmed m/z Assignment 
583.5 111 llt(i: 'I'-2-Py)21* 
734.5 111 Pt0-T-2-Py)(DMSO)CI2j* 
A 1045.5 111 
13 1087.5 DNiSo)(CI)I* 
c 1123.5 111 
Figure 3.42. A selected range of nilz in the FAB mass spectrum of crude Pt(ET-2- 
Py)(DMSO)CI21 showing peaks A, B and C. 
Trans-Pt(ET-2-Py)(DMSO)CI2 is purified using a long (I m) column eluted with a 98: 2 
dichloromethane: methanol mixture. The first half of the single yellow band contains trans- 
Pt(ET-2-Py)(DMSO)CI2 whilst the second half trans-Pt(ET-2-Py)(DMSO)CI2 and the 
impurities which are shown around 8.90 ppm in Figure 3.43 and are seen as 2 doublets 
with broadening indicating 3j(pt_M coupling. A smaller third doublet may be observed at 
8.80 ppm. 
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Figure 3.43. The 2 nd half of the single yellow band from the purification of tmns-Pt(ET-2- 
Py)(DMSO)CI2 using column chromatography. 
A COSY spectrum shows the two singlets around 8.90 ppm are coupled to the signal at 
7.48 ppm. The 7.48 ppm signal is coupled to a resonance under the large signal at 7.96 
ppm which in turn is coupled to the 7.60 ppm signals. From this data it appears there arc 
two different environments for the pyridine in the impurities although their identity has not 
been confinned. The overall data suggests the trans-Pt(E-T-2-Py)(DMSO)C[2 has been 
successfully synthesised and purified. The trans stereochernistry was confirmed, by single 
crystal X-Ray crystallography (Figure 3.44). 
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Figure 3.44. The X-ray crystal structure of trans-Pt(ET-2-Py)(DMSO)CI2 showing trans 
chloride ligands. 
3.2.8.4. Trans-Pt(ET-3-Q)(DMSO)Cl2 
7, 
OH 
18 F\ 
, ý12.1-3-17 11 \ 
19 16 
0,9", 8 ý, 
l 4-1/5 
, -l-; l 
III 
5-, ,ý7 46 
C33H39Cl2NO3PtS 
Reacting cis-bis(dimethylsulphoxide)dichloroplatinum(II) and ET-3-Q in methanol gave 
the desired product in excellent yield and required flash column chromatography to 
separate platinum(II) complexes of the type PtL2X2 and [Pt(L)2(X)(DMSO)]+ where L= 
ET-3-Q and X= Cl and ET-3-Q as identified by mass spectroscopy (ESI, +ve) as 
monocations and 1H NMR (Figure A. 5.7). The compound was soluble in most organic 
solvents, although partial solubility was observed in methanol. The compound is insoluble 
in diethylether and water. 
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Elemental analysis shows the chemical formula expected for the dcsircd products and the 
mass spectrum peak at nz1z = 784 corresponds to [II(Pt(ET-3-Q)(DMSO)CI2)]'- The 111 
NMR spectrum (Figure 3.45) may be assigned by inspection of the coupling constants and 
is confirmed by a COSY spectrum (Figure A. 5.8). NOE differential or NOESY NMR 
techniques are required for a full assignment, with particular reference to the peaks 
assigned to H9' (could be 116') and 118' (could be 11T). The signals present, 2 singlets, 2 
doublets and 2 triplets (ignoring 4j coupling) is correct for a 3-substituted quinoline ring. 
The correct number of steroid protons (26) are found at high ficid and the quinoline : 
steroid ratio is 1: 1. Although no distinct platinum satellites may be observed either side of 
any peak(s), the broadening of the signals assigned to 112' and the DMSO mcthyl proton 
resonances, a feature not found on other signals, allows the assignments to be conrirmed. 
Some 4j U 1_1 1) is observed on 112', 114' and 118' and the broadening of the DMSO mcthyl 
peak indicates this is not 4j(pt., 1), thus implying sulphur bound DMSO. 
Further evidence of platinum binding is found by comparison with the chemical shifts of 
ET-3-Q (Figure A. 5.9). In every case a downfield shift is observed, consistant with 
electron donation from nitrogen to platinum(li) making the aromatic ring system more 
electron poor and the hydrogens resonate at higher chemical shifts. Downficld shifts of 
0.20,0.14,0.12,0.11 and 0.09 ppm are observed compared to ET-3-Q for 112', 114', 1169, 
HT and 1-18'. In common with other complexes, the 119' rcsonancc is shifted 1.32 ppm 
downfield, possibly indicating direct interaction between platinum and 119'. 
Ile 13 C DEPT NMR spectrum (Figure 3.46) may be assigned by examination of the 
chemical shifts and carbon hybridization. The spectrum is consistant with the structure of 
the desired product at it contains the correct number and type of carbon atom resonances. 
The 2 low field signals are assigned to C3 and C5 as they belong to an a, p-unsatured 
ketone. The carbons C 10' and C6' are assigned from inspection of the signals and the fact 
that CIO' is a to the nitrogen atom of quinoline and C6' is y. The other aromatic signals, 
C4 and the DMSO carbons are assigned by inspection of the 1IMQC spectrum (Figures 
A. 5.10 and A. 5.1 1). 
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Figure 3.45. The 1H NMR spectrum of trans-Pt(ET-3-Q)(DMSO)CI2- 
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Figure 3.46. The 13C NMR spectrum of trans-Pt(ET-3-Q)(DMSO)CI2 in CDC13- 
In addition to NMR spectroscopy the infrared spectrum (Figure A. 5.12) suggests sulphur 
bound DMSO by the position of the vS=O stretching frequency which relative to DINISO 
has increased in wavcnumbers. The infrared spectrum (Figure A. 4.12) shows the vS=O 
fundamental stretching vibrational band is at 1124 cm'I compared to 1042 cnf 1 in free 
DMSO and is consistant with sulphur bound DMSO. 15231 All the data is consistent %kith the 
structure of trans-Pt(ET-3-Q)(DMSO)CI2 and the yield is 70 
3. Z9. The syntheses ofplatinum(II) starting materials 
The syntheses of the platinum(II) starting materials CiS-Pt(NI13)212 15241, cis-Pt(NI13)2Cl2 15241 
trans-Pt(NH3)2CI2 [5251 and cis-Pt(DMSO)2CI2 (5261 are from publishcd methods and wcre 
identified by colour, infrared spectroscopy (Figures A. 6.1 to A. 6.4), 111 NNIR spectroscopy 
(Figure A. 6.5) and elemental analysis. Yields were in line with those cxpcctcd from 
literature reports. 
3. Z1O. Conclusions andfurtlier investigations 
In total II platinum(II) complexes have been synthesiscd which will be used for further 
investigations. These may be split into three groups and are shown in Table 32 and will 
from this point on be known by their shorthand designations, Le. CC-ET-3-Py. 
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C4 
DMSO 
Table 3.2. Platinum(II) complexes that are to be used in further investigations 
Non-steroidal or control Trans-cationic Cis-cationic 
complexes 
cl cl 
I+I+ H3N-Pt-NH3 H3N-pjt-NH3 
NN 
TC-ET-3-Py 
ET 
TC-Py cl 
ýH3 H3N-Plt-NH3 
H3N-Pt-Cl 
N TC-ET-4-Py 
ET 
CC-Py cl 
I+ cl H3N-Plt-NH3 
H+N 3N- t-NH3 TC-ET-3-Q 
ET 
cl 
TC-Q H3N-ýýtNH3 
N 
TC-ET-4-IQ 
ET 
91+ 
H3N-Plt-NH3 
TC-ET-6-Q N aET 
H3N-Plt-Cl 
N 
CC-ET-3-Py 
ET 
NH3 
H3N- ý-Cl 
N 
CC-ET-4-IQ 
ET 
ýý3 
H3N-Plt-CI 
CC-ET-6-Q 
1NN 
5ý I-:, 1 ET 
3.3. Experimental Details 
All Sonogashira reaction reagents were fully dried before use and solvents degassed and 
followed the original protocol with the exception of using THF as a solvent. [5121 17a- 
ethnynyltestosterone, copper(l) iodide, dimethylsulphoxide and silver nitrate were obtained 
from Aldrich. Bis(triphenylphosphine)dichloropalladium(II), 2-bromopyridine, 3- 
bromopyridine, 4-bromopyridine hydrochloride, 3-bromoquinoline, 4-bromoisoquinoline, 
diisopropylarnine and potassium tetrachloroplatinate(II) were obtained from Avocado. 
Potassium chloride, potassium iodide and all common organic solvents were obtained from 
Fisher Scientific. 
lH NMR and 13 NMR spectra were recorded on Brucker DPX300 or AMX400 
spectrometers operated in fourier transform mode. 195 Pt NMR and Far IR spectra were 
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obtained by Dr Adoracion Gomez Quiroga at the UAM, Madrid, Spain. Chemical shifts 
were referenced to tetramethylsilane or II2PtC16 as an internal standard or to residual 
solvent peaks. ESI mass spectra were recorded on a Brucker esquire 2000. Ultraviolet and 
visible spectrophotometry was performed using a Jasco V-570 spectrophotometcr using 
spectroscopy grade solvents. Infrared spectra were recorded on a Nicolet Avatar 320 
spectrophotometer with an ATR attachment. Melting points were determined using a 
Sturat SMP 10 apparatus. Microanalyses were performed by Warwick Analytical Services 
on a Leeman Labs Incorporated CE440 elemental analyscr. Flash column chromatography 
was carried out using Merck 9385 Kieselgel 60 silica (0.040-0.063mm, 230400 mesh). 
3.3.1. Syntheticprocedurefor ]7a-pyriditi-2-yielltytiyl-testosterolle 
A Schlenk tube was charged with cthisterone (2.5 g, 8 mmol), 
bis(triphenylphosphine)dichloropalladium(II) (0.224 g, 0.32 mmol, 4 molVo) and copper 
iodide (0.121 g, 0.64 mmol, 8 mol%). TIIF (25 ml), diisopropylaminc (5 ml) and 2- 
bromopyridine (0.82 ml, 8.4 mmol) were added resulting in a deep red coloured 
suspension. The reaction was stirred for 72 hours under a nitrogen atmosphere with light 
exclusion. The resulting yellow suspension was reduced in vacuo to a paste. Methanol (20 
ml) was added and the suspension was stirred for 5 minutes. Upon the addition of water 
(200 ml) a yellow precipitate formed; stirring was continued for 30 minutes. The 
precipitate was then collected by filtration and re-dissolvcd in 20 ml of methanol. Water 
(200 ml) was added resulting in a yellow precipitate which was collected by filtration and 
re-crystallised twice by slowly cooling a boiling acetonitrile solution to -20T yielding fine 
white needles which were collected by filtration. 2.37 g, 76 % yield. 
'H-NMR (300 MHz, CDC13): c5 8.56 (ddd, 111, J=4.9,1.7,0.9 liz, 116% 7.63 (dt, 111, J= 
7.7,1.8 Hz, 114'), 7.40 (td, 111, J=7.9,1.0 llz, 113'), 7.21 (ddd, 111, J=7.6,4.9,1.2 liz, 
HF), 5.71 (s, IH, H4), 2.50-1.30 (m, 1811, steroid), 1.18 (s, 311, Me19), 1.15 - 0.98 (m, 
211, steroid), 0.94 (s, 311, Me19). 
13 C-NMR (100 MlIz, CDC13): 6 199.5 (0), 171.2 (C5), 149.8 (C6'), 142.9 (C2'), 13 6.2 
(C4'), 127.7 (C3'), 123.8 (C4), 122.9 (CF), 93.0,85.3,79.8,53.2,50.1,47.2,38.8,38.6, 
36.2,35.6,33.9,32.8,32.7,31.4,23.2,20.7,17.4 (C19), 12.8(CI8). 
IR: v 3200m (041 str), 3175m (C-11.,,,,, tjc str), 2932m (C-11 str), 2878m (C-11 str), 2856m 
(C-H str), 2219w (C-=C str), 1665s (C=O str), 1615m, 1585m, 1560m, 1497%v, 1467m, 
1427m, 1382m, 1358m, 1332m, 1273m, 1233m, 1189m, 1149m, 1149m, 1126m, 1062s, 
1026m, 999m, 968m, 950m, 920m, 890m, 868m, 840w, 820w, 768s (C-11 'oop'), 742m, 
700m, 677m cnf 1. 
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Mass spectrum (ESI, +ve): nilz = 390 [H(C26H31NO2)1+- 
MP (uncorr. ): 253-2550C. 
Elemental analysis: Calculated for C26H31NO2; C, 80.2; H, 8.0; N, 3.6. Found C, 80.05; H, 
7.98; N, 3.52. 
3.3. Z Syntheticprocedurefor 17a-pyridin-3-ylethynyl-testosterone 
A Schlenk was charged with ethisterone (2.5 g, 8.00 mmol), 
bis(triphenylphosphine)dichloropallladium(II) (0.224 g, 0.32mmol) and copper iodide 
(0.121 g, 0.64 mmol). Tetrahydrofuran (40 ml), diisopropylamine (5 ml) and 3- 
bromopyridine (0.82 ml, 8.4 mmol) were added resulting in a deep red coloured solution. 
The reaction was stirred for 72 hours under a nitrogen atmosphere wth the exclusion of 
light. The resulting black mixture was reduced in vacuo producing a black solid which 
was collected by filtration. Methanol (20 ml) was used to re-suspend the solid. Water 
(200 ml) was added resulting in a brown precipitate and the suspension was stiffed for I hr 
and filtered to collect a brown solid. This was purified using a silica column to remove the 
first yellow band (eluent dichloromethane) and the product (eluent 98: 2 
dichloromethane: methanol). Yield 2.05 g, 68 %. 
'H-NMR (300 MHz, CDC13): 6 8.72 (m, IH, H2% 8.53 (s, IH, H6% 7.73 (d, IH, J=7.9 
Hz, H4'), 7.27 (s, IH, H5% 5.73 (m, 1H, H4), 2.48-2.25 (m, 5H, steroid), 2.15-2.05 (m, 
2H, steroid), 1.90-1.37 (m, IOH, steroid), 1.21 (s, 3H, Mel9), 1.13-0.98 (m, 2H, steroid), 
0.96 (s, 3H, Mel8). 
13C-NMR (100 MHz, CDC13): 6 198.2 (0), 171.1 (C5), 151.5 (CT), 147.5 (C6'), 138.7 
(C4'), 123.5 (C4), 97.5 (C17/20/21), 81.6 (CI7/20/21), 79.1 (CI7/20/21), 53.2 (C8/9/14), 
50.0 (C8/9/14), 47.0,38.8,38.3,36.0 (C8/9/14), 35.5,35.3,33.6,32.7,32.5,31.2,30.7, 
23.0,20.5,17.1 (C 19), 12.8 (C 18). 
IR: v 3351m (0-H str), 2941m (C-H str), 2894m (C-H str), 1657s (C=O str), 1614m, 
1475m, 1444m, 1425m, 1408m, 1381m, 1375m, 1352m, 1274m, 1232m, 1188m, 1125m, 
1061m, 1025m, 948m, 866m, 807m, 700s cm". 
Mass spectrum (ESI, +ve): Wz = 390 [H(C26H3IN02)1+- 
Elemental analysis: calculated for C26H31NO2; C, 80.2; H, 8.0; N, 3.6. Found C, 80.01; H, 
8.2 1; N, 3.3 8. 
3.3.3. Synthetic procedurefor I 7a-pyridin-4-yletitynyl-testosterone 
A Schlenk tube was charged with ethisterone (2.50 g, 8.00 mmol, 
bis(triphenylphosphine)dichloropalladium(II) (0.224 g, 0.16 mmol), copper iodide (0.121 
g, 0.64 mmol) and 4-bromopyridine hydrochloride (1.64 g, 8.4 mmol). Tetrahydrofuran 
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(25 ml) and diisopropylamine (10 ml) were added resulting in a red / brown colourcd, 
solution. The reaction was stirred for 72 hours at room temperature undcr a nitrogen 
atmosphere in the absence of light. The resulting yellow / brown solution %%ras reduced in 
vacuo to a brown solid. Methanol (20 ml) was added and the mixture stirred for 5 minutes 
before water (200 ml) was added resulting in a yellow flocculent precipitate which %%, as 
collected by filteration. The solid was dissolved in chloroform (40 ml) and this solution 
was washed with water (15 x 20 ml). The chloroform solution was reduced in racuo to ca. 
5 ml and purified using a silica column (elutent dichloromethanc: mcthanol, 98: 2) to 
separate the desired product from palladium salts. 2.12 g, 68 % yield. 
'H-NMR (300 MfIz, CD30D): 6 8.44 (s, 111,112'& 116% 7.35 (d, 111, J=5.6 1 1z' 113' & 
1-15'), 5.66 (s, I H, 1-14), 2.42 (m, 21-1, steroid), 2.25 (m, 3f1, steroid), 2.03 (m, 211, steroid), 
1.86 (m, IH, steroid), 1.79-1.30 (m, 1011, steroid), 1.21 (s, 111, steroid), 1.10-0.85 (m, 511, 
steroid). 
IR: u 3189m (0-H str), 2932m (C-11 str), 2886m (C-11 str), 2856m (C-11 str), 2220w (C=-C 
str), 1663s (C=O str), 1614m, 1596m 1540w, 1492m, 1467m, 1436m, 1417m, 1383m, 
1356m, 1333m, 1291m, 1269m, 1231m, 1215m, 1187m, 1149m, 1126m, 1058m, 1027m, 
1002m, 962m, 921m, 889m, 963m, 824s (C-11 'oop' bend), 775m, 747m, 699m, 678m, 
664m cm" 
UV / Visible (methanol): 242nm (e = 30800 mol*1 dM3 CM-1) 
Mass spectrum (EST, +ve): 390.3 [fl(C26113IN02)1+ 
Elemental Analysis: calculated for C26113IN02; C, 80.2; 11,8.2; N, 3.6. Found C, 80.05; 11, 
8.01; N, 3.48 
3.3.4. Synthelicprocedurefor 17a-quinolin-3-yletliyityl-testosterone 
A Schlenk tube was charged with ethistcronc (2.5 g, 8 mmol), 
bis(triphenylphosphine)dichloropallladium(II) (0.112 g, 0.16 mmol and copper iodide 
(0.060 g, 0.32 mmol). Tetrahydrofuran (25 mi), diisopropylamine (5 ml) and 3- 
bromoquinoline (0.82 ml, 8.4 mmol) were added resulting in a deep red colour solution. 
The reaction was stirred for 48 hours under a nitrogen atmosphere with the exclusion of 
light. The resulting reaction suspension was reduced to a paste in vacuo and methanol (20 
ml) added. The addition of water (200 ml) resulted in a brown precipitate. Ile suspension 
neutralised with several drop of concentrated hydrochloric acid. The brown solid was 
filtered and acetonitrile (300 ml) added to the solid. Ile mixture was heated to boiling for 
30 minutes until a black solid precipitated from the orange / yellow solution. The 
precipitate was filtered off through celite and the filtrate reduced in volume to ca. 200 ml. 
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This mixture was cooled quickly to -20'C and the precipitated crude ET-3-Q was 
immediately filtered, dissolved in chloroform (50 ml) and extensively washed with water 
(15 x 15 ml). The solution was dried over MgS04 and reduced to a solid in vacuo. The 
slightly yellow solid was crystallized slowly from boiling acetonitrile twice to yield large 
bright crystals which were collected by filtration, 2.8 1 g, 80% yield. 
'H-NMR (400 MHz, CDC13): 8 8.99 (d, 1H, J=2.1 Hz, HT), 8.20 (d, III, J=2.0 Hz, 
114% 8.09 (d, 1H, J=8.5 Hz, 119'), 7.77 (d, 1H, J=8.1 Hz, H6'), 7.56 (ddd, III, J=8.1, 
7.0,1.1 11z, H8% 7.71 (ddd, I H, J=8.4,6.9,1.4 Hz, HT), 5.72 (s, I H, H4), 3.81 (s, I H, 
17a-011), 2.55-2.25 (m, 5H, steroid), 2.16 (ddd, IH, J= 13.9,11.9,3.9 Hz, steroid), 2.03 
(ddd, III, J= 13.4,11.9,4.9 Hz, steroid), 1.95-1.35 (m, 1111, steroid), 1.20 (s, 3H, Mel9), 
1.15-0.96 (m, 5H, steroid). 
13 C-NMR (100 MHz, CDC13): 8 199.5 (0), 17 1.0 (C5), 151.9 (C9'), 146.4 (C 10'), 138.6 
(C4'), 130.2 (C8'), 129.0 (C9'), 127.5 (C6'/C7'), 127.4 (C7'/C6'), 127.2 (C5'), 123.9 
(C4), 117.1 (CY), 96.8,83.0,79.9,50.4,47.3,39.1,3 8.6,3 6.3,35.7,33.9,33.0,32.8,31.5, 
23.3,20.8,17.4 (C 19), 13.0 (C 18). 
IR: v 3210m (0-H str), 2943m (C-H str), 2883m (C-H str), 2862m (C-H str), 2837m (C-H 
str), 2215w (C=-C str), 1667s (C=O), 1610m, 1570m, 1491m, 1448m, 1429m, 1385m, 
1343m, 1286m, 1273m, 1240m, 1231m, 1150m, 1130m, 1072m, 1002m, 964m, 949m, 
I 922m, 871m, 863m, 837w, 787s, 760s, 725m, 691m, 673m cm' . 
Mass spectrum (ESI, +ve): nzlz = 440 [H(C3oH33NO2)1+- 
MP (uncorr. ): 223 - 224 'C. 
Elemental analysis: calculated for C3oH33NO2; C, 82.0; H, 7.6; N, 3.2. Found C, 81.61; H, 
7.19; N, 3.23. 
3.3.5. Synthetic procedurefor I 7a-isoquinoline-4-ylethynyl-testosterone 
A Schlenk was charged with ethisterone (4.00 g, 12.8 mmol), 
bis(triphenylphosphine)dichloropalladium(II) (0.359 g, 0.51 mmol) and copper iodide 
(0.195 g, 1.02 mmol) and 4-bromoisoquinoline (3.13 g, 15 mmol). THF (35 ml) and 
diisopropylarnine (10 ml) were added resulting in a deep red coloured solution. The 
reaction was stirred for 72 hours under a nitrogen atmosphere excluding light. The 
resulting yellow / brown solution was reduced to a paste in vacuo. The paste was 
dissolved in chloroform (50 ml) and extensively washed with water (15 x 25 ml). The 
chloroform layer was reduced to a solid in vacuo, acetonitrile (500 ml) added and the 
mixture heated to boiling for 30 min until the solution was orange. It was then reduced in 
volume to ca. 200 ml. This solution was cooled quickly to -200C and precipitated crude 
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ET-4-IQ was immediately filtered. The slightly yellow solid was slowly re-crystallised 
twice from boiling methyl cyanide to yield a bright white crystalline material which was 
collected by filtration, 5.03 g, 89% yield. 
1H-NMR(CDCl3,40OM1Iz): 69. I4 (s, 111,112'), 8.77(m, 111,1110'), 8.15 (d, 111, J=8.3 
Hz, 1-18'), 7.75 (ddd, I H, J=8.1,7.1,0.9 11z, 115% 7.63 (t, III, J=7.5 1 Iz, 117% 7.52 (t, 
IH, J=7.6 11z, H6% 5.72 (s, 111,114), 4.15 (s, 111,17a-011), 2.55-2.15 (m, 611, steroid), 
2.02 (m, IH, steroid), 1.92-1.75 (m, 411, steroid), 1.70-1.55 (m, 411, steroid), 1.55-1.40 (m, 
4H, steroid), 1.20 (s, 3 H, Me 19), 1.10-0.9 (m, 5 11, steroid). 
13 C-NMR (125 MHz, CDC13): b 199.5 (0), 171.0 (C5), 151.5 (C2% 146.0 (CIO'), 135.7 
(C4% 131.3 (CT), 128.0 (C5'/C6), 128.0 (C5'/C6'), 127.7 (CT), 124.9 (CV), 123.9 
(C4), 115.9,101.2,80.9,80.0,50.5,47.3,39.4,38.6,36.3,35.7,33.9,33.1,32.7,31.6, 
23.3,20.8,17.4 (C 19), 13.0 (C 18). 
IR: v 3326m (0-11 str), 2940m (C-H str), 2916m (C-11 str), 2892m (C-11 str), 2854m (C-11 
str), 1645s (C=O str), 1607m, 1562m, 1497w, 1442m, 1416w, 1389m, 1362m, 1332m, 
1285m 1263m, 1253m, 1233m, 1221m, 1192m, 1155w, 1130m, 1118m, 1069m, 1056m, 
1045m, 1031m, 1009m, 1000m, 970w 948m, 921w, 897m, 880m, 838w, 797m, 785s, 
760s, 717m, 767m cm7l. 
MP (uncorr. ) : 213 - 215 T. 
Mass spectrum (ESI, +ve): nVz = 440 [II(C301133NO2)1+- 
Elemental analysis: calculated for C301133NO2; C, 82.0; 11,7.6; N, 3.2. Found C, 82.06; 11, 
7.32; N, 3.27. 
3.3.6. Syntheticprocedurefor 17a-quinolitte-6-yletliyiiyl-testosterone 
A Schlenk tube was charged with ethisterone (2.5 g, 8 mmol), 
bis(triphenylphosphine)dichloropalladium(II) (0.112 g, 0.16 mmol and copper iodide 
(0.060 g, 0.32 mmol). Tetrahydrofuran (25 ml), diisopropylarnine (10 ml) and 6- 
bromoquinoline (0.82 ml, 8.4 mmol) were added resulting in a deep red colour solution. 
The reaction was stirred for 48 hours under a nitrogen atmosphere with the exclusion of 
light. The resulting reaction suspension was reduced to a paste in vacuo and methanol (20 
ml) added. The addition of water (200 ml) resulting in a brown / yellow precipitate and the 
suspension neutralised with several drop of concentrated hydrochloric acid. Tlic brown / 
yellow solid was collected by filtration and acetonitrilc (300 ml) added to the solid. I'lie 
mixture was heated to boiling for 30 minutes until a black solid precipitated from the 
orange / yellow solution. The Precipitate was collected by filtration through cclite and 
discarded. Filtrate reduced in volume to ca. 200 ml and cooled quickly to -20'C and the 
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precipitated crude ET-6-Q immediately collected filtration, dissolved in chloroform (50 
ml) and extensively washed with water (15 x 15 ml). The solution was dried over MgS04 
and reduced to a solid in vacuo. The slightly yellow solid was crystallized slowly from 
boiling acetonirile twice and the large bright white crystals collected by filtration, 2.10 g, 
60 % yield. 
'H-NMR (300 MIIz, CD30D): 6 8.79 (dd, 1H, J=1.7 Hz, J=4.3 Hz, HT), 8.29 (dd, IH, J 
= 8.5,1.0 Hz, H4'), 7.97 (d, IH, J=1.7 Hz, 1-16% 7.93 (d, IH, J=8.8 Hz, H9% 7.70 (dd, 
IH, J=8.8,1.8 Hz, H8% 7.50 (dd, Iff, J=8.4,4.3 Hz, H3'), 5.65 (s, IH, H4), 2.52-2.16 
(m, 5H, steroid), 2.12-1.98 (m, 2H, steroid), 1.94-1.30 (m, IIH, steroid), 1.20 (s, 3H, 
Mel9), 1.05-0.88 (m, 511). 
IR: v 3156m (0-H + C-H str), 2938m (C-H str), 2858m (C-H str), 1673s (C=O str), 1614m, 
1571m, 1492m, 1435m, 1417m, 1378m, 1342m, 1284m, 1271m, 1231m, 1187m, 1148m, 
1125m, 1067m, 1010m, 999m, 960m, 946m, 910m, 865m, 836m, 785s, 753s, 724m, 689m, 
67 1m crif 1. 
Mass spectrum (ESI, +ve): nzlz = 440 [H(C3oH33NO2)1+- 
Elemental analysis: calculated for (C30H33NO2); C, 82.0; H, 7.6; N, 3.2. Found C, 81.79; 
H, 7.52; N, 3.00. 
3.3.7. Syntheticprocedurefor trans-[Pt(NH3)2(PY)CIjjNOjJ 
To a solution of trans-diamminedichloroplatinum(II) (0.200 g, 0.667 mmol) in DMF (I ml) 
was added a silver nitrate (0.111 g, 0.653 mmol) in DMF (I ml) and stirred over night at 
40 C in the absence of light. Silver chloride was removed by filration through celite 
yielding a pale yellow solution. The solution was cooled to -18 C and pyridine (54 ýLl, 
0.053g, 0.667 mmol) added with a micro syringe with stirring. The solution was allowed 
to reach room temperature over 4 hours and the mixture stirred overnight. The slow 
addition of diethylether (200ml) yielded an off-white precipitate that was collected by 
filtration. The precipitate was dissolved in warm methanol (10 ml) and diethylether (10 
ml) slowly added resulting in a small amount of off-white precipitate and this was 
collected by filtration and discarded. Diethylether (100 ml) was added to the remaining 
filtrate resulting in a white precipitate and this was collected by filtration. This procedure 
was repeated 3 times further and the final bright white precipitate collected by filtration 
and washed with diethylether (2 x5 ml) and dried over phosphorus pentoxide. 0.058g, 
20% yield. 
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'H-NMR (400 MHz, CD30D): 6 8.79 (ddt, 211, J(h. 10 = 22.12 11z, J(1141) = 5.1 11z, 1.45 Hz' 
H2'/fl6'), 7.97 (tt, I H, J=7.8,1.5 11z, 114% 7.51 (ddd, 211, J=7.7,5.2,1.4 11z, 113'/H5'). 
IR: 3271m, 3124m, 161 Im, 1586m, 1488w, 1457m, 1343s, 1306s, 1241m, 1162m, 1078m, 
1048m, 102 1 m, 98 1 m, 932m, 87 1 m, 825m, 761 m, 688m cm". 
Mass spectrum (ESI, +ve): nVz = 343 [Pt(NI13)2(PY)Clj+- 
Elemental analysis: calculated for C51 III C IN403Pt; C, 14.8; 11,2.7; N, 13.8; Cl, 8.7. Found 
C, 15.15; H, 2.90; N, 13.92; Cl, 8.89. 
3.3.8. Syntheticprocedurefor trans-IPI(NI13)., (Quitiolitte)CIIINOiI 
To a solution of trans-diarnminedichloroplatinum(II) (0.200 g, 0.67 mmol) in DMF (I ml) 
was added a silver nitrate (0.11 g, 0.65 mmol) in DMF (I ml). The mixture NNms stirred 
over night in the absence of light. Silver chloride was removed by filtration through cclite 
resulting in a pale yellow solution. The solution was cooled to -18 C and quinoline (79 pl, 
0.087g, 0.67 mmol) added with a micro syringe with stirring. The solution %Nms stirred, 
reached room temperature and stirred overnight. The slow addition of diethylethcr 
(200ml) yielded an off-white precipitate that was filtered off. Ile precipitate was 
dissolved in warin methanol (10 ml) and dicthylether (10 ml) slowly added resulting in a 
small amount of off-white precipitate and this was collected by filtration and discarded. 
Diethylether (100 ml) was added to the remaining filtmte resulting in a white precipitate 
and this was collected by filtration. This procedure was repeated 3 times further and the 
final bright white precipitate was collected by filtration and washcdwith dicthylcther (2 x 
5 ml) and dried over phosphorus pentoxide. 0.045g, IS% yield. 
111-NMR (300 MIIz, CD30D): 6 9.71 (d, 111, J= 8.6 Ift, 119') 9.44 (dd, 111, J=5.2,1.2 
Hz, HT), 8.66 (d, 111, J=8.3 11z, 114') 8.12 (m, 211,1167118'), 7.83 (t, I 11, J=7.4 1 Iz, 
113'), 7.66 (dd, I H, J=8.3,5.4 fiz, 11T). 
IR: v 3266m, 2781m, 1743m, 1622m, 1590m, 1509m, 1458w, 1338s, 1314s, 1262m, 
1207m, 1163m, 1139m, 1128m, 1040m, 978m, 924s, 871m, 829m, 813s, 777s, 751m cm-1 
Mass spectrum (ESI, +ve): nVz = 394 [Pt(NI13)2(Quin)Cl]+. 
Elemental analysis: calculated for C91113CIN403Pt; C, 23.7; 11,2.9; N, 12.3; CI, 7.8. Found 
C, 23.41; H, 2.83; N, 12.20; Cl, 7.58. 
3.3.9. Synthetic procetlurefor trans-[R(NIBWET-34ýv) CIIINOil 
To a solution of trans-diamminedichloroplatinum(li) (0.200 g, 0.67 mmol) in DINIF (I ml) 
was added a silver nitrate (0.11 g, 0.65 mmol) in DMF (I ml). Ile mixture N%-as stirred 
overnight in the absence of light. Silver chloride was removed by filtration through celite 
resulting in a pale yellow solution. The solution was cooled to -18*C and 17a-pyridin-3- 
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ylethynyl-testosterone (0.254 g, 0.653 mmol) added with stirring. The solution reached 
room temperature and the mixture stirred for a further 8 hours. The slow addition of 
diethylether (200 ml) yielded a white precipitate which was collected by filtration off. The 
crude product was dissolved in warm methanol (25 ml), decolourising charcoal (0.02 g) 
was added and the resulting suspension stirred for 10 minutes. The charcoal was removed 
by filtration through celite and the filtrate reduced in vacuo to ca. 10 ml. The addition of 
diethylether (10 ml) resulted in a small amount of yellow precipitate which was discarded. 
Diethylether (100 ml) was added to the remaining filtrate resulting in a white precipitate 
and this was collected by filtration. This procedure was repeated 3 times further and the 
final bright white precipitate was washed with diethylether (2 x5 ml) and dried over 
phosphorus pentoxide. 0.125 g, 28% yield. 
'H-NMR (400 MHz, CD30D): 6 8.93 (d, IH, J=1.8 Hz, HT), 8.78 (dd, IH, J=5.8,1.1 
Hz, H6'), 8.02 (td, 1 H, J=8.0,1.6 Hz, H4'), 7.52 (dd, 1 H, J=8.0,5.8 Hz, H5'), 5.71 (s, 
IH, H4), 2.60-1.40 (m, 18H, steroid), 1.26 (s, IH, Mel9), 1.15-0.90 (m, 5H, steroid). 
IR: v 3279m, 2944m (C-H str), 2876m (C-H str), 1644m (C=O str), 1474m, 1330s, 1233m, 
1190m, 1125m, 1059m, 947m, 868m, 812m, 691m em". 
Mass spectrum (ESI, +ve): nilz = 654 [Pt(NH3)2(ET-3-Py)Cl]+. 
Elemental analysis: calculated for C26H37CIN405Pt; C, 43.6; H, 5.2; N, 7.8; Cl, 5.0. Found 
C, 43.25; H, 5.25; N, 7.85; Cl, 5.20. 
3.3.10. Synthetic procedurefor trans-[PI(NH3)2(ET-4-Py)CII[NO31 
To a solution of trans-diamminedichloroplatinum(II) (0.200 g, 0.67 mmol) in DMF (I ml) 
was added silver nitrate (0.11 g, 0.65 mmol) in DMF (I ml) and the mixture stirred 
overnight in the absence of light. Silver chloride was collected by filtration through celite 
and discarded. The solution was cooled to -I 8'C and 17a-pyridin-4-ylethynyl-testosterone 
(0.254 g, 0.653 mmol) added with stirring. The solution reached room temperature and the 
mixture stirred for a further 8 hours. The slow addition of diethylether (200 ml) yielded a 
white precipitate and this was collected by filtration. The crude product was dissolved in 
warm methanol (25 ml). Decolourising charcoal (0.05 g) was added and the resulting 
suspension stirred for 5 minutes. The charcoal was discarded after filtration through celite 
and filtrate reduced in vacuo to ca. 5 ml. The addition of diethylether (10 ml) resulted in a 
small amount of yellow precipitate which was discarded. Diethylether (100 ml) was added 
to the remaining filtrate resulting in a white precipitate which was collected by filtration 
and this procedure repeated twice. The final precipitate was collected by filtration, washed 
with diethylether (2 x5 ml) and dried over phosphorus pentoxide. 0.104 g, 22% yield. 
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1H-NMR (300 MHz, CD30D): 6 8.72 (d, 111, J=6.7 11z, 112'/116'), 7.46 (d, 111, J=6.6 
Hz, H3'/li5'), 5.66 (s, 1H, H4), 2.6-1.4 (m, 1811, steroid), 1.21 (s, 311, Me19), 0.91-0.81 
(m, 5H, steroid). 
195Pt-NMR (64 MHz, CD30D): 6 -2874 ppm. 
IR: v 3350m (0-H str), 3281m (N-11 and C-11 str), 2940m (C-11 str), 2227w (C-=C str), 
1669m (C=O str), 1615m, 1493w, 1416s, 1377s, 1307vs, 1231m, 1184m, 1148%v, 1125m, 
1069m, 106m, 1044m, 1027m, 1013m, 950m, 921w, 868m, 825m (C-11 'oop'), 780%v, 
730w, 680w cin". 
UV / Visible (Methanol): 242run (e = 20500 mol" dM3 CM-1). 
Mass spectrum (ESI, +ve): tnlz 654 [Pt(N[13)2(ET-4-PY)Cll+- 
Elemental analysis: calculated for C261137CIN405Pt; C, 43.6; 11,5.2; N, 7.8; Cl, 4.9. Found 
C, 43.78; H, 5.00; N, 7.89; Cl, 4.96 
3.3.11. Synth etic procedurefor trans-jPt(NI13)2(ET-3-Q) CIIINOjI 
To a solution of trans-diamminedichloroplatinum(li) (0.200 g, 0.67 mmol) in DMF (I ml) 
was added silver nitrate (0.11 g, 0.65 mmol) in DMF (I ml) and the mixture stirred 
overnight in the absence of light. Silver chloride was discarded after filtration through 
celite leaving a pale yellow filtrate. The solution was cooled to -1 8*C and 17a-quinolin-3- 
ylethynyl-testostcrone (0.287 g, 0.65 mmol) added with stirring. TIc solution reached 
room temperature and the mixture stirred for a further 8 hours. Ile slow addition of 
diethylether (200 ml) yielded a white precipitate which was collected by filtration. The 
crude product was dissolved in wann methanol (50 ml), decolourising charcoal (0.1 g) was 
added and the resulting suspension stirred for 5 minutes. The charcoal discarded after 
filtration through celite and filtrate reduced in vacuo to ca. 15 ml. The addition of 
diethylether (15 ml) resulted in a small amount of yellow precipitate which was discarded 
after filtration through celite. Diethylethcr (100 ml) was added to the remaining filtrate 
resulting in a white precipitate and this was collcctcd by filtration. This procedure was, 
repeated 3 times further and the final bright white precipitate was washed with diethylether 
(2 x 10 ml) and dried over phosphorus pentoxide. 0.128 g, 28% yield. 
11I-NMR (300 MlIz, CD30D): J 9.62 (d, 111, J=8.5 liz, 119'), 9.44 (d, 111, J=1.811z, 
112'), 8.63 (d, 111, J=1.2 lIz, 114'), 8.02 (m, 211,1167118% 7.76 (t, I 11, J=7.6 1 1z' 117% 
5.67 (s, IH, H4), 2.55-1.40 (m, 1811, steroid), 1.23 (s, 111, Me19), 1.10-0.90 (m, 511, 
steroid). 
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IR: v 3255m, 2938m (C-H str), 1646s (C=O str), 1496m, 1332vs, 1243m, 1125m, 1059m, 
1026m, 947m, 869m, 835m, 779m, 754m, 677m, 667m cnf I. 
Mass spectrum (ESI, +ve): nVz = 704.2 [Pt(NH3)2(ET-3-Q)Cll+. 
Elemental analysis: calculated for C30H39CIN405Pt; C, 47.0; H, 5.1; N, 7.3; Cl, 4.6. Found 
C, 48.39; H, 5.25; N, 7.32; Cl, 4.93. 
3.3.1Z Synthetic procedurefor trans-[Pt(NH3)2(ET-4-IQ)CII[NO31 
To a solution of trans-diamminedichloroplatinum(II) (0.200 g, 0.67 mmol) in DMF (I ml) 
was added a silver nitrate (0.11 g, 0.65 mmol) in DMF (I ml) and the mixture stiffed 
overnight in the absence of light. The removal of silver chloride by filtration through celite 
yielded a pale yellow filtrate. The solution was cooled to -180C and 17a-isoquinolin-4- 
ylethynyl-testosterone (0.287 g, 0.65 mmol) added with stirring. The solution reached 
room temperature and the mixture stiffed for a further 8 hours. The slow addition of 
diethylether (200 ml) yielded a white precipitate which was filtered off. The crude product 
was dissolved in wann methanol (50 ml), decolourising charcoal (0.1 g) was added and the 
resulting suspension stirred for 5 minutes. The charcoal was filtered off using celite and 
filtrate reduced in vacuo to ca. 15 ml. The addition of diethylether (15 ml) resulted in a 
small amount of yellow precipitate which was collected by filtration and discarded. 
Diethylether (100 ml) was added to the remaining filtrate resulting in a white precipitate 
and this was collected by filtration. This procedure was repeated 3 times further and the 
final bright white precipitate which was collected by filtration and washed with 
diethylether (2 x 10 ml) and dried over phosphorus pentoxide. 0.128 g, 28% yield. 
'H-NMR (300 MHz, CD30D): 6 9.62 (d, 1H, J=8.5 Hz, 119'), 9.44 (d, 1H, J=1.8Hz, 
HT), 8.63 (d, IH, J=1.2 Hz, H4'), 8.02 (m, 2H, H6'/fl8'), 7.76 (t, 1H, J=7.6 Hz, HT), 
5.67 (s, 1H, H4), 2.55-1.40 (m, 18H, steroid), 1.23 (s, IH, Mel9), 1.10-0.90 (m, 5H, 
steroid). 
IR: v 3255m, 2938m (C-H str), 1646s (C=O str), 1496m, 1332vs, 1243m, 1125m, 1059m, 
1026m, 947m, 869m, 835m, 779m, 754m, 677m, 667m cnf 1. 
Mass spectrum (ESI, +ve): nzlz = 704.2 [Pt(NH3)2(ET-3-Q)Cl]+. 
Elemental analysis: calculated for C30H39CIN405Pt; C, 47.0; H, 5.1; N, 7.3; Cl, 4.6. Found 
C, 48.24; H, 5.12; N, 7.5; Cl, 4.89. 
3.3.13. Syntheticprocedurefor trans-jPt(NH3)2(ET-6-Q)CIJjN0jJ 
To a solution of trans-diamminedichloroplatinum(II) (0.20 g, 0.67 mmol) in DMF (I ml) 
was added a silver nitrate (0.11 g, 0.65 mmol, 0.98 eq. ) in DMF (1 ml) and the mixture was 
stirred overnight in the absence of light. The silver chloride precipitate was collectred, by 
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filtration and discarded leaving a pale yellow solution filtrate. The solution %%-as cooled to - 
180C and 17a-quinolin-6-ylethynyl-tcstostcrone (0.254 g, 0.653 mmol) added with stirring. 
The solution reached room temperature and the mixture stirred overnight. The slow 
addition of diethylether (200ml) yielded a white / yellow precipitate which was collected 
by filtration. The solid was dissolved in methanol (50 ml) and decolourising charcoal (0.2 
g) was added and the mixture stirred for 20 minutes. The dccolourising charcoal %%-as 
removed by filtration through Mite and filtrate reduced in vacuo to approximately 5 ml. 
The addition of diethylether (10 ml) resulted in a small amount of yellow precipitate which 
was filtered off. Diethylether (100 ml) was added to the remaining filtrate resulting in a 
white precipitate which was collected by filtration. The solid %%-as dissolved in %%rarrn 
methanol (15 ml) and diethylether was added (150 ml) resulting in a white precipitate 
which was collected by filtration and the procedure repeated twice before the final 
precipitate was collected by filtration, washed with dicthylcther (5 x5 ml) and dried over 
phosphorus pentoxidc. 0.151 g, 34 % yield. 
111-NMR (400 MHz, CD30D): 6 9.60 (d, 111, J=9.0 11z, 119'), 9.38 (dd, 111, J=5.3, 
I. 8Hz, HT), 8.57 (d, III, J=8.3 11z, 114'), 8.14 (d, 211, J=1.6 11z' 116'), 8.80 (dd, III, J- 
9.0,1.8 Hz, 118'), 7.62 (dd, 111, J=8.4,5.3 Ifz, 113'), 5.69 (s, 111,114), 2.50-1.40 (m, 1811, 
steroid), 1.25 (s, 111, Mel9), 1.10-0.88 (m, 511, steroid). 
IR: v 3298m, 2974m, 2945m, 2858m, 2830m (C-11 str), 1666m(C=O str), 1616m, 1590m, 
1504m, 1435m, 1332s, 1326s, 1309s, 1271m, 1231m, 1187m, 1147m, 1129m, 1060m, 
1028m, 1014m, 998m, 962m, 933m, 892m, 855m, 835m, 825m, 762m, 673m cin". 
Mass spectrum (ESI, +ve): mlz = 704.2 [Pt(NI13)2(ET-6-Q)Clj+. 
Elemental analysis: calculated for C301139CIN405Pt; C, 47.0; 11,5.1; N, 7.3; Cl, 4.6. Found 
C, 48.36; H, 5.00; N, 7.45; Cl, 4.28. 
3.3.14. Synthetic procedurefor cis-jPt(NI13)2(PY)CIJjNOjj 
To a solution of cis-diamminedichloroplatinum(II) (0.200 g, 0.67 mmol) in DMF (I ml) 
was added silver nitrate (0.111 g, 0.63 mmol) in DMF (I ml) and the mixture %vas stirred 
over night at 40'C in the absence of light. Silver chloride was removed by filtration and 
discarded leaving a pale yellow filtrate. The solution was cooled to -18 C and pyridine (54 
jil, 0.053g, 0.67 mmol) added with stirring. The solution reached room temperature the 
mixture stiffed overnight. The slow addition of diethylether (200ml) to the solution 
yielded an off-white precipitate that was collected by filtration. The precipitate was 
dissolved in warm methanol (10 ml) and diethylethcr (10 ml) slowly added resulting in an 
off-white precipitate which was collected by filtration and discarded. Dicthylcther (100 
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ml) was added to the remaining filtrate resulting in a white precipitate which was 
collectred by filtration. This procedure was repeated 3 times, the final bright white 
precipitate was collected by filtration, washed with diethylether (2 x5 ml) and dried over 
phosphorus pentoxide. 0.065g, 23% yield. 
'H-NMR (400 MHz, CD30D): 6 8.68 (dd, IH, J(pt-H) = 21.6 Hz, J(H-1i) = 5.4 Hz, H2'/H6'), 
7.92 (t, IH, J=7.8 Hz, H4'), 7.43 (t, IH, J=7.0 Hz, H3'/H5'). 
195Pt-NMR (65 MHz, CD30D): 6 -2375. 
IR: v 3256m, 3187m, 3123m, 1655w, 161 Im, 1586m, 1488w, 1456m, 1345s, 1305s, 
1241m, 1213m, 1162m, 1124m, 1078m, 1049m, 1021m, 978m, 870m, 824m, 760s, 687s 
cm-'. 
Mass spectrum (ESI, +ve): nilz = 343 [C6Hl5CIN3Ptl+- 
Elemental analysis: calculated for C5HjjClN403Pt; Cý 14.8; H, 2.7; N, 13.8; Cl, 8.7 Found 
C, 15.00; H, 2.84; N, 13.79; Cl, 8.62. 
3.3.15. Syntioeticprocedurefor cis-jPt(NH3)2(ET-3-Py)CIJ[NO3j 
To a solution of cis-diammincdichloroplatinum(II) (0.400 g, 1.14 nimol) in DMF (3 ml) 
was added silver nitrate (0.22 g, 1.13 mmol) in DMF (I ml) and this mixture was stirred 
overnight in the absence of light. The silver chloride precipitate was removed by filtration 
leaving a pale yellow filtrate. To the filtrate was added 17a-pyridin-3-ylethynyl- 
testosteronc (0.508 g, 0.1.14 mmol) and the solution stiffed overnight. The slow addition 
of diethylether (200 ml) to the solution yielded a white precipitate which was filtered off. 
The crude product was dissolved in warm methanol (25 ml), decolourising charcoal (0.05 
g) was added and the resulting suspension stiffed for 5 minutes. The charcoal was 
collected by filtration through Mite and discarded. The filtrate was reduced in vacuo to 
ca. 10 ml and the addition of dicthylethcr (15 ml) resulted in a small amount of yellow 
precipitate which collected by filtration and discarded. Diethylcthcr (100 ml) was added to 
the remaining filtrate resulting in a white precipitate and this was collected by filtration and 
procedure repeated twice. The final precipitate, after collection by filtration was washed 
with diethylether (2 x5 ml) and dried over phosphorus pcntoxide. 0.110 g, 12% yield. 
'H-NMR (300 MHz, CD30D): 6 8.74 (s, IH, 112% 8.62 (d, IH, J=5.6 Hz, H6'), 7.93 (d, 
1 H, J=8.3 Hz, H4'), 7.41 (dd, 1 H, J=7.8,6.2 Hz, HF), 5.65 (s, I H, H4), 4.57 (s, I H, 
170-OH), 1.20 (s, IH, steroid), 2.51-1.30 (m, 20H, steroid), 1.20 (s, 3H, Me19), 1.05-0.95 
(m, 5H, steroid). 
195Pt-NMR (65 MHz, CD30D): 6 -2280 ppm. 
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IR: v 3281m, 2940m, 1644m, 1357s, 1293m, 1233m, 1124m, 1048m, 927m, 869m, 834m, 
807m, 691 m cnf 1. 
Mass spectrum (ESI, +ve): 654 [Pt(NH3)2(ET-3-Py)Cl]+. 
Elemental analysis: calculated for C261137CIN40SPt; C, 43.6; 11,5.2; N, 7.8; Cl, 5.0. Found 
C, 43.28; H, 5.22; N, 7.82; Cl, 5.15 
3.3.16. Syntheticprocethirefor cis-jPt(NI13)2(ET-4-IOCIjjNOjj 
To a solution of cis-diamminedichloroplatinum(II) (0.20 g, 0.67 mmol) in DMF (I ml) %vas 
added a silver nitrate (0.11 g, 0.65 mmol) in DMF (I ml) and the mixture stirred overnight 
in the absence of light. The silver chloride precipitate was removed by filtration through 
celite. The pale yellow filtrate was cooled to -18"C and 17a-isoquinolin4-ylcthynyl- 
testosterone (0.254 g, 0.653 mmol) added with stirring. TIc solution reached room 
temperature and the mixture stirred overnight. The slow addition of diethylcther (200ml) 
yielded a yellow precipitate which was collected by filtration. This was dissolved in 
methanol (15 ml) and the suspension immediately filtered and the white / yellow solid 
discarded. The addition of diethylether (10 ml) to the mcthanolic solution resulted in a 
small amount of yellow precipitate which was collected by filtration and discarded. 
Diethylether (100 ml) was added to the filtrate and the precipitate collected by filtration. 
The solid was dissolved in wann methanol (15 ml) and diethylethcr was added (150 ml) 
resulting in a white precipitate which was collected by filtration and the procedure repeated 
twice. The solid was then dissolved in methanol (50 ml) and decolourising charcoal (0.5 
g) was added and the suspension stiffed for 35 minutes. Charcoal was removed by 
filtration through celite and discarded. The colourless solution was reduced in vacuo to ca. 
15 ml and the addition of dicthylcthcr (10 ml) caused a yellow precipitate which, after 
collection by filtration was discarded. Addition of diethylcthcr (200 ml) to the filtrate 
caused white precipitate which was collected by filtration, dissolved in methanol (20 ml) 
and the solution filtered through celite. To the filtrate was added diethylethcr (100 ml) and 
the white precipitate was collected by filtration and dried over phosphorus pcntoxide. 0.85 
g, 27 % yield. 
111-NMR (300 MHz, CD30D): 6 9.45 (s, 111,112'), 8.65 (s, 111,1110'), 8.29 (d, 111, J=8.4 
Hz, H8'), 8.18 (d, IH, J=8.2 11z, 115'), 7.99 (ddd, 111, J=1.2 11z, J=7.0 11z, J=8.3 Hz, 
HT), 7.82 (ddd, 111, J=1.0 liz, 7.1 liz, 8.1 11z, 116'), 5.66 (s, 111,114), 2.60-1.40 (m, 1811, 
steroid), 1.23 (s, 311,1.22 (s, 311). 
195 Pt-NMR (65 MHz, CD30D): J -2283 ppm. 
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IR: v 3284m, 2939m, 2875m, 1646m (C=O str), 1329m, 1233m, 1161m, 1127m, 1068m, 
1043s, 960s, 907s, 872s, 834m, 780m, 754m cm-1. 
Elemental analysis: calculated for C30H39CIN405Pt; C, 47.0; H, 5.1; N, 7.3; Cl, 4.6. Found 
C, 46.68; H, 5.21; N, 7.58; Cl, 4.76. 
3.3.17. Synthetic procedurefor ds-[Pt(NH3)2(ET-6-Q)CIj[NO3j 
To a solution of cis-diamminedichloroplatinum(II) (0.20 g, 0.67 mmol) in DMF (I ml) was 
added a silver nitrate (0.11 g, 0.65 mmol) in DMF (I ml) and the mixture stirred overnight 
in the absence of light. The silver chloride precipitate was removed by filtration through 
celite resulting in a pale yellow filtrate. The filtrate was cooled to -18'C and 17a-quinolin- 
6-ylethynyl-testosterone (0.254 g, 0.65 mmol) added with stirring. The solution reached 
room temperature and the mixture stirred overnight. The slow addition of diethylether 
(200ml) yielded a yellow precipitate which was collected by filtration. This was dissolved 
in methanol (15 ml) and immediately filtered through celite. The addition of diethylether 
(10 ml) to the methanolic solution resulted in a small amount of yellow precipitate which 
was discarded after being collected by filtration. Diethylether (100 ml) was added to the 
remaining filtrate resulting in a white precipitate which was collected by filtration. The 
solid was dissolved in warm methanol (15 ml) and diethylether added (150 ml) resulting in 
a white precipitate which collected by filtration and this procedure repeated twice. The 
precipitate was collected by filtrationd, dissolved in methanol (50 ml) and decolourising 
charcoal (1.0 g) added. The suspension stirred was for 45 minutes and decoloursing 
charcoal removed by filtration through celite and discarded. The colourless solution was 
reduced in vacuo to ca. 15 ml and the addition of diethylether (10 ml) caused a yellow 
precipitate which was collected by filtration and discarded. Addition of diethylether (200 
ml) to the filtrate caused white precipitate which was collected by filtration, re-dissolved in 
methanol (20 ml) and filtered again through celite. To the filtrate was added diethylether 
(100 ml) and the white precipitate was collected by filtration and dried over phosphorus 
pentoxide. 0.72 g, 24 % yield. 
'H-NMR (300 MHz, CD30D): 6 9.53 (d, IH, J=9.0 Hz, H9'), 9.20 (dd, IH, J=1.2Hz, J= 
5.2 Hz, HT), 8.47 (d, I H, J=8.2 Hz, H4'), 8.06 (d, I H, J=1.3 Hz, H6% 7.89 (dd, I H, J= 
1.8 Hz, 8.9 Hz, H8'), 7.54 (dd, IH, J=5.3 Hz, 8.5 Hz, H3'), 5.65 (s, IH, H4), 2.54-1.30 
(m, 18H, steroid), 1.21 (s, 3H, Mel9), 1.10-0.85 (5H). 
IR: v 3284m, 2939m, 2876m, 1646m, 1329m, 1233m, 1161m, 1127m, 1043s, 960s, 906s, 
872s, 779m, 754m cm". 
Mass spectrum (ESI, +ve): nVz = 704 [Pt(NH3)2(ET-6-Q)Cl]+. 
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Elemental analysis: calculated for C3oH39CIN405Pt; C, 47.0; 11,5.1; N, 7.3; Cl, 4.6. Found 
C, 46.61; 11,5.01; N, 7.36; Cl, 4.82. 
3.3.18. Syntheticprocedurefor trans-PI(Py)(D)VISO)CI2 
A suspension of cis-bis(dimethylsulphoxide)dichloroplatinum(II) (0.350 g, 0.83 mmol) in 
methanol (20 ml) was stirred for 10 minutes. Pyridine (67 Pl, 0.065 g, 0.83 mmol) was 
added via a microsyringe and stirring continued for 8 hours. The resulting suspension was 
reduced in vacuo to ca. 2 ml and diethylether (50 ml) added. The precipitate was collected 
by filtration, washed with methanol (2 x5 ml) and dicthylcther (3 x5 ml), resulting in a 
bright yellow solid, 0.33 g, 95 % yield. 
111-NMR (400 MIIz, CDC13): J 8.79 (ddd, 211, J(N-10 = 20.3 11z, J(11-10 = 6.6,1.5 11z, 
H2'/H6'), 7.8 8 (tt, I H, J=7.7,1.5 11z, 114'), 7.41 (ddd, 211, J=7.7,5.2,1.4 1 Iz, 113'/115'), 
3.52 (d, 6H, J(pt-10 -= 11 .9 11z). 
19SPt-NMR (65 MfIz, CD30D): 6 -2902 ppm 
IR: v 2995w (C-11 str), 2913w (C-11 str), 1609m, 1483w, 1447m, 1422wm 1402%v, 1349%v, 
1317w, 1240w, 121 1w, 1150s (S=O str), 1072m, 1028m, 981m, 944m, 924m, 765s, 734m, 
I 691 s cm' . 
Elemental analysis: calculated for C7111IC12NOPtS; C, 19.9; 11,2.6; N, 3.3; C1,16.8. 
Found C, 19.89; 11,2.60; N, 3.25; Cl, 16.85. 
3.3.19. Synthelicprocedurefor trans-PI(Quinoline)(DAtSO)CI2 
A suspension of cis-bis(dimethylsulphoxide)dichloroplatinum(II) (0.350 g, 0.83 mmol) in 
methanol (20 ml) was stirred for 10 minutes. Quinolinc (98pl, 0.107g, 0.83 mmol) was 
added via a microsyringe and stirring continued overnight. 'Me resulting yellow 
suspension was reduced in vacuo to ca 10 ml and dicthylcther (50 ml) added. 'Me 
precipitate was collected by filtration, washed with ethanol (2 x 10 ml) and diethylcther (2 
x 10 ml) resulting in a bright yellow solid. 0.38 g, 98 % yield. 
111-NMR(40OMflz, CDC13): 69.33 (dd, 111, J(pt-lo= 15.2,8.8 liz, 119'), 9.01 (dd, 111, J= 
5.3,1.5 Hz, 112'), 8.31 (d, If1, J=8.2 liz, 114'), 7.87 (m, 211,118'1116'), 7.64 (ddd, I 11, J 
8.1,7.0,1.4 11z, 113'), 7.48 (dd, I 11, J=8.3,5.3 liz, 11T), 3.45 (d, 611, J(PI. 11) = 8.8 1 lz) 
DMSO methyls). 
195Pt-NMR (65 MlIz, CDC13): 6 -3035. 
IR: v 3057w (C-fl str), 2997w (C-11 str), 2915w (C-11 str), 1588m, 1507m, 1459m, 1437m, 
141 Im, 1393m, 1379m, 131 Im, 1232m, 1210m, 1150m, 1132s (S=O str), 1124s (S=O). 
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1061m, 1016s, 977m, 956m, 933m, 913m, 868m, 81 Is (C-H oop), 779s (C-H oop), 739s 
(C-S str), 698 (C-S str) cm-1. 
Mass spectrum (ESI, +ve): nVz = 474 [H(Pt(Quin)(DMSO)CI21+ 
3.3.20. Synthetic procedurefor trans-Pt(ET-2-Py)(DMSO)CI2 
To a stirring suspension of cis-bis(dimethylsulphoxide)dichloroplatinum(II) (0.5 g, 1.18 
mmol) in methanol was added, in 10 portions, solid 17a-pyridin-2-ylethynyl-testosterone 
(0.5 g, 1.13 mmol) over an 8 hr period. Stiffing was continued for a further 24hrs resulting 
in a bright yellow precipitate which was collected by filtration. The product was purified 
on aIm long silica column, using dichloromethane : methanol, 98: 2 as eluent and the first 
half of the single yellow band was collected, 0.635 g 72 % yield. 
111-NMR (300 MHz, CDC13): & 8.53 (d, IH, J=5.1 Hz, H6') 7.79 (dt, IH, J=1.5 Hz, 7.8 
Hz, H4') 7.5 5 (d, 1 H, J=7.9 Hz, H3') 7.3 8 (ddd, I H, J=7.4,5.8,1.4 Hz, H5') 5.72 (s, 
1H, H4) 3.44 (s, 6H, DMSO-Methyls) 2.70-1.30 (m, 18H, steroid) 1.20 (s, 3H, Mel9) 
1.18-1.00 (m, 2H, steroid) 0.97 (s, 3H, Mel8) ppm 
13 C-NMR (101 MHz, CDC13): (5 199.6 (0), 171.2 (C5), 152.2 (C6'), 144.3 (CT), 138.9 
(C4'), 129.1 (C3'), 124.6 (C5'), 123.8 (C4), 104.4,80.3,53.2,50.4,47.5,43.5 (DMSO 
Methyls), 38.6,38.4,36.3,35.6,33.9,33.1,32.8,31.4,23.3,20.8,17.4 (Mel9), 12.8 
(Mel 8) ppm 
195Pt-NMR (64 MHz, (CD3)2CO): 6 -3106.6 
IR :v 3428m(O-H), 2939m(C-H str), 2858m(C-H str), 2227m(C-=C str), 1657s(C=O str), 
1615w, 1599m, 1562w, 1476s, 1450m, 1433m, 1418m, 1379m, 1358m, 1331m, 1292m, 
1231m, 1187m, 1147s(S=O str), 1127s(S=O str), 1060m, 1023s(C=O bend), 972m, 948m, 
919m, 889m, 866m, 839m, 840m, 821m, 747s(C-H oop), 694m, 679m, 665m cm" 
ESI-MS m/z = 734.5 [H(Pt(ET-2-Py)(DMSO)CI2A+ 
3.3.21. Synthetic procedurefor trans-PY(ET-3-Q)(DMSO)CI2 
A suspension of cis-bis(dimethylsulphoxide)dichloroplatinum(II) (0.500g, 1.18 mmol) in 
methanol (20 ml) was stirred for 10 minutes before ET-3-Q (0.520 g, 1.18 mmol) was 
added and stirred for 24 hours resulting in a yellow suspension. The yellow solid was 
collected by filtration and purified on a silica column (eluent dichloromethane : methanol 
98: 2) collecting the first half of the single yellow band, 0.575 g, 62 % yield. 
'H-NMR (400 MHz, CDC13): 6 9.30 (d, IH, J=8.7 Hz, H9'), 9.05 (d, IH, J=1.8 Hz, 
HT), 8.31 (d, IH, J=1.4 Hz, H4'), 7.86 (ddd, 1H, J=8.6,7.0 Hz, H8'), 7.77 (d, IH, J= 
8.2 Hz, H6'), 7.62 (t, IH, J=7.5 Hz, HT), 5.71 (s, 1H, H4'), 3.05 (s, 6H, DMSO methyls), 
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2.47-1.36 (m, 18H, steroid), 1.18 (s, 311, Me19), 1.16-1.02 (m, 211, steroid), 0.94 (s, 3H, 
Me18). 
13 C-NMR (124 MlIz, CDC13): 6 200.0 (C3), 171.5 (C5), 155.9 (C2'), 145.0 (CIO), 142.3 
(C4'), 132.6 (C8'), 129.4 (CT), 128.9 (C9'), 128.4 (C6'), 124.4 (C4), 118.6,98.8,81.2, 
80.7,53.5,50.8,47.7,44.3 (DMSO Methyls), 39.5,39.1,36.7,36.0,34.4,33.4,33.2,31.8, 
23.7,21.1,17.8 (C 19), 13.3 (C 18). 
195Pt-NMR (65 MfIz, CDCI*J -3042. 
IR: 2940m (C-11 str), 2858m (C-11 str), 2226w (C-=C str), 1707m, 1660s (C=O str), 1615m, 
1570w, 1497m, 1450m, 1434m, 1416m, 1361m, 1294m, 1273m, 1231m, 1222m, 1146s 
(S=O str), 1057m, 1023s, 965m, 947m, 915m, 865m, 839m, 802m, 778s, 751s, 734m, 
I 694m, 677m cm'. 
Mass spectrum (ESI, +ve): nVz = 785 [II(Pt(ET-3-Q)(DMS0)CI2)]. 
Elemental analysis: calculated for C331139Cl2N03PtCI; C, 49.0; 11,5.0; N, 1.8; Cl, 9.0. 
Found C, 49.22; 11,4.99; N, 1.78; Cl, 9.21. 
3.3.2Z Synthetic procedurefor cis-(Iiamminediio(loplatititim(li) 
According to the procedure of Dhara, [524) potassium iodide (5 g, 30 mmol) %vas added to 
potassium tctrachloroplatinate(IT) (2.75 g, 6.60 mmol) in water (50 ml) resulting in a 
change from light red to dark red solution almost instantanously and %%ras stirred for 30 
minutes. Ammonium hydroxide as a 25 % solution (1.03 ml, 13.26 mmol) was added over 
a period of 10 minutes with stirring which continued for a further 30 minutes resulting in a 
dark yellow / brown precipitate which was collccted by filtration, washcd with ice cold 
water (2 x 10 ml), ethanol (2 x 10 ml) and diethylether (10 ml) and air dried. 3.15 g, 99 % 
yield. 
IR: v 3274m (N-11 str), 3212m (N-11 str), 3166m (N-1 I str), 1594m (N-1 I dcf), 1514m (N-11 
def), 1288s (N-H def), 1271s(N-11 deo, 752s (N-11 deo cm". 
Elemental analysis: calculated for for PtN211612; lip 1.3; N, 5.8; 1,52.6. Found 11,1.10; N, 
5.53; 1,52.48. 
3.3.23. Syntheticprocedurefor cis-diammittedicitioroplatitium(II) 
Following the procedure of Dhara, [5241 to a suspension of cis-diammincdiiodoplatinum(II) 
(2 g, 4.15 mmol) in water (50 ml) was added silver nitrate (1.376 g, 8.1 mmol) in %%rater 
(10 ml) and the mixture stirred at 400C for 48 hours in the absence of light resulting in a 
yellow suspension and a clear solution. Silver iodide was removed by filtration through 
celite. Potassium chloride (0.340 g, 4.57 mmol) was added and dissolved with brief 
stirring. The solution was left to stand at room temperature for 24 hrs in the dark and 
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bright yellow crystals formed. The mixture was cooled to O'C and the bright yellow / 
orange crystals collected by filtration, washed with ice-cold water (10 ml), ethanol (15 ml) 
and diethylether (15 ml) and air dried. 1.18g, 95%yield. 
IR: v 3284m (N-H str), 3204m (N-H str), 1623m (N-H deo, 1539m (N-H def), 1317m (N- 
H def), 1293s (N-H def), 798s (N-H def) cnf 1. 
Elemental analysis: calculated for PtN2H6CI2; H, 2.0; N, 9.3; Cl, 23.6. Found H, 2.10; N, 
9.36; Cl, 23.62. 
3.3.24. Syntheticprocedurefor trans-diamminedichloroplatinum(II) 
Following the reaction scheme of Kauffman and Cowan, [5251 a solution of potassium 
tetrachloroplatinate(II) (2 g, 4.82 mmol) in water (40 ml) was acidified with concentrated 
hydrochloric acid (1.25 ml) and heated to boiling in a large diameter vessel. 6M aqueous 
ammonia (1.5ml) was added dropwise immediately above the boiling solution in aliquots 
(0.2 ml) allowing 10 minutes between each addition whilst continuing heating and topping 
up with water to maintain 40 ml volume. A further portion of 6M aqueous ammonia 
(13.5ml) was added dropwise over a period of 30 minutes with continued boiling for 2 
hours. The mixture was kept to 40 ml volume by the addition of water. Faster addition of 
ammonia led to precipitation of [Pt(NH3)41[PtCI41 (Magnus Green salt) as a green 
precipitate. The resulting clear colourless solution was evaporated to ca. 20 ml and 6M 
hydrochloric acid (200ml) was added and the solution boiled and reduced to 15 ml - 20 ml 
whereas a fine yellow power is deposited. The solution was refrigerated overnight and a 
fine yellow power was collected by filteration, washed with ice-cold water (2 x 10 ml), 
ethanol (15 ml) and diethylether (15 ml). A further crop was obtained by adding 6M 
hydrochloric acid (200 ml) to the filtrate and boiling until reduced to ca. 20 ml and cooled 
until a fine yellow deposited. The compound was recrystallised from 0.1 M hydrochloric 
acid. 1.1 6g, 80% yield. 
IR: v 3287m (N-H str), 3203m (N-H str), 1634m (N-H def), 1544m (N-H deý, 1289s (N-H 
def), 81 Os (N-H def) cni»l. 
Elemental analysis: calculated for PtN2H6CI2; H, 2.0; N, 9.3; Cl, 23.6. Found H, 1.83; N, 
9.13; Cl, 23.83. 
3.3.25. Syntheticprocedurefor cis-bis(dimetloyisulphoxide)dicliloroplatinum(II) 
Following the synthesis of Wayland et a115261 , 
dimethylsulphoxide (1.142 g, 14.46 mmol) in 
water (5 ml) was added to a solution of potassium tetrachloroplatinate(II) (2 g, 4.82 mmol) 
in water (5 ml) and the mixture allowed to stand. Over a period of an hour the red solution 
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becomes clear and overnight fine yellow needle-like crystals form. The material was 
collected by filtration, washed with ice cold water (2 x 10 ml), ethanol (10 ml) and 
dicthylcthcr (10 ml) and air dried. 0.8275 g, 81 % yield. 
111-NMR (400 MlIz, CDC13): 83.52 (s, 121 1) 3jpt_l I= 21.6 1 Iz 
IR: v 3037m (C-11 str), 3010m (C-11 str), 2990m (C-11 str), 2926m (C-11 str), 2917m (C-11 
str), 2906m. (C-11 str), 1412m, 1400m, 1384m, 1315m, 1305m, 1299m, 1250m, 1154s 
(S=O str), 1131s (S=O str), 1018s, 982m, 941m, 920m, 736m, 690m cm*'. 
Elemental analysis: calculated for C41112CI202PtS2; C, 11.4; 11,2.9; Cl, 16.8; S, 15.2. 
Found C, 11.29; Ht 2.76; Clt 17.03; St 15.10. 
3.4. Attempted syntheses 
3.4-1. Attempted synthesis of cis and tranS-lPt(NI13)2(lsoqiiitioline)CIIINOjI 
'Me synthetic method is identical to that of trans-[Pt(NI13)2(Quinoline)Cl][NO3] using 
transplatin to produce trans complexes and cisplatin to produce cis complexes. The 
reaction produced mixtures of cis- and trans- [Pt(NI 13)2(isoqui nol i ne)Cl]+ and 
[Pt(NH3)(Isoquinoline)212+ that could not be purified to obtain the desircd product. 
3.4. Z Attempted synthesis of cis-lPt(NI13)2(QllitlOliile)CIIINOjI 
The synthetic method is identical to that of trans- [Pt(NI 13)2(Quinol ine)CI] [NOjj using 
cisplatin instead of transplatin as the intial starting material. Despite many different 
solvent combinations the products stubbornly remained as an oil and could not be 
seperated as a solid. 
3.4-3. Attempted synthesis of cis and trans-IPI(N[13)2(ET-2., fý)CIIINojI 
Following the synthetic method of trans-[Pt(NI13)2(ET-3-Py) the compounds idcntiried at 
the end were the platinum starting material (cisplatin or transplatin) and the ligand ET-2- 
Py. No binding of ET-2-Py to platinum was evident 
3.4.4. Attempted synthesis Of CiS-IPI(NI13)2(ET-4. Py)CjJjNojj 
Following the synthetic method of trans-[Pt(NI13)2(ET-3-Py) the product turned from white 
to grey upon attempting to isolate using filtration. 
3.4.5. Attempted synthesis of cis-jPI(NI13)2(ET-3-Q)CIJjNOjj 
Following the synthetic method of trans-[Pt(NI13)2(E-T-3-Py) the product turned from white 
to grey upon attempting to isolate using suction filtration. 
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3.4.6. Attempted syn thesis of trans-R(ET-44Q) (DMSO) C12 
Following the synthetic method of trans- [Pt(ET-3-Q)(DMSO)C, 2 the reaction product was 
contaminated with trans- [Pt(ET-4-IQ)2CI2] and the desired product could not be isolated. 
3.4.7. Attempted Sonogashira reactions to produce TC, CC, TN and CN complexes 
Attempts were made to react the TC, CC, TN and CN complexes with 3-bromopyridine as 
a ligand with ligands LI - L6 under varied Sonogashira conditions using potassium 
carbonate as a base. All solvents used were anhydrous and included tetrahydrofuran, 
acetone, chloroform, DMF and DMA. Catalyst loading varied from 4 mole % to 50 mole 
%. No coupling was observed in all cases. 
3.4.8. Conclusions 
A range of 6 ligands combining a steroidal domain and linker domain have been 
synthesised by the Sonogashira palladium cross-coupling reaction in good to high yields. 
All required simple purification techniques. The 6 ligands were designed to have affinity 
for the testosterone based on literature reports whilst also possessing a hetroatom 
(nitrogen) having a good affinity for platinum(II). In the platinum domain 5 different 
coordination spheres were proposed and 2 of these proved successful, leading to the 
possibility of 18 complexes to be synthesised. Despite synthetic problems and light- 
sensitivity issues a total of II platinum complexes were synthesised, including some 
containing pyridine or quinoline ligands as positive controls to compare to the steroidal 
counterparts. Complexes of the type trans- [Pt(L)(DMS O)C121 where L is an aromatic 
amine were synthesised successfully but aqueous insolubility precluded biological testing. 
Aiming to increase solubility by a substitution reaction to synthesise 
[Pt(L)(L')(DMSO)Cl]+ where L is pyridine or quinoline and L' ligand L, - L6 proved 
elusive. Also proving elusive was the successful synthesis of trans- and cis-neutral 
complexes using very standard procedures which work well for ligands such as pyridine or 
quinoline but not for steroidal ligands. Attempts to use other methods, i. e. forming TN and 
CN complexes with 3-bromopyridine and then substituting the bromine for an 
ethnynyltestosterone via Sonogashira coupling also proved unsuccessful. Despite this, 
should the complexes have been synthcsised they would be electrically neutral with a large 
hydrophobic ligand. These two characteristics are likely to have made the complex 
unattractive from a clinical point of view due to the likely poorly water solubility. The 
complexes likely relatively high lipophilicity would be too high for tissue selective uptake. 
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Despite the synthetic challenges, two ranges of complex have been synthcsiscd, trans- and 
cis-cationic with a variety of steroidal ligands and those containing pyridine or quinoline, 
to act as positive controls. 
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Chapter Four - Hydrolysis and binding to nucleo bases 
4.1. Introduction 
Steroidal metal complexes reported herin have been designed specifically for ultimate use 
in vivo which involves an aqueous environment of pH 7.4 and a temperature of 37'C. The 
in vivo behaviour of the clinical platinum(II) drugs is very important; hydrolysis is required 
for the complexes to develop its clinical potency. Determining the in vivo behaviour of 
cisplatin for example, presents several difficulties that are overcome employing a 
simplified system. Such systems model the interaction between DNA and a platinum(II) 
complex, in well defined conditions, using model nucleobases representing DNA. This 
chapter reports and discusses the behaviour of steroidal platinum(II) complexes in aqueous 
solution and any interaction occuring between complex and DNA base. 
4.1.1. Hydrolysis ofplatinum(II) complexes 
Platinum(Il) complexes frequently undergo solvolysis reactions and their behaviour in 
aqueous solution has been thoroughly investigated. The [PtC14]2- ion undergoes reversible 
hydrolysis in aqueous acid, water and dilute aqueous NaCl, forming [PtC13(H20)]' and 
[PtC12(H20)21 J5271 The complex [Pt(NH3)CI31- forms [Pt(NH3)CI2(H20)] and 
[Pt(NH3)CI(H20)21+ in aqueous solution; [528,5291 these may be separated using 
elcctrophoresis and ion-exchange and monitored using uv-visible spectrophotometry and 
pH changes. The rate of hydrolysis of cisplatin has been measured using several different 
[530-535] [53 [5361 techniques including UV / vis. spectrophotometry, ion-exchange , 
01 HPLC , 
TLC '[5371 eletrophoresiS[5371 and 
195Pt NMR; [530-535,537] the hydrolysis of newer drugs such 
as carboplatin have also been researched. [5381 The main products depend on pH and [Cl'] 
but under physiological conditions are cis- [Pt(NH3)(OH2)Cll+ and cis- 
[Pt(NH3)2(OH)(Cl)]. [5391 
The pK,, of a H20 molecule is decreased on bonding to a platinum(II) centre; this favours 
the formation of hydroxide complexes which may dimerise to form hydroxide-bridged di- 
nuclear species and even higher order oligomers, whose structures have been investigated 
using X-ray diffraction. 1540,5411 The literature is quite clear: Pt-CI bonds are labile in the 
aqueous environment. 
4. LZ Hydrolysis of cisplatin 
Dissolving Pt(en)C12 (similar to cisplatin) in aqucous solution produccs scvcral spccics as 
the chloride ions are displaced by water molecules as shown in Table 4.1. 
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Table 4.1. The approximate relative amounts ofhydrolysed species in aqueous solutions 
of Pt(en)C12 where [Pt(en)(11, O)Cl I*= 100, as a function of chloride concentration. ['421 
Complex Relative amount in 100 Relative amount in -4 mM 
mM chloride chloride 
H2N-Pt-Cl 
ýýNH2 
373 145 
9H2 + 100 100 
H2N-Pt-Cl 
1, \ 
, ýNH2 
9H2 2+ 3.5 
H2N-Pt-OH2 
,,, 
NH2 
OH 100 100 
1 H2N-Pt-CI 
NH2 
OH + 0.5 138 1 H2N-RUOH2 
lý, 
ýNH2 
OH 0.3 86 
1 H2N- pl t-OH 
ýýNH2 
The close relationship between cisplatin and llt(en)(-'I,. suggests results I'Or llt(en)('I, are 
representative of cisplatin at intracellular and intercellular chlofide concentrations. In 
acidic media - p1l -5 - the formation ot'hydroxide products is dislavoured and primarily 
cis-[Pt(NIl3)2(A(ll2())1' is produced, in a reversible reaction, with %-cry small amount of 
cis-[ Pt(N 113)2( 1120)2 12 f present. The opposite p1l range - p1l -9 results in irreversible 
hydrolysis to relatively inert cis-[ Pt(NI 13)2(()11)2 1. although acidification results in 
protonation of the hydroxide forming a labi le complex. 
' ý 111 
The most important pf I from a biological viewpoint is pf 1 7.4. in this environment of 
IOOmM chloride, hydrolysis of cisplatin occurs with a half life ol'approximately I hour 
and an equilibrium of cis-IN(NI102021, cis-jPt(Nllj)2Cl(ll, ())'j and Cis- 
[Pt(NIl3)2(()ll)(ll2())'j exists in 50: 20: 30 ratios, in the low Cl'cnvironmcnt of intercellular 
space, cis-[ Pt(NI13)2CIO 120)'1 and cis-[I)t(Niii)2(()11)(11--, ())*I are the pnmary products, in 
approximately 50: 50 ratio in rapid equilibrium with almost no cis-Pt(Nll; ), Cl, 
remaining. 15321 
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4.1.3. Model systems to probe DNA binding of Pt(H) complexes 
In the first instance DNA may be modelled by its components, the nucleobases guanine, 
adenine, cytosine and thymine. The purine base derivative 9-ethylguanine, shown in 
Figure 4.1 is modified in the 9 position where in DNA the ribose unit is connected and may 
be used as a model; guanosine Y-monophosphate (5'-GMP) is also a model nucleobase, 
but unlike 9-cthylguanine it contains a ribose and phosphate group; however, 5'-GMP has 
a free phosphate group not found in DNA. 
0 
<N 
Nýl N'TNH2 
9-ethylguanine 
0 
N-- 
N 'TNH2 
-o-p 0-ýý 
0- 
OH OH 
5'-GMP 
Figure 4.1. The structure of Hrngua and 5'-guanosine-monophosphate. 
The benefits of using systems such as 9-ethylguanine and 5'-GMP as models for DNA 
bases is experimental simplicity, and the interaction between a complex and models for 
each individual model base (i. e., adenosine 5'-monophosphate, 5'AMP) can be used. The 
relatively low molecular weight and gram scale quantities available allow application of 
mass spectrometry and NMR techniques, in addition to UV / vis. spectrophotometry, to 
observe changes and identify the species involved. 
4.2. Results 
During characterisation charged platinum(II) complexes proved readily identifiable by 
ESI-mass spectrometry (ESI-MS); this justifies the use of ESI-MS for analysis of aqueous 
solutions of such complexes. All the results were collected using the materials and 
methods described in § 4.5. 
4.21. Hydrolysis of non-steroidalplatinum(H) complexes 
A peak at nVz = 343 is observed when TC-Py and CC-Py are dissolved in water and 
incubated for 3 days at 37 *C; when exposed to the same conditions the spectrum of TC-Q 
displays a peak at nilz = 394; these peaks correspond to those expected from the parent 
ions. In all three cases small peaks are observed nilz = 19 below that ascribed to the parent 
ion; these correspond to the places where it is expected the aqua or hydroxide complexes 
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would be found, if created. However, these addition peaks are small, indicating either little 
hydrolysis has occurred or the newly created complexes have poor sensitivity towards ESI 
mass spectrometry. A summary of the peaks found is presented inTable 4.2. 
Table 4.2. Signals seen in the ESI-MS spectra of control platinum(II) complexes. 
Complex Peaks (mlz) Peak identity Appendix 
Figure 
TC-Py 343.3 [Pt(N I 13)2(PY)C I I* A. 7.1. 
324.2 Pt(N I 13)2(PY)(()l 1) A. 7.1. 
CC-Py 343.2 [ Pt(N I 1-1)2(PY)C II* A. 7.2. 
324.2 Pt(N I 13)2(PY)(() 11) A. 7.2. 
TC-Q 394.2 Pt(N I 13)2(Qui n)C II A. 7.3. 
375.3 [Pt(NI13)2(Quin)CI I*A. 7.3. 
4.2.2. Hydrolysis of TC steroidal platinum(H) complexes 
After standing for three days in aqueous solution two sets of peaks may be identified from 
TC complexes in ESI-MS: those complexes containing a pyridine linker-ligand, i. e. TC- 
ET-3-Py, exhibit two sets of significant, large peaks; the first at "Ll: = 654 and the second 
at m1z = 63 5. The first corresponds to the parent complex and the second to 
[Pt(NH3)2(L)(OH)]+ where L is a steroidal ligand. Those complexes with a quinollne or 
isoquinoline containing linker-ligand, i. e. TC-FIT-3-Q, exhibit sets of peaks at m/z = 704 
and m1z = 685. Like their pyridine-containing counterparts these peaks correspond to the 
parent complex and [Pt(NH3)2(L)(01 1)1'-, where 1, is a steroidal ligand. 
The pH of the solutions used for ESI-MS analysis were checked and found to be neutral 
indicating no acid-base chemistry is present. The direct attachment of 01 F to the platinum 
complex is therefore discounted. Substitution of chloride by water would result in the 
complex [Pt(NH3)2(L)(OH2) ]2+' where L is a steroidal ligand; however no 2+ ions are 
observed. Given the tendency for lowering of the pKa of hydrogen atoms on co-ordinated 
water molecules, it is reasonable to suggest the parent complexes have had chlorides 
substituted by water with subsequent loss of 11', as shown in Figure 4.2, using TC-ET-4-Py 
as an example. Table 4.3, below, shows the assignment of each peak observed. 
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OH NH3 OH ýH3 
N-ýe-CI 
C\/N-Plt-OH2 G/ 
Ofisý 
NH3 NH3 
654 mlz 315 mlz 
OH NH3 
/N-P -OH 
NH3 
635 mlz 
Figure 4.2. The hydrolysis of TC-ET-4-Py with expected m1z values. 
Table 4.3. Summary of the findings in identifying species during the hydrolysis of TC 
complexes. 
Complex Peaks (mlz) Peak identity Appendix 
Figure 
TC-ET-3-Py 654.2 [Pt(NH3)2(ET-3-Py)Cl]+ A. 7.4. 
635.3 [Pt(NH3)2(ET-3-Py)(OH)]+ A. 7.4. 
'FC-E'l'-4-Py 654.2 [Pt(NH3)2(ET-4-Py)Cl]+ A. 7.5. 
635.2 [Pt(NH3)2(ET-4-Py)(OH)]+ A. 7.5. 
TC-FIT-3-Q 704.2 [Pt(NH3)2(ET-3-Q)Cl]+ A. 7.6. 
685.3 [Pt(NH3)2(ET-3-Q)(OH)]+ A. 7.6. 
TGEIT-4-IQ 704.2 [Pt(NH3)2(ET-4-IQ)Cll+ A. 7.7. 
685.3 [Pt(NH3)2(ET-4-IQ)(OH)]+ A. 7.7. 
TC-E'r-6-Q 704.2 [Pt(NI13)2(ET-6-Q)Cll+ A. 7.8. 
685.3 [Pt(NH3)2(ET-6-Q)(OH)]+ A. 7.8. 
4.2.3. Hydrolysis of CC steroidal platinum(II) complexes 
Three cis-cationic complexes (CC-ET-3-Py, CC-ET-4-IQ, CC-ET-6-Q) were analysed 
using ESI-MS to ascertain their behaviour in aqueous solution. The complex CC-ET-3-Py 
displays three significant peaks at m1z = 654,635 and 617; the complexes CC-ET-4-IQ and 
CC-ET-6-Q display three significant peaks at m1z = 704,685 and 667. The highest peaks, 
in similar fashion to TC complexes are assigned to the parent complex, [Pt(NH3)2(L)Cll+, 
where 1, is a steroidal ligand. The peaks at m1z = 685 and 635 may be assigned to 
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respective complexes having the chloride substituted by water-, followed by loss of H% 
yielding [Pt(NH3)2(f-)(O1l)jý, where 1, is a steroidal ligand. Unlike TC complexes, CC 
complexes exhibit a further series of peaks m/z = 37 units less than the parent compound 
and m1z = 18 less than the hydroxide complex. The isotope distribution pattern suggests 
the complex does not contain a chloride ion; the ntlz value suggests loss of steroidal ligand 
may be ruled out and it appears the complex is singularly charged. The difference of 18 
atomic mass units immediately suggests loss of' 11,0; however this is difficult to envisage 
given the structure of the complex. Since this is not observed in spectra of steroidal ligand, 
the m1z - 617 and 667 peaks must be f'Ormed due to changes at the metal centre. The loss 
of Of F and N 113 ligands may be discounted on the basis of, restvctively, complex charge 
and m1z value as can bridged dimers. These particular peaks remain to be identified. Table 
4.4 contains a summary of the peaks found. 
'Fable 4.4. A summary of the ESI-MS spectra of cis-cationic complexes. 
Complex Peaks (mlz) Assignment Appendix 
Figure 
CC-ET-3-Py 654 1 Ilt(N I 1; )2(1-"l'-3-Py)(('I) I* A. 7.9. 
635 Pt(N I 13)2(1-"l'-3-Py)(()l 1) A. 7.9. 
617 A. 7.9. 
CC-F'F-4-IQ 704 Ilt(N I A. 7.10. 
685 Pt(N I 13)2(1-', 'I'-4-IQ)(()l 1) A. 7.10. 
667 A. 7.10. 
CC-ET-6-Q 704 1 Pt(N I 1; )2(1-', 'I'-6-Q)(C 1) 1' A. 7.1 1. 
685 1 Pt(N 113)20 " F-6-Q)(O 11) A. 7.1 1. 
667 A. 7.11. 
4.2.4. Binding of non-steroidalplatinum(H) complexes to model nucleobases 
The binding of TC-Py, CC-Py and TC-Q to 5'AMP, 5'-GM13,5'-'I'Ml' and 5, -CMP was 
ascertained by I'SI-MS (Figures AXI - A. 8.3); the complex and nucleobase were 
incubated for 72 hours at 37'C in the presence of TAE buffer as outlined in §4.5. No 
evidence of unreacted complex is present in the spectrum indicating the complexes have 
completely reacted. However, no peaks are present corresponding to those expected to 
arise from an interaction with nucleobases; this is a very surprising result given the aftmity 
of nucleobases for platinum(II), further techniques such as NMR are required to fully 
investigate the interaction. In the case of TC-Py peaks at nvz = 452 and 291 are observed. 
In relation to the three complexes peaks at m1z -I 10 higher and 52 lower than in z value of 
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the parent complex are observed. Hence, these peaks are likely to arise from the 
complexes reacting with TAE buffer although no simple complexes, such as 
[Pt(NH3)(L)(OAc)], where L is pyridine or quinoline, have m1z values corresponding to 
those observed, as shown in Table 4.5. 
'rable 4.5. The peak observed in the ESI-MS spectra of the control complexes and 5'- 
GMP. 
Complex Peaks (mlz) Appendix 
Figure 
TC-Py 452 A. 8.1. 
291 A. 8.1 
CC-Py 452 A. 8.2. 
291 A. 8.2. 
TC-Q 504 A. 8.3. 
321 A. 8.3. 
4.2.5. Bin ding of steroidal platin um (II) complexes to model n ucleobases 
Four model nucleobases, 5'-GMP, 5'-AMP, 5'-CMP and 5'-TMP were assessed in their 
ability to bind steroidal platinum(II) complexes as described in § 4.5. A summary of the 
results can be found in Table 4.6 and the spectra are contained in Figures A. 8.4 - A. 8.12. 
No signal is observed that may be interpreted as an interaction between the nucleobases 5'- 
TMP / 5'-CMP and platinum(II) complexed studied. Of particular note is that no sets of 
peaks corresponding to the parent complex are observed whilst those of the complex 
[Pt(NI13)2(L)(011)] where L is a steroidal ligand are clearly present. This indicates an 
interaction has occurred with the buffer. 
When mixed with 5'-AMP the results were almost identical to that of 5'-TMP / 5'-CMP in 
that no peaks are observed corresponding to the steroidal platinum(II) complexes reacting 
with 5'-AMP. In a single case, a significant set of peaks at 964 M1z are observed when 
CGET-3-Py and 5'-AMP are mixed and incubated for 3 days. The peak at 964 m1z may 
be ascribed to an adduct formed between 5'-AMP and CGET-3-Py with the formula 
H[Pt(NH3)2(ET-3-Py)(5'-AMP)]+. Other complexes apart from CC-ET-3-Py are capable 
of binding to 5'-AMP. The complexes, TC-ET-3-Q, TGET-3-Py and TC-ET-6-Q, when 
mixed with 5'-AMP produced peaks corresponding to H[Pt(NH3)2(ET-3-Q)(5'-AMP)I+ 
(mlz = 1014), H[Pt(NH3)2(ET-3-Py)(5'-AMP)]+ (mlz = 964) and H[Pt(NH3)2(ET-6-Q)(5'- 
AMP)]+ (mlz = 1014), respectively; a high signal to noise ratio precluded definitive results. 
175 
The weak signals may indicate the three other complexes bind poorly to 5'-AMP or that 
once bound or the resulting adduct is not sensitive to ESI mass spectrometry. 
Mixing 5'-GMP and steroidal complexes produced a large set of results: all steroidal 
complexes produced an adduct, [Pt(NI13)2(L)(5'-GMP)l as summeriscd in Table 4.6 and an 
example of which is shown in Figure 4.3. A set of peaks #Vz = 16 units below those 
attributed to the adduct are currently unidenti f W. 
OH NH 
0NY NH2 
3N 
N-P, t-M 
NH3ýý-N"" 
H 
0 Of 
Figure 4.3. The adduct between TC-ET-4-Py and 5'-GMP 
In addition to peaks from adducts, peaks corresponding to the parent complex are not 
observed in the spectra. It appears the hydrolysed complex remains in solution whilst the 
parent complex has reacted. Other peaks are observed at nVz -I 10 and - 23 units above 
the parent complex are likely to rise from reactions of the complexes with buffer. The 
peak nzlz - 23 units above the parent complex match the isotope distribution pattern of 
[Pt(NH3)2(L)(OAc)]+, where L is a steroidal ligand and an example spectrum is shown in 
Figure A. 8.7. The peaks nilz - 110 higher are as yet unassigned and do not correspond to a 
simple co-ordination of the buffer components (Tris, Acetate and EDTA) and complex. 
Similar peaks, nilz -I 10 higher than the parent complex ion are observed in the case of 
TC-Py, CC-Py and TC-Q indicating steroidal complexes react slower with the buffer than 
those without steroid groups. 
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Table 4.6. Summary of the binding of complexes with model nucleobases. 
Complex Peaks (mlz) Peak identity Appendix 
Figure 
TC-ET-3-Py + 981.2 [Pt(NH3)2(ET-3-Py)(5'- A. 8.4. 
5'-GMP GMPI+ 
635.3 [Pt(NH3)2(ET-3-Py)(OH)]+ A. 8.4. 
TC-FT-4-Py + 981.3 [Pt(NH3)2(ET-4-Py)(5'- A. 8.5. 
5'-GMP GMPJ+ 
635.2 [Pt(NH3)2(ET-4-Py)(OH)]+ A. 8.5. 
TC-ET-3-Q + 1030.2 [Pt(NH3)2(ET-3-Q)(5'- A. 8.6. 
5'-GMP GMP)]+ 
685.3 [Pt(NH3)2(ET-3-Q)(OH)]+ A. 8.6. 
TC-ET-4-IQ + 1030.3 [Pt(NH3)2(ET-4-IQ)(5'- A. 8.7. 
5'GMP GMP)j+ 
727.2 [Pt(NH3)2(ET-4-[Q)(OAc)]+ A. 8.7. 
685.3 [Pt(NH3)2(ET-4-IQ)(OH)]+ A. 8.7. 
, rc-ET-6-Q + 704.2 [Pt(NH3)2(ET-6-Q)Cll+ A. 8.8. 
5'-GMP 685.3 [Pt(NH3)2(ET-6-Q)(OH)]+ A. 8.8. 
CC-ET-3-Py + 981.2 [Pt(NH3)2(ET-3-Py)(5'- A. 8.9. 
5'GMP GMP]+ 
635.3 [Pt(NH3)2(ET-3-Py)(OH)]+ A. 8.9. 
CC-ET-3-Py + 964.2 [Pt(NH3)2(ET-3-Py)(5'- A. 8.10. 
5'-AMP AMP]+ 
635.3 [Pt(NH3)2(ET-3-Py)(OH)]+ A. 8.10. 
CC-ET-4-IQ 1030.3 [Pt(NH3)2(ET-4-IQ)(5'- A. 8.11. 
GMP)j+ 
685.3 [Pt(NH3)2(ET-4-IQ)(OH)]+ A. 8.1 1. 
CC-ET-6-Q 1030.2 [Pt(NH3)2(ET-6-Q)(5'- A. 8.12. 
GMP)] + 
4.3. Discussion 
The relative lability of Pt-CI bonds, seen so often in the literature, is apparent for all the 
complexes; all form primarily one species when exposed to aqueous solution, a peak 19 
amu below that of the original complex and assigned to an hydroxyl-species. This species 
may be formed by the technique used to analyse the behaviour of the complexes, rather 
than be actually present in solution, as solutions of all the complexes remain pH neutral. 
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Interestingly CC complexes exhibit an additional signal - as yet unidentified - that 
suggests these complexes are less stable than their trans counterparts; this adds additional 
evidence to that found in Chapter Three, that TC complexes are more stable than their cis 
counterparts. Information regarding the kinetics of hydrolysis was not investigated, but the 
endpoint remains clear: the complexes behave in a similar manner in that they all 
hydrolyse. 
The mixing with nucleobases gave several important pieces of information: firstly, all the 
steroidal platinum complexes bind to 5'-GMP, some bind to 5'-AMP and, none bind to 51- 
TMP and 5'-CMP. This appears in-line with that expected from the literature 1132,1331 but it 
is reasonable to suggest, given no evidence of an interaction between, say TC-Py and 
5'GMP, that some of the complexes may not be so sensitive to detection using ESI-MS. 
Secondly, the complexes react with the buffer used as shown by the observation of peaks 
in the same position relative to the parent compound; and thirdly, when mixed with a 
buffered solution of nucleobase, the parent ion peak is not observed, as if all had reacted. 
The second point is unsurprising; TAE contains several nucleophiles both capable and 
likely to react with a platinum(II) centre; one is identified, resulting from the acetate 
substitution of either chloride or water ligand. One other, - 110 nvz above the parent 
complex also arises ftom an interaction between buffer and complex. In the case of the 
non-steroidal complexes, the reaction with the buffer is total, no parent ion peaks are not 
observed and given literature reports that TC-Py and TC-Q react with 5'-GMP and 9- 
ethylguanine in cacodylate huffer. 15431 This suggests the reaction with buffer is inhibited in 
complexes containing the steroid skeleton, as the corresponding peaks (- 110 nvz higher) 
are seen alongside those complexes bound to the nucleobases, indicating reduced kinetics 
at the platinum(II) centre due to the presence of the steroid. One of the design briefs - to 
design complexes that possibly have reduced ability to react with sulphur-containing bio-ý 
molecules - may have been fulfilled. 
The third point is crucial, it suggests that upon exposure to nucleophiles - those present in 
the buffer, nuctcobase or both - the species primarily reacting is the parent complex and 
not the hydrolysed product, which remains in solution. Substitution at 4-coordinate metal 
sites can take two pathways: direct substitution by the nucleophile or via a solvento 
species; here the data suggests the first pathway, very much more than the latter, is in 
operation. Figure 4.4 illustrates the two pathways. 
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Figure 4.4. The pathways of the nucleophilic substitution reactions at square planar 
complexes. 
It appears the triammine complexes studied, whether containing a steroid or not, proceed 
primat-ily via direct nucleophilic substitution; this is not unsurprising given the two path 
system has been identified for platinum(II) complexes containing one leaving group and 
three inert nitrogen-containing ligands [544-5461 and, that direct substitution is thought the 
pathway these types of compounds take in nucleophilic reactions. [547,5481 
4.4. Conclusion 
Using FISI mass spectrometry it is shown that the Pt-Cl bond in cis- and trans- 
[Pt(N113)(I. )(CIjf is labile in nearly all cases. It is clear the complexes react with the model 
nucleobase 5-GMP; although only some appear to react with 5'-AMP; and none react with 
5'-'I'Ml' or 5'-CMP. I lydrolysis appears to be unnecessary for the complexes to bind to 
model nucleobases: here direct substitution of a Pt-CI bond by the incoming nucleophile - 
likely the N7 of guanine for example - occurs, leaving only hydrolysed complex in 
solution. The complexes are shown to react with the buffer medium, a reaction which 
shows the addition of a steroidal skeleton to the coordinating aromatic amine reduces the 
rate or substitution at platinum(II) centres, very likely due to steric factors. 
4.5. Materials and Methods 
5'-GMP was obtained from Sigma (Poole, UK) and stored at VC in a dessicator; it was 
dissolved freshly in IX TAE buffer before each experiment. Fresh solution of complexes 
in ultra-pure water were used and mixed with 5'-GMP in a 1: 1 ratio. The stock solutions 
of base and complex were both I mM. All the solutions were incubated for three days at 
37'C in the dark. ESI-MS spectra were taken on a Bruker Esquire 2000 spectrometer and 
were recorded in positive mode between 0 and 2000 m1z using the low ionisation strength 
of 20%. 
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BLANK IN 
ORIGINAL 
Chapter Five - DNA binding of steroidal platinum(II) 
complexes 
5.1. Introduction 
S. I. I. The discovery of DNA and its structure 
DNA research began in the late 1860's, when the Swiss scientist Johann Fredrich Miescher 
isolated a crude extract of DNA from the nuclei of pus cells and determined the elemental 
composition of the weakly acidic substance; high in phosphorus and containing various 
elements including carbon, hydrogen, oxygen and unlike proteins, no sulphur. Miescher 
had isolated what he termed 'nuclein' (recently reviewed1549) and what is now called 
DNA. The chemical composition of DNA - the nucleic acids - was determined by Albrect 
KosseII5503 (Nobel Prize 1910) and found to contain 4 bases: adenine and guanine (based 
on purine) together with cytosine and thymine (based on pyrimidine). In addition to 4 
nucleobases, nuclein also contained a 5-membercd sugar ring and phosphorus moiety; we 
now know these, respectively, as dexoyribofaranose and the phosphodiester backbone. 
In the 1950s Chargaff and co-workersý5513 found the ratio of purine and pyrimidine bases in 
DNA to be close to I and the molar ratios of guanine and cytosine were equivalent as were 
the molar ratios of adenine and thymine. In 1953 Watson and Crick15523 proposed the now 
accepted structure of DNA: their paper beginning with the words "We wish to suggest a 
structure for the salt of deoxyribose nucleic acid (D. N. A. ). This structure has novel 
features which are of considerable 
biological interest. " 
DNA is composed of two strands of 
phosphodiester groups linked 
covalently to deoxyribofuranose 
bound to a nucleobase. The two 
strands are held together by hydrogen 
bonding between the purine bases (G 
and A) and the pyrimidine bases (A 
and T) as shown in Figure S. 1. 
Figure 5.1. The structure of a DNA 
strand. 
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Each strand of DNA is made of three elements: 
1) Deoxyribofuranose, a 5-membercd sugar hetrocylic ring 
2) The nucleobases, G, C, A and T covalently bound to the sugar ring 
3) The phosphodiester backbone, linking the sugar - base functionalitics together in a 
chain. A single nucleobase, sugar and phosphate are known as a nuclcotide. 
The DNA strands have directionality; the nucleobases are attached to deoxyribofuranose 
forming a nucleoside; the nucleosidcs have a specific direction by being bonded to the 
phosphate groups; the phosphate groups are linked to the 5' hydroxyl group of one sugar 
and the 3' hydroxyl group of the next sugar (5' - 3'); and the opposite strand has the 
reverse directionality (3' - 5'). 
Cytoslne Guanine 
H 
Major groove 
N-H ---- 0N 
---- H-N N 0 
0 ---- H-N 
0 
minor groove H 
\\ 
p 100 IA 
Majorgroove 
N N-H ---- 000 0 
-N , N-ý' 
N .... H ý-N 
Minorgroove 0 
Adenine Thymine 
Figure 5.2. The hydrogen bonding arrangement between individual nucleobascs in double 
stranded DNA forming major and minor grooves. 
The molecular structure of DNA is a double helix in which guanine always pairs with 
cytosine and adenine with thymine (Figure 5.2). Primarily, three different forms of DNA 
are found in the biological arena, A, B and Z; the most common form of DNA is B-DNA 
and will be discussed. B-DNA is a helix. A helix is mathematically defined as a three- 
dimensional curve that lies on a cylinder so that its angle to a plane perpendicular to the 
axis is constant. In the case of DNA the curve is traced by the phosphodicster backbone, 
the pairs of planar bases approximately 90 degrees to the helical axis; the bases pairs are 
attached to the sugar-phosphate backbone asymmetrically and the helical structure gives 
rise to grooves in the DNA of two difference sizes. As shown in Figure 5.3, the major 
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groove is approximately 12 angstroms wide and the smaller minor groove is approximately 
6 angstroms wide. 
1, igure 5.3. The structure of B-DNA. 
5.1.2. Techniques 
Several techniques are used to investigate the interaction between steroidal platinum(II) 
complexes and DNA and elucidate their effect. More detailed information regarding the 
theory of absorbance spectropscopy, supercoiled DNA and linear dichroism may be found 
is Appendix Nine and will only be very briefly described here. 
Absorption spectroscopy is the investigation of the interaction between electromagnetic 
radiation and molecules. It is used to probe the movement of electrons in a molecule 
excited by absoption of electromagnetic radiation. The main use of absorption 
spectroscopy in this thesis is to determine exactly which chromophore(s) (moieties of the 
molecule absorpting light) are responsible for the absorbance of light at a particular 
wavelength in a steroidal platinum(II) complex. Following on from this is linear dichroism 
(LD): once a sample is orientated in a specific direction, e. g long strands of DNA forced 
roughly parallel to each other, the difference in absorption between light linearly polarised 
parallel and perpendicular to the orientation axis yields an LD spectrum. An LD spectrum 
may elucidate the global effects a complex being bound to a DNA helix can cause; such as 
bending. Furthen-nore, the spectrum is very informative regarding the orientation of a 
molecule (say a metal complex) bound to DNA. This assumes where the complex (and its 
components) absorb is known (hence absorption spectroscopy) and that the exact angle of 
a transition (the precise direction of movement of electrons occuring in a transition) is 
known from LD obtained of molecules aligned using a stretched film. Finally gel 
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electrophoresis of supercoiled DNA, once analysed may yield the angle a complex 
unwinds the DNA helix. 
5.2. Results and discussion 
In total, the ability of II individual complexes to bind to DNA by elcctrophorcsis and 
linear dichroism was assessed; the effect on the DNA structure due to such binding %vas 
investigated with a view to understanding, at the molecular level, the binding of complex 
and DNA. Of the II complexes 8 are steroidal metal complexes and three contain only 
simple aromatic ligands such as pyridine. All results were colicctcd using the materials 
and methods as described in § 5.7. The results fall into three categories; those relating to 
the control complexes, TC-Py, CC-Py and TC-Q; those relating to trans-cationic steroidal 
platinum(II) complexes; and those relating to cis-cationic steroidal platinum(II) complexes. 
However the superhelicity constant for the DNA must first be calculated using cisplatin 
and the plasmid DNA pBR322. 
S. Zl. Gel Electrophoresis 
5. Z 1.1. Cisplatin andpBR322 
The plasmid pBR322 is a closed circular DNA containing 4361 base pairs; it is negatively 
supercoiled and will be used to determine the unwinding angles for steroidal platinum(II) 
complexes using the methods in § 5.7.1. Further, more detailed information on supercoilcd 
DNA may be found in § A. 9.3.5. Briefly, closed circular supercoiled DNA consists of 
sections of helix wrapped around itself to create an additional layer of coiling. Such DNA 
can also exist without supercoiled and can often appear as a ring of DNA, otherwise known 
as relaxed. The supcrhelicity constant for pBR322 is not known and is determined by 
treating the plasmid with cisplatin and monitoring the point where the supcrcoiled and 
relaxed forms migrate at the same position on the gel. Figure 5.10 shows the 
electrophoresis get in which increasing amounts of cisplatin have been bound to pBR322. 
Two bands are observed, supcrcoiled and relaxed (refer to Figure 5.4) in untreated plasmid 
(far lcft and far right lanes of the gel). As the amount of cisplatin bound to pBR322 
increases the mobility of the supercoiled band begins to decrease and it travels less 
distance in the gel and indicates the amount of supcrcoiling is reducing. Tlic mobility of 
the relaxed DNA begins to increase slightly and eventually the point where supcrcoiled 
and relaxed DNA travel to in the gel co-insidc - this is the co-migration point. At this 
point all the supercoils in the original plasmid have been removed. The ratio at which this 
occurs is converted into rb(, ), where rb(, ) is the inverse of the ratio of the number of bases : 
platinum(II) atoms at which co-migration occurs. Further cisplatin binding results in the 
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mobility of supercoiled plasmid increasing, a sign that pBR322 is gaining positive 
supercoils. In effect, it is observed as the amount of cisplatin bound to pBR322 increases, 
it unwinds the plasmid before winding the plasmid back up, forming positive supercoils. 
The unwinding angle of 13' has already been determined for cisplain [5531 and using rb(, ) = 
0.083 as the co-migration point (from Figure 5.4. ), the superhelical density is calculated 
after rearranging the equation in § A. 9.3 to be -0.059; that is the plasmid, on average, 
contains 26 supercoils in its native state. The negative sign indicates pBR322, similar to 
nearly all naturally occuring supercoiled DNA's, is negatively supercoiled. This and 
subsequent experiments require the point at which supercoiled DNA (SC) and relaxed (R) 
co-migrate to determine the unwinding angle and due to the nature of the experiment this 
point is subjective. I lence a relatively narrow range of rb(c) values were chosen and the 
experiment repeated to confirm the values chosen are reproducible. 
Relaxed 
Super-coiled 
Figure 5.4. Agarose gel of cisplatin and pBR322 at various loadings. 
5.2.1.2. Non-steroidal complexes (the control complexes) andpBR322 
Treatment of pBR322 with the three non-steroidal complexes resulted in the mobility of 
the SUpercoiled plasmid in agarose gel decreasing in proportion to the ratio of 
DNA: complex as shown for all three in Table 5.1. This is indicative of a loss of the 
number of supercolls in the plasmid. This strongly suggests the complexes bind to DNA. 
The loss of supercoils may be explained as a result of the plasmid accommodating local 
unwinding of the DNA helix at the binding site. Unlike that of cisplatin at the same range 
of ratios, TC-Py, CC-Py and TC-Q only cause the plasmid to loose supercoils and 
approach the relaxed conformation (the point of co-migration) and not introduce positive 
supercoils (Table 5.1). The complex TC-Py (Table 5.1) caused the two types of plasmid to 
co-migration at rb(, ) = 0.5, corresponding to an unwinding angle of 2' ± 1.5', the large 
error due to the difference between rb(c) values in adjacent lanes. It is reasonable to suggest 
the effect on the structure of DNA, in terms of unwinding, is small and unwinding angles 
are of the order < 3.5' for all three complexes. 
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Table 5.1. Images of pB R322 treated with TC-Py, CC-Py and TC-Q as measured by 
ethidium bromide stained gel electrophoresis. Complex loading from right to left, 
pBR322, I Obp: 1,8bp: 1,6bp: 1,4bp: 1,2bp: I and I bp: 1. SC - supercoiled and R -- relaxed 
plasmid 
Fthidium bromide stained gel of pBR322 Complex 
1 10 
pBR322 
1 10 
pBR322 
1 10 
sc 
R 
4 
sc 
4 
4 sc 
4 
T 
pBR322 
cl 
H jN -Pt-NH 1 
N u: - 11 
TC-Py 
ýH3 
H jN Pt-Cl I 
N 
CC-Py 
cl 
HýN Pt-NH3 I 
,N I 
DO 
TC-Q 
5.2.1.3. Trans-cationic complexes 
The effect of five trans-cationic complexes on p1311322 DNA was studied by gel 
electrophoresis. The complexes are similar to those discussed in 5.2-1.2. in that they are 
able to form only a single metal-ligand bond with DNA, except now a steroidal group is 
attached to the aromatic amine. The effect on the clectrophoretic mobility of' SC and 
relaxed plasmid is similar to that of their non-stcroidal counterparts, in that primarily the 
SC plasmid mobility decreases, eventually co-migrating with the rclaxed form, which can 
be ascribed to a loss of supercoiling resulting in 100 % relaxed DNA. At higher complex 
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loadings (expect in the case of TC-ET-4-Py), the mobility of SC plasmid begins to increase 
indicating the size of the plasmid is becoming smaller and is commensurate with the 
induction of positive supercoils. At the very highest loadings in all cases, except TC-ET-4- 
IQ, such positive supercoiling is replaced by dramatic slowing of the migration of SC and 
relaxed plasmids. This is a strong indication of DNA aggregation; these structures are 
poorly stained, presumably due to lack of access of ethidium bromide to the DNA helices. 
The presence of the steroid in all five complexes results in an increased ability for those 
complexes to unwind the DNA helix (as measured by a loss of supercoiling) compared to 
the control complexes in Table 5.1. In the case of TC-ET-4-IQ, ý= 4", where 0 is the 
angle that the DNA helix is unwould; unwinding angles for all other TC complexes are 
?: I I ". This provides evidence that the presence of an ethynyl-testosterone group is causing 
the complex to possess a far greater ability to unwind DNA and the large unwinding angles 
suggest a direct interaction of the testosterone group and the DNA helix. Within the group 
of 5 complexes, three may be compared; TC-ET-3-Py; TC-ET-3-Q; TC-ET-4-IQ. Each 
complex possesses an identical nitrogen containing ring with the steroidal group '6 to that 
of the nitrogen donor; this allows the effect of the additional aromatic ring system in TC- 
ET-3-Q and TC-ET-4-IQ compared to TC-ET-3-Py to be assessed. The addition of an 
extra ring system causes a slightly reduced unwinding angle (15* Cf 19") in the case of 
TC-ET-3-Q and a substantially reduced angle in the case of TC-ET-4-IQ (4* Cf 19'), 
indicating in the case of 3-substituted pyridines rings, an additional ring is detrimental to 
DNA unwinding, particularly when located close the ethynyltestosterone substituent. 
Whilst aromatic amines, such a pyridine and quinoline are capable of intercalation, the 
presence of an ethynyltestosterone bound to the aromatic ring system precludes this and 
intercalation can be disregarded as a possible mechanism of binding. 
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Table 5.2. The effect on pBR322 ofsteroidal trans-cationic complexes as measured by 
electrophoresis gels. The numbers refer to DNA bp : complex and supcrcolled (SC) and 
relaxed (R) conformations. 
1-thidium Bromide Stained Gel Complex I'n%%indingAngle 
2468 10 
C 
cl 
H, jN-Pt-NH3 I 
N 
TC-ET-3-Py Igo 
ET 
pBR322 
1 10 
cl 
H jN Pt-NH3 
TC-ET4-Py 110 
ET 
I 
pBR322 
, *-- 
sc 
cl 
H3N-Pjý-NH3 
N 
TC-ET-3-0 
FT 
15* 
pBR322 
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1 10 
sc 
cl 
H3N4ýtNH3 
N 
TC-ET-4-IQ 
ET 
4 
R 
9+ 
H3N-Plt-NH3 
TC-ET-6-Q 190 N,, 
I -, 
M'-ET 
pBR322 
5.2.1.4. Cis-calionic complexes andpBR322 
Three cis-cationic complexes, CC-ET-3-Py, CC-ET-4-IQ and CC-ET-6-Q were assessed in 
their capacity to cause a loss of supercoiling in the plasmid pBR322. At the concentrations 
used the reduced migration of SC plasmid caused by a loss of supercoiling is not seen and 
the co-migration points for CC-ET-3-Py and CC-ET-6-Q occur towards the lowest 
complex loadings. What is observed is the plasmid traveling further in the agarose gel, 
indicating it is getting physically smaller due to the production of positive supercoils. For 
CC-ET-3-Py and CC-ET-6-Q, rb(c) values of 0.050 and 0.055 respectively are observed 
yielding respective unwinding angles of 21' and 19'; in the case of CC-ET-4-IQ, SC and R 
forms co-migrate where rb(c) '-S 0.05, giving an unwinding angle of > 21'. 
In the case of CC-ET-4-IQ and CC-ET-6-Q, at the higher loading values electrophoretic 
migration slows dramatically indicating DNA aggregation, which in the case of CC-ET-6- 
Q presumably blocks intercalaction of ethidiurn bromide as no band is observed. The 
alterations to electrophoretic mobility of SC plasmid are fully consistent with complex 
binding to DNA, unwinding the negative supercoils at lower loadings as a result of 
unwinding the DNA helix at a local level; additional local unwinding causes the 
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introduction of positive supercoils and the plasmid is wound back up. Of the complexes, 
cc-f-'. 'r-3-Py and CC-ET-4-IQ and, TC-ET-3-Py and TC-FT-3-Q may be directly 
compared; the only difference between them is the presence or absence of an additional 
aromatic ring. 'rhe presence of the additional ring caused the complex to unwind DNA to 
an event greater extent and more importantly compared to the controls, the un%%inding 
angles are substantially greater. 
Table 5.3. The 1% agarose gels of cis-cationic complexes together with their structures 
and unwiding angles. SC and R refer to supercoiled and relaxed plasmid and the numbers 
refer to the DNA bp : complex ratio 
Ethidium Bromide stained gel Complex Unwinding 
Angle 
10 
-sc 
H3N Plt-Cl 
N 
CC-ET-3-Py -)JO 
ET 
4-10C 
pB1322 
NH3 
HiN Pt+Cl 
I 
N 
CC-ET-4-10 
>210 
ET 
190 
12468 10 
1 10 
sc 
R 
ý$ 
H3N-Pt-Cl I CC-ET-6-Q 190 Nýz ; zzz 
z" ET 
pBR322 
5.2.1.5. Gel electrophoresis discussion 
When the complexes were assessed for their ability to unwind DNA a wide variety of 
unwinding angles were found; the amount of unwinding affected primarily by whether the 
aromatic amine contained an ethynyl-testosterone group, or not. The non-steroidal 
complexes, TC-Py, CC-Py and TC-Q do not effect unwinding of the helix to any great 
extent. Low levels of unwinding are observed, a fact not unsurprising given the complexes 
[554 1 [Pt(NI13)3CI]CI and [Pt(dien)CI]CI unwind the plasmid pUC 19 by only 6'. It appears 
that non-steroidal complexes, even with a pyridine ligand cis to any metal-ligand DNA 
interaction, can be accommodated by the helix without substantional unwinding. It is also 
unlikely, given the small unwinding angles and steric constraints of the complexes that 
intercalation forms part of the binding mode to DNA as intercalators tend to cause large 
unwinding angles, typically > 300. [555,5561 
Substituting an ethynyltestosterone group onto the aromatic amine, in various positions, 
induced substantially greater unwinding of the helix compared to TC-Py, CC-Py and TC- 
Q; this fact holds true for both cis-cationic and trans-cationic complexes. All the 
complexes are only able to bind to DNA monofunctionally and large unwinding angles 
compared to the control complexes must be addressed to the presence of a bulky steroidal 
group; in order for this group to affect the DNA structure, a helix-steroid interaction must 
occur, a reasonable proposition, given that structure of the complexes means the steroid 
and DNA must be in proximity to each other. In the case of TC-ET-4-Py, the 
ethynyltestosterone group is pointing away from the helix but it is reasonable to assume 
(from the crystal structure data reported in Chapter Three) that an approximate 900 bend at 
carbon-17 of the steroid may bring the steroidal skeleton into close proximity to DNA; it 
must be remembered the steroidal skeleton is free to rotate relative to the platinum(II) 
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centre. In the other complexes, the P-position of ethynyltestosterone to the nitrogen atom 
of the aromatic ring suggests testosterone and DNA will be in close proximity to each 
other. Such proximity is likely even closer in the cis-cationic complexes, whereby the 
steroidal ligand is cis to any metal-ligand DNA interaction. It should be noted that the cis- 
cationic complexes induce equal or greater unwinding than their trans-cationic 
counterparts; this may be interpreted as the complexes being more sterically demanding 
once bound to the DNA helix and accommodation results in greater helical unwinding. 
Interestingly TC-ET-4-IQ only unwinds DNA by V and compared to TC-ET-3-Py the 
complexes are identical except for the addition of an extra aromatic ring to form an 
isoquinoline; when the aromatic amine is a quinoline, in the case of TC-ET-3-Q, the angle 
is between these values. All complexes are shown in Figure 5.5. It is isoquinoline and its 
interaction with the DNA helix which, perhaps, precludes or reduces contact between the 
ethynyltestosterone group and DNA helix. 
H3 
N N. 
_pt. 
NH3 
0 
O\N/ 
H3N' *-Cl 
0 :" 
TC-ET-3-Py 
OH 
5ý: 
Niý 
pt NH3 
H3N' % cl 
TC-ET-4-IQ 
Figure 5.5. The molecular structures of TC-ET-3-Py, TC-ET-3-Q and TC-ET4-IQ. 
5. Z4. UVIvisible spectroscopy 
5.24.1. UVI visible absorption ofsteroidal platinum complexes 
Steroidal platinum complexes have many distinct chromophores; an understanding of these 
is crucial to have deeper understanding of LD spectroscopic data. Formation of the six 
organic ligands via the joining of ethisterone to a planar aromatic molecule creates a UV / 
visible spectrum which may be described, to a good first approximation, as an addition of 
the two spectra, with very little change occurring to band shape, position or relative 
intensity. Upon binding to platinum(II), the spectra of the newly bonded ligand changes 
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TC-ET-3-Q 
(representative spectra may be found in Appendix Ten) with the longer wavelength band(s) 
of pyridine (260 nm), quinoline (275 mn) and isoquinoline (275 nin) found at higher 
wavelengths in the complexes, Le. a bathochromic shift of approximately 25 nm. In 
complexes containing quinoline and isoquinoline, the long wavelength transitions lie 
outside all other transitions of the molecule chromophores. The new wavelengths of the 
quinoline and isoquinoline transitions lie > 300 nrn and as such when complexes 
containing quinoline or isoquinoline are mixed with DNA (in LD experiments) absorption 
above 300 rim is primarily due to the quinoline and isoquinoline longer wavelength 
transitions. Any LD in this area is therefore due to the transitions of the quinoline or 
isoquinoline chromophores of the steroidal metal complex. The same cannot be said for 
pyridine containing complexes whose longer wavelength transitions (275 M-n) will overlap 
with the main transition of DNA in the region (260 nm). 
Regarding the complexes in general, there is an important feature to note: CC and TC 
complexes possessing the same ligand have very similar spectra; hence, the spectrum of 
TC-ET-3-Py is very similar to that of CC-ET-3-Py; the same may be said of TC-ET-4-IQ / 
CC-ET-4-IQ, TC-ET-6-Q / CC-ET-6-Q and TC-Py / CC-Py. The different geometries do 
not result in observable differences in absorption; from this it is reasonable to assume any 
absorption due to the platinum(II) chromophore, such as d -> d transitions, are a constant 
feature when using the same ligands. 
5.2.4.2. Film linear dichroism ofquinoline and isoquinoline 
A more detailed molecular picture of the binding of steroidal metal complexes to the DNA 
helix may be elucidated by determining the transition moments of quinoline. Using film 
LD the angle of each ;r -* ;r* of quinoline and isoquinoline may be determined. If the 
relative orientation of quinoline (from, say, TC-ET-3-Q) and DNA is known, the steroidal 
skeleton position is known (from the crystal structure data of Chapter Three) and this give 
insight into DNA binding at the molecular level. Calculation of the transition moments of 
quinoline and isoquinoline according to the method of Rodger and Norden are contained in 
Appendix Eleven and only the main results will be. discussed here. Calculations show 
quinoline and isoquinoline display 10 individual transitions between 190 and 400 nm (from 
Appendix Eleven) and the most important are shown in Figure 5.6. Two solutions exist for 
the angle of each transition moment (clockwise and counter-clockwise from the z-axis). 
The solutions near 0 or 90" therefore have a very small range of angles the transition may 
occupy and thus may be described as primarily z-axis or primarily y-axis polarised 
transitions. 
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Figure 5.6. The most important transition moments present in quinoline and 'so u1nolin 44 e 
as suggested using film linear dichroism. 
The most important transitions from a point of view of elucidating DNA binding - the 
ultimate aim of using LD - are those outside the absorption cn%elorvs due to 
chromophores present in ethisterone, Pt(II) and DNA. In this respect. the 314 nm 
transition of quinoline (z-polarised) and 313 nm transition of isoquinoline (v-polarised) 
may allow determination of the angles of quinoline / isoquinoline relative to the long axis 
of the DNA helix. The two transition moments are very close to the :- and y-axes-, 
therefore the two possible solutions for each are relatively close to cach-other in terms of 
direction, particularly the 3 14 nm band of quinoline. It should at this point be stressed that 
these results should be viewed as *remaining to tx- confirmed'. Other data, for example IR 
linear dichroism, fluorescence anisotropy and molecular orbital calculations are required 
before the angle of each transition is confirmed and also to confirm the presence of a 
transition at all, some changes to the reduced LD were subtle, despite this, the calculations 
above can be relied upon to give a good description of the approximate angles between 
DNA and any quinoline or isoquinoline molecules contained within a bound complex. 
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5.2.4.3. Flow linear dichroism ofsimple platinum(II) complexes and ct-DNA 
All flow LD experiments were carried out according to procedures outlined in § 5.5. All 
the results presented were duplicated in follow up experiments, which are presented in 
Appendix Twelve. All experiments used a constant DNA concentration (200 ýM) in the 
same couette cell and IX TAE buffer. The results of the flow LD DNA binding 
experiments falls into three categories: those of the control complexes TC-Py, CC-Py and 
TC-Q; those relating to trans-cationic complexes, TC-ET-3-Py, TC-ET-4-Py, TC-ET-3-Q, 
TC-ET-4-IQ and TC-ET-6-Q; and those relating to cis-cationic complexes, CGET-3-Py, 
CC-ET-4-IQ and CGET-6-Q. The LD of ct-DNA consists of a single band, at -260 nm, 
due to ir -> ir * transitions of the nucleobases; this signal is negative, as expected; using 
couette flow alignment the transition moments are - 90' to incident radiation. 
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Figure 5.7. The LD (A), absorbance spectra (B) and change in LD versus loading of TC- 
Py and ct-DNA (C). 
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The LD spectrum of TC-Py and ct-DNA in Figure 5.7 (also A. 12.1) shows a single, 
negative LD signal around 260 nm. The addition of TC-Py causes this peak to become 
more positive from -0.031 to -0.027 at the highest ratio of complex: DNA and, the change 
in sample absorbance is <0.1. The change in absorbance is due to TC-Py, whose 
absorption spectrum overlaps with that of DNA. The complex causes a measurable effect 
on the LD spectrum of DNA at loadings > 16: 1; below this the LD is effectively constant at 
ratios >16: 1 the linear nature of the increase of LD versus complex : DNA ratio indicates 
TC-Py is bound in a single binding mode. There is evidence of an induced LD around 295 
nm; however this signal is small, although representative of the interaction between DNA 
and complex. Similar changes are observed when ct-DNA is mixed with CC-Py (Figure 
5.8 and A. 12.2) indicating both complexes have a very similar effect on the structure of 
DNA. 
(A) (13) 
0 
-OM5 
. 0.01 
-0015 
-OM 
-0.025 
DNA 
so 
40 
30 
2, 
20 
01 ý 
04 
03 
02 
" DA 
" A(Ol) 
At. 30 I) 
Ar. 10 I) 
At. (31( 
-0.03 
0 035 
[ 
220 300 320 
(C) 
220 240 280 280 300 320 
-0024 
. 0025 
. 0,026 
-0.027 oo 
9 
-OMS 
-0,029 o 
o o 
-003 
-0.031 o 
0,032 
0 10 20 30 40 w 
DNA PI ROW 
Figure 5.8. The LD (A), absorbance spectra (B) and change in LD versus loading of CC- 
Py and ct-DNA (C). 
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The LD spectrum of ct-DNA mixed with TC-Q is shown in Figure 5.9. An induced LD 
signal is observed at longer wavelengths, its magnitude is negative and outside the 
absorption envelope of DNA. The absorption spectrum (Figure 5.9) shows increases in the 
regions around 235 run and > 300 nm; a small increase is observed between 240 and 300 
nm. Such increases may be attributed, primarily, to the quinoline chromophore of TC-Q; 
this is confirmed by comparison with the UV / visible spectrum of TC-Q (Figure A. 10.1) 
whose main absorbance lies at -235 nin and >275 nm. 
In the case of the three control complexes, TC-Py, CC-Py and TC-Q the magnitude of the 
LD signal -260 nm become more positive but by no means dramatic. 
Considering LD" = 
LD 
and LD =3 S(COS2 a- 1), this may be explained in 3 possible A2 
ways: 1) the increase is due to a positive induced LD at -260 nm; 2) a decrease in the 
orientation factor, S; 3) a combination of one or more of the previous two explanations. 
For TC-Py, on average, the LD increased - 31 % and the absorbance -17%; in the case of 
CC-Py the LD increased -31 % and the absorbance -21 %: this indicates increased 
isotropic absorbance - proportional to any induced LD signal - does not fully account for 
the change in LD. The rate of change of LD is fairly constant across the wavelengths 
studied and if induced LD were responsible for the increasing LD signal, then it may be 
reasonably expected such change would not be constant (due to varying angles of 
transitions); therefore the change in LD of ct-DNA, exposed to TC-Py and CC-Py to ct- 
DNA, is primarily due to a decrease in the orientation of DNA. This could be due to the 
DNA condensing, bending or changing structure from B-DNA; the most likely 
explanation, given the gel electrophoresis results, is binding of TC-Py and CC-Py to the 
DNA helix cause the helix to bend. 
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Figure 5.9. The LD (A), absorbance spectra (B) and change in LD versus loading of TC-Q 
and ct-DNA (C). 
The evidence for TC-Q bending the DNA helix is more pronounced than TC-Py or CC-Py; 
a decrease in the magnitude of LD at 260 nm of -26 % is accompanied by an increase of 
absorbance of - 10%, thereby indicating TC-Q causes greater DNA bending that TC-Py 
and CC-Py. Unlike TC-Py and CC-Py, an induced LD signal is found above 300 nm, 
which may be attributed to quinoline and the angle of the transition moment in the region 
(314 nm), to first approximation, runs along the z-axis. 
The induced LD can be used to calculate the angle that exists between the z-polarised 
transition at 314 nrn and the helical axis. In determining the angle, three reasonable 
assumptions have been made: 1) the orientation factor, S, is unaffected by complex binding 
at low loadings; 2) the origin of the absorbance around 314 nm is from bound complex; 3) 
the complex binding to DNA does not affect the 314 transition. Using the area of 
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constantLY around 260 nm at low loadings (Figure A. 12.4) and an angle between 
nucleobases of 86' allows the orientation factor, S, to be calculated from 
LD 
3 
S(3 cos 2a- 1), yielding a result of S=0.0514. Using the same equation, the 2 
value of S just determined and LD"314nin - -0.028 (from A. 10.4), the angle of the 314 nm 
transition of quinoline is calculated to be - 63", relative to the DNA helical axis. The sign 
of the LD signal at 314 run is negative and the transition angle should be < 54.7*; the 
disparity between -63* and < 54.7" may explained by two factors: 1) the DNA helix is 
bent by the complex, reducing S; 2) the reduced LD assumes all the absorbance is from 
bound complex. However a reduction in S (due to DNA bending) and a reduction in 
reduced LD cause the angle, in calculations, to increase from -63". The disparity may be 
attributed to experimental error, which considering both induced LD and absorbance in the 
region are small with a low signal to noise ratio, is likely to account for the difference. 
5. Z 4.4. Flow linear dichroism ofpyridine-containing steroidal platinum complexes and ct- 
DNA 
The effect of three trans-cationic complexes contain pyridine, TC-ET-3-Py, CC-ET-3-Py, 
and TC-ET-4-Py on the structure of ct-DNA were studied by flow linear dichroism. The 
spectra of all three complexes and ct-DNA are very similar; therefore, TC-ET-3-Py is 
chosen to be representative (the others are contained in Figures A. 12.5 - A. 12.9). The LD 
spectrum exhibits a negative LD signal at - 260 mn, assigned to the presence of DNA. 
Increasing the concentration of complex leads to the negative peak becoming more 
positive; this is noticeable at very low levels of binding - 100: 1 for all three complexes. At 
such low concentrations of complex the influence of induced linear dichroism can be 
discounted and the change in the LD may be ascribed to a change in the orientation factor, 
S, of DNA, Le. the DNA helix is being bent, a suggestion supported by gel electrophoresis 
data. The rate of change of LD versus complex loading of the - 260 nm peak is linear at 
low loading of complexes up to 30 bp: 1, although the overall spectra could be described in 
terms of a curve or two regions of linearity joined by a curve. The plots (Figure 5.10; 
Figures A. 12.5 - A. 12.9) suggest a single binding mode at low loading of complex up to - 
30: 1 where the reduction in the magnitude of the LD signal is linear. Above 30: 1 a curve 
is observed before at higher loading the reduction in the magnitude of the LD signal at 260 
nm become linear. The two regions of linearity suggest the complexes have two different 
modes of binding to DNA with the curved section where the complex begins to attach to 
DNA in its second binding mode. However, evidence to changes in the shape of the LD 
signal at 260 nm suggest the influence of a positive induced LD originating from the 
complex bound to the helix. The rate of change of complex concentration versus ratio of 
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DNA : complex is not linear - in fact it is described by y= 200x-'- where y is the 
complex concentration and x the ratio of DNA : complex. The growth of a positive LD 
arising from the absorbance of the complex in the region of 260 nm would also follow this 
power rule and may explain curved shape of the LD versus DNA : complex, if a single 
binding mode was in operation. It is difficult to ascertain which explanation may be 
applied to the complexes discussed. 
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Figure 5.10. The LD (A), absorbance spectra (B) and change in LD versus loading of TC- 
ET-3-Py and ct-DNA (C). 
The complexes cause a large change to the LD of DNA; the % change in absorbance 
(discounting the very highest loadings) is similar to that of the control complexes whereas 
the increases to the LD signal are very much greater. Table 5.4 is a summary of the data 
for pyridine-containing steroidal platinum complexes. 
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Table 5.4. Summary of LD data for pyridine-containing steroidal platinum(II) complexes. 
Pyridine-containing steroidal platinum 
complexes (up to 9: 1 DNA: complex) 
Control complexes (up to 
3: 1 DNA: complex) 
Complex TC-ET-3-Py CC-ET-3-Py TC-ET-4-Py TC-Py CC-Py 
Changein 23% 23% 33 % 17% 21% 
absorbance 
Changein 53% 61 % 36% 31 % 31 % 
LD 
The steroidal complexes in Table 5.4 possess a greater ability to affect the LD of ct-DNA 
than non-steroidal complexes at 3 times less the loading; this strongly suggests the steroid- 
containing complexes bend DNA to a greater extent that either TC-Py or CC-Py; this 
suggestion is backed up by gel electrophoresis data, whereby steroidal-containing 
complexes unwound and bent DNA to a greater extent than those not containing steroids. 
The complex possessing the greatest ability to bend DNA is CC-ET-3-Py, followed by TC- 
ET-3-Py and TC-ET-4-Py. Interestingly, the order reflects the likely proximity of the 
steroidal skeleton to the DNA helix; for TC-ET-4-Py the steroid is pointing away from the 
DNA skeleton, whereas in TC-ET-3-Py the steroid is likely to be in closer proximity due to 
the 3-substitution of the pyridine ring and even closer in CC-ET-3-Py. 
5.2.4.5. Flow linear dichroism of quinoline-containing steroidal platinum(II) complexes 
and ct-DNA 
Solutions of TC-ET-3-Q, TC-ET-6-Q and CC-ET-6-Q were mixed with ct-DNA at various 
ratios and an LD spectrum taken of each. The linear dichroism spectra of all three 
complexes are very similar and that of TC-ET-3-Q will be used as an example (other 
spectra, including repeat experiments can be found in Figure A. 12.10 - A. 12.14. ). The LD 
spectrum of ct-DNA and TC-ET-3-Q shows a single negative peak at 260 nm, originating 
from ct-DNA. As the amount of complex bound to DNA increases, the LD signal 
magnitude decreases towards zero; the LD is significantly affected at - 60: 1 and above for 
all three complexes. A summary of the change to the LD spectra due to complex binding 
may be found in Table 5.5. 
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Table 5.5. The effect of quinoline-containing complexes on the LD of ct-DNA. 
Quinoline-containing steroidal platinum Control complex (up to 3: 1 
complexes (up to 9: 1 DNA: complex) DNA: complex) 
Complex TC-ET-3-Q TC-ET-6-Q CC-ET-6-Q TC-Q 
Change in 34% 45% 24% 10% 
absorbance 
Changem 51 % 54% 58% 26% 
LD 
The reduction in the LD signal may be attributed to two factors: 1) a reduction in the DNA 
orientation; 2) positive contributions due to induced LD originating from the complexes. 
Compared to the control complex, all three steroidal complexes cause greater unwinding 
and bending of the helix; the complexes, in order of ability to bend DNA are CC-ET-6-Q, 
TC-ET-3-Q and 'I'C-ET-6-Q as indicated by the change in the LD signal, relative to the 
change in absorbance at 260 nm. At low and high DNA: complex ratios, the rate of change 
in the LD signal is linear but overall the change resembles a curve, reflecting the fact that 
at higher concentrations of complex, contributions from induced LD may begin to affect 
the signal - 260 nm as discussed in § 5.2.4.4. 
There is evidence of a positive induced LD in the spectra of each complex and DNA; at 
270 nm (TC-ET-3-Q); 260 nm (TC-ET-6-Q); 255 and 310 - 320 nm (CC-ET-6-Q); each of 
these matches a strongly absorbing transition in the absorption spectrum of each complex. 
The induced LD appears as clearly observable bands overlapping the LD of ct-DNA, 
except in the case of the 310 - 320 nm induced LD of CC-ET-6-Q and ct-DNA, where it is 
outside the ct-DNA absorption envelope. The band is weak and calculation of the relative 
angle of this transition to the DNA helix is not possible. The positive sign of the induced 
LD of CC-ET-6-Q shows the angle of the transition relative to the DNA helix is > 54.7' 
but little more information may be obtained from the data. 
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Figure 5.11. The LD (A), absorbance, spectra (B), change in LD versus DNA: complex 
ratio (C) and LD(D) of the complex TC-ET-3 -Q with ct-DNA. 
5.2.4.6. Flow linear dichroism of isoquinoline-containing steroidal platinum (H) complexes 
and ct-DNA 
Two isoquinoline-containing complexes, TC-ET-4-IQ and CC-ET-4-IQ were assessed for 
their ability to affect the linear dichroism spectrum of ct-DNA. The spectra of DNA 
exposed to different concentrations of complex are shown in Figure 5.12 and 5.13; each 
shows the expected negative signal originating from orientation ct-DNA. Increasing the 
concentration of complex relative to that of ct-DNA causes the LD signal to become less 
negative for both complexes. Table 5.6 presents a summary of the changes caused by the 
two complexes to the LD spectrum of ct-DNA: it is clear both complexes have a significant 
effect on DNA as the LD approaches very close to zero. The relative changes in 
absorbance and LD signify that an positive induced LD cannot account for the change to 
the LD signal; therefore, a change in the orientation factor, S, may explain the observed 
data. This indicates the complexes are causing the complexes to bend the DNA helix. The 
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positive LD observed between 300 - 350 nm in the LD spectrum of TC-ET-4-IQ and ct- 
DNA (Figure 5.12 and A. 12.15. ) shows the transition moments (almost exclusively from 
isoquinoline) in this region have an angle, relative to the DNA helix of > 54.7'. However 
the exact angle, for comparison to TC-Q and CC-ET-6-Q cannot be accurately calculated 
as relatively low signal magnitude around 300-350 nrn does not produce an induced LD 
spectrum that may be analysed. 
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Figure 5.12. The LD (A), absorbance spectra (B), change in LD versus DNA: complex ratio 
(C) and expansion of the LD spectrum (D) of TC-ET-4-IQ with ct-DNA. 
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Figure 5.13. The LD (A), absorbance spectrum (B) and change in LD versus 
DNA: complex ratio (C) of the complex CC-ET-4-IQ with ct-DNA. 
Table 5.6. The effect on the LD of ct-DNA by the complexes TC-ET-4-IQ and CC-ET-4- 
IQ 
Isoquinoline-containing steroidal platinum complex (up to 9: 1 
DNA: complex) 
Complex TC-ET-4-IQ CC-ET-4-IQ 
% changein 18% 13% 
absorbance 
% change in 42% 64% 
LD 
The relatively small and large changes in the absorbance and LD, respectively due to CC- 
ET-4-IQ indicate that this complex is potent, with reference to changing the S factor of ct- 
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250 300 
W-lerx4h I nm 
DNA; in short it is the best complex, as measure by LD, in unwinding and bending the 
DNA helix or possibly causing the DNA to condense. 
5.3. Discussion 
The similarities in the absorption spectra between complexes with the same organic ligands 
but different geometry at the platinum(II) centre is unsurprising as the spectra suggest 
significant absorption above 225 nin is due to organic ligands. The bathochromic shift to 
the transitions of nitrogen-containing heterocycles after metal co-ordination is very useful 
- it places the long wavelength transitions of isoquinoline and quinoline outside absorption 
envelopes of all the other chromophores, including that of DNA. Unfortunately the 
absorption envelope of pyridine, even with a bathochromic shift due to being bound to 
platinum still overlaps with absorption arising from DNA. 
Whilst all the transition moments of quinoline and isoquinoline have been solved the most 
important transitions are those around 314 tun, z-polarised in quinoline and y-polarised in 
isoquinoline. In total three complexes mixed with DNA exhibited induced LD, 
surnmerised in Table 5.7. 
The calculated angles for the specific transitions of the three complexes are very 
interesting; in each case the aromatic planar ligand is not in a similar location indicating 
the complexes possess different modes of binding to DNA. The negative signal of 
quinoline in TC-Q and the calculated angle do not match but the disparity may be 
explained by experimental error - the induced LD signal is small, as is the absorbance in 
the region. The calculated value does suggest the long axis polarized transition has a 
magnitude closer to 54.7* as angles of < 20" are unlikely due to steric crowding between 
the planar ligand and DNA helix. Hence an angle may be suggested of 20 - 55'. This 
angle is different to that suggested for TC-ET-6-Q, indicating the quinoline moiety in the 
two complexes occupy different positions, relative to the DNA helix. Following on from 
this, the two complexes have different binding modes to DNA and this may be ascribed to 
the presence of the steroidal skeleton. This is true for CC-ET-6-Q, whose angle of the 313 
run transition is > 54.7' to DNA, indicating this transition lies more parallel to the DNA 
helix that perpendicular. However the transition is - 90* to that in quinoline indicating that 
the isoquinoline rings in CC-ET-6-Q are in a different location, relative to the DNA helix, 
showing that this complex occupies a different position compared to TC-Q and TC-ET-4- 
IQ. 
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Table 5.7. A summary of induced LD signals observed in mixtures of complex and ct- 
DNA 
Complex Sign of induced Angle of 313 (quinoline) 
LD and 314 nm (isoquinoline) 
cl 
H3N- t-NH3 
N 
TC-Q 
91 
H3N-P, ý-NH3 
N 
TC-ET-4-IQ 
ET 
H3N-Plt-Cl 
CC-ET-6-Q 
: aET 
Negative 
Positive 
Positive 
transition relative to DNA 
axis 
< 54.70; 
actual angle 40 - 60'. 
> 54.70; 
actual angle 55 - 75' 
54.70; 
Actual angle 55 - 75' 
In dramatic contrast to the control complexes, the addition of a steroid causes very much 
greater perturbation to the DNA helix with the LD reduced to almost zero as a result of a 
reduction in the orientation of DNA and the contribution from positive induced LD bands 
hidden by the 260 nrn band of DNA. It is difficult to compare the potency of individual 
complexes as the change in LD is due, not only to the helix being bent, but unquantifiable 
contributions from induced LD; however the change in LD compared to that of absorbance 
suggests the most potent complexes are TC-ET-3-Py, CC-ET-3-Py, CC-ET-6-Q and CC- 
ET-4-IQ, the latter having the largest effect. The large effect to the DNA helix caused by 
the presence of a steroid is very likely due to an interaction between the DNA helix and the 
steroidal skeleton. Such large changes are difficult to rationalise without a direct 
interaction occurring; moreover, cis complexes would force the steroidal skeleton closer to 
the DNA, and perhaps not surprisingly, trans complexes, whilst potent, are not so efficient 
at affecting DNA. 
The unwinding of the DNA helix, as shown by gel electrophoresis, is an effect common 
when platinum(II) complexes bind to DNA. 15541 In the case of TC and CC complexes the 
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results are similar and a range of unwinding angles are observed with the CC complexes 
being more effective at unwinding the helix. When a supercoiled plasmid DNA helix is 
unwound, it must also bend to accommodate such unwinding; this has been shown by the 
reduction in the magnitude of the LD signal in the spectrum of ct-DNA and complex. 
When comparing results from gel electrophoresis and LD, the most potent complexes at 
unwinding are also the most potent at bending (measured approximately by reduction in 
the LD signal); the two individual sets of results suggesting the complexes unwind and 
bend the DNA helix. The unwinding and bending of the DNA, plus the presence of a 
steroid is likely to produce adducts on DNA that are unlike cisplatin-DNA adducts; the 
helix is unwound to a greater extent in nearly all cases and the presence of a steroid means 
a different surface results from the new adduct. This fulfils one of the most important 
design briefs for new platinum(II) complexes. 
5.4. Conclusion 
The platinum(II) complexes discussed in this chapter all bind to DNA and the effect they 
have on the mobility of plasmid DNA in agarose gels possesses all the hallmarks of 
covalent binding. Once bound, all the complexes affect the DNA helical structure, causing 
unwinding and bending - but to differing degrees, depending on 1) the presence or absence 
of a steroidal group attached to an bound aromatic amine and 2) the exact position on the 
aromatic amine to which the steroidal group is bound. The details of the interactions 
between the platinurn(II) complexes and DNA are not known, nor fully understood. The 
immediate conclusion is that there is a direct interaction between the DNA helix and the 
steroidal skeleton. The key conclusion is this: the presence of a steroid transforms an 
otherwise mediocre complex, in terms of altering DNA structure, to a one causing high 
levels of unwinding and bending of the helix of DNA. 
5.5. Experimental Details 
S. S. I. Gel electrophoresis 
Plasmid pBR322 (New England Biolabs, UK) and varying amount of complex mixed and 
incubated for 72 hours. The total solution of 20 gl consists of I gl (stock =I gg / jil ) 
pBR322, between 1.7 and 17 [d of complex (stock = 600 [M) and the rest with ultra-pure 
water. After an incubation period of 3 days at 37 'C, 10 gl was removed and added to 3 gI 
of loading buffer and 10 Itl loaded onto an agarose gel. The loading buffer consisted of 30 
% glycerol, 0.05% bromophenol blue and 0.025 % cyanol xylene in ultra-pure water. The 
agarose (Fisher, UK) gel was prepared from 100 ml of Ix TAE buffer and 0.20 g of 
agarose the gel cast and run using a HE99X Maxi (Amersham Biosciences, UK) submarine 
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gel kit. The gel was loaded with 8 ýtl of DNA / loading buffer solution and ran using Ix 
TAE for 250 minutes at 5V cm ". The gel was stained after electrophoresis in TAE buffer 
containing ethidium. bromide (0.5 mg ml" for 40 minutes. The gel was visualized using a 
UVIdoc Platinum system (UViDoc, Cambridge, UK) at 312 nm. 
5.5.2 Machine settings 
All UV/vis. spectra were recorded on a Jasco V-570 spectrophotometer operating with the 
following parameters: dual beam mode; start wavelength, 400 nm; end wavelength, 200 
nm; data pitch, 0.5 nm; scanning mode, continuous; scanning speed, 200 nm per min; 
response, 0.25 seconds; bandwidth, 2.0. 
All LD spectra were recorded on a Jasco J-715 spectropolarimeter modified for LD 
spectroscopic measurement. The spectropolarimeter was operated in LD mode with the 
following parameters: sensitivity, 100 mdeg; start wavelength, 400 nm; end wavelength, 
200 nm; data pitch, 0.5 nm; scanning mode, continuous; scanning speed, 200 Mn per min; 
response, 0.25 seconds; bandwidth, 2.0; accumulation, 4. The LD experiments were 
conducted in duplicate and consistent results were obtained. 
5.5.3. Film linear dichroism spectroscopy 
A 20 % w/v solution of quinoline in chloroform was added dropwise to a5 cm x3 cm strip 
of PE until the PE was covered in the solution. Once the chloroform had evaporated, 
further chloroform was added, covering the PE to aid absorption of quinoline into the PE, 
before more quinoline solution was added, dropwise to begin the process again. Once 
enough quinoline - as defined by good spectral quality was added - the PE was briefly 
washed in chloroform and excess chloroform removed using a hair dryer briefly. The PE 
was immediately stretched to 2.5 times its previous length and a LD spectrum obtained. 
5.5.4. Flow linear dichroism spectroscopy 
Stock solutions of ct-DNA (500 ItM) and complex (500 gM) were mixed in varying 
proportions and made up to 50 jil with IX TAE to achieved DNA: complex ratios of 150: 1, 
100: 1,80: 1,70: 1,60: 1,50: 1,40: 1,30: 1,25: 1,20: 1,16: 1,12: 1,10: 1,9: 1,8: 1,7: 1,6: 1,5: 1, 
4: 1 and 3: 1. The solutions were incubated at 37 'C for 3 days. The spectrum was 
measured in a couette flow cell containing 20 pl of solution, rotating at - 1000 rpm, 
ensuring no bubbles were present in the cell. Each experiment was repeated twice and 
found to duplicate. 
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Chapter Six - The biological effects - in vitro - of 
steroidal platinum(II) complexes 
6.1. Introduction 
Biological evaluation - evaluating the effect of substances in vitro - is the first step in 
determining whether the complexes synthesised possess any potential in becoming 
clinically useful drugs. The primary question - are these complexes cytotoxic? - may be 
answered using a growth inhibition assay commonly used to assess platinum(II) 
complexes; 15571 the second question - is cytotoxicity independent of steroid concentration - 
may yield information regarding if the steroid component is having any effects. This 
chapter will detail the biological evaluation of TC and CC steroidal platinum(II) complexes 
against the non-steroidal complexes: TC-Py, CC-Py and TC-Q. 
6.2. Results 
The inhibitor effects were ascertained using three cell lines: an ER+ and AR+ ovarian 
cancer cell line, SKOV-3; an ER+ and AR+ breast cancer cell line, T471); and an ER- and 
AR- immortalised breast cell line HBL-100; the results may be found in Figure 6.1. The 
IC50 of a complex is the concentration of substance required to inhibit 50 % of growth, 
relative to a positive control; the higher the IC50, the less cytoxic a complex is, IC50 values 
under 50 gM are considered as hits. It should be noted that the cytotoxicity of cisplatin, 
very generally, is often < 15 gM in many cell lines. 
In the three cell lines studied the IC50 of cisplatin is around that expected and in SK- 
OV3 15581 and HBL-100, although higher than some reports for T47D . 
1559,5101 It is 
immediately apparent that the control complexes possess poor cytotoxicity towards the 
three cells lines with IC50 values between - 75 - 240 [tM, greatly more than that of 
cisplatin (6 - 32 gM) and steroidal platinum(II) complexes (12.4 - 70 IM). The order of 
resistance of the three cell lines towards steroidal platinum complexes is, generally, SK- 
OW > T47D > HBL-100 and reflects the intrinsic sensitivity of the three cell lines to 
platinum(II) complexes. The fact that HBL-100 is more sensitive to the complexes is 
unsurprising; being a non-tumourigenic cell line it is unlikely to possess the resistance 
mechanisms so often associated with tumourigenic cell lines. 12481 Another important 
observation is that the cytoxicity of cis-cationic complexes is great than that of trans- 
cationic complexes, indicating adoption of a cis-geometry rather than trans imparts greater 
activity; an important exception being TC-Py and CC-Py, where no significant difference 
is observed. The fact that TC-Py and CC-Py possess very much the same levels of 
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cytotoxicity, whereas TC-ET-3-Py and CC-ET-3-Py do not, suggests the presence of the 
cis geometry and steroidal ligand impart cytotoxicity; although this cannot be confirmed 
for the remaining complexes. For the other complexes the presence of the steroid skeleton 
imparts several fold greater activity compared to the controls-, comparisons with the 
steroidal ligand itself are superfluous: a potentially androgenic steroidal ligand would not 
be considered as a treatment for breast cancer, although the IC50 of the ligand FIT-3-Py is 
very much greater (200 ýtm) . 
15611 
The most interesting complexes are CC-ET-3-Py and CC-ET-6-Q; they are the most active 
of all the steroidal platinum(II) complexes, in some cell lines they are more cytotoxic than 
cisplatin; however nearly all of the complexes may be considered to possess good 
cytotoxicity towards the cell lines studied. 
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Figure 6.1. The IC50 values for a range of platinum(II) complexes. 
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Table 6.1. The cytoxicity of a range of platinum(II) complexes 
Complex SK-OV-3 IC5o ([tM) T47D ICý() (ýM) HBL- 100 IC50 (PM) 
CDDP 6+ 1 32 ±5 8±0.5 
TC-Py 98 ±6 181 ± 11 198 ± 10 
CC-Py 115 ±5 197 ± 17 2104: 15 
243 ±7 75 ±5 98 10 
TC-ET-3-Py 39 ±2 63 ±8 27 2 
CC-ET-3-Py 16 ± 0.5 16 ± 0.5 71 
'FC-ET-4-Py 27 ±2 19 ± 0.1 12 ±I 
TC-ET-3-Q 50 ±5 51 ±2 24 ±I 
TC-ET-4-IQ 71 ±3 51 ±4 28 ±2 
CC-ET-4-IQ 26 ± 0.5 33 ±1 28 ±I 
TC-ET-6-Q 4514 39 ±2 26 ±3 
CC-ET-6-Q 16+ 1 14 ±1 12 ±I 
One of the hypotheses of this thesis - the addition of a testosterone skeleton to a 
platinum(II) complex can aid uptake via transportation by steroid receptors - can be tested 
by removing a significant proportion of androgens from the medium in which the cells are 
cultured; in this case the cytotoxicity should not be modulated if steroids are removed. A 
stripping technique (to remove lipids, e. g. steroids) using charcoal / dextran, removes 
significant amounts of steroids from the media, [5621 although phenol red - which has weak 
estrogenic properties [5631 _ remains. Removing too many growth factors may cause poor 
cellular growth and is to be avoided. Figure 6.2 shows the ratio of the IC5o values in 
normal media (IC50(+)) compared to reduced steroid media (IC5o(-)) and displays some 
very interesting results. Given the errors present in cell tests, ratios of between 0.5 and 2 
are considered normal and values outside this range indicate the cytotoxicity of the 
complex is modulated, in part at least, by steroid concentration. 
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Figure 6.2. The ratio of IC50 values in steroid-contaning (+) and steroid-reduced (-) cell 
media 
The most striking feature is the significant enhancement of cytotoxicity of CC-FT-4-lQ 
between - 4.4 - 6.4 fold, observed in all cell lines at reduced steroid concentration; the 
isomer TC-F, 'l'-4-lQ has striking enhancement in SK-OV-3 of - 9.4 fold and also - 2.4 in 
T47D; as does TC-ET-4-Py (in T47D and SK-OV-3); in addition to CC-ET-6-Q in SK- 
OV-3. This indicates perhaps other factors are determining the cytotoxicity of the 
complexes in steroid-reduced media. 
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Table 6.2. The cytotoxicity of platinum(II) complexes using media with (+) and without 
steroids. 
Complex SK-OV-3 IC5o (ýLkl) T47D IC5o (jiM) HBL- 100 IC5o (liM) 
steroids steroids steroids steroids steroids steroids 
CDDP 61 11 ±4 32 ±5 22 2 8±0.5 7±0.5 
TC-Py 98 6 75 ±2 181 ± 11 106 24 198± 10 385 33 
CC-Py 115 15 101 4-21 197 ± 17 102 14 210 351 3 
15 
TC-Q 243 7 127 3 75 ±5 54 4 98 10 108 3 
TC-ET-3-Py 39 2 30 1 63 ±8 44 2 27 2 10 4 
CC-ET-3-Py 16 ± 0.5 11 1 16 ± 0.5 11 0.5 71 71 
TC-ET-4-Py 27 ±2 11 4: 0.5 19 ± 0.1 91 12 1 7±0.5 
TC-ET-3-Q 50 ±5 28 1 51 ±2 26 ±2 24 ±1 30 ±I 
TC-ET-4-IQ 71 ±3 71 51 ±4 21 ±1 28 ±2 2610.5 
CC-ET-4-IQ 26 ± 0.5 4±0.1 33 ±1 7±0.5 28 ±1 4±I 
TC-ET-6-Q 45 ±4 27 ±2 39 ±2 105 ± 11 26 ±3 22 ± 0.5 
CC-ET-6-Q 16 ±1 7±0.5 14 ±1 13 ± 0.5 12 ±1 7±0.5 
Perhaps the most significant result is that of TC-ET-6-Q in T47D; reducing the steroid 
concentration causes proliferation of the cell line and TC-ET-6-Q is androgenic at low 
steroid concentrations. This suggests that the effects of the complexes may be two fold: 
the IC5o is a balance between growth inhibition and proliferation, due to the steroidal 
ligand and platinum(II) centre, respectively; this has been found previously by Jaouen et 
aL [4281 linking tamoxifen to platinum(II). Almost all the increases in cytotoxicity are 
observed for SK-OV-3 and T47D and as these contain the greatest concentration of 
androgen receptors, this gives validity to the results observed, although the increased 
activity of TC-ET-3-Py and CC-ET-4-IQ in HBL-100 may indicate other factors in 
addition to steroid concentrations may modulate the IC50- Cisplatin, TC-Py, CC-Py, TC-Q, 
CC-ET-3-Py, TC-ET-3-Q are complexes whose IC50 is not significantly different in the 
presence or absence of steroids; the IC5o of other complexes is modulated. 
6.3. Discussion 
In relation to treating cancerous cells with cytotoxic drugs, IC50 values are important; they 
give the first insight into the biological activity of a complex and any structure activity 
rules that may, or may not exist. When normal levels of steroids are present in the media 
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the cytotoxicity of the steroidal complexes is very good, in some cases excellent (i. e. better 
than cisplatin) and they represent potential cytotoxic anti-tumour drugs. 'Me presence of 
an ethynyltestosterone results in substantially increased cytoxicity of the complex relative 
to the control and in the case of TC- and CC-ET-3-Py, the steroidal ligand itself, 15611 this is 
something that did not occur in previous attempts to link bio-active ligands to platinum 
complexes. [339,340,347,3481 It should be stated at this point that in vitro activity might not 
directly relate to in vivo activity; there exists a very large difference between the two 
environments and cytotoxicity, in vivo, depends on many more factors than in vitro. 
The change in the IC50 values for some complexes when low levels of steroids are present 
in the media indicates steroids modulate cytotoxicity - as would be expected to happen - 
of steroidal platinum(II) complexes; however, increased cytotoxicity in the cell line HBL- 
100 of TC-ET-3-Py and CC-ET-4-IQ indicates that other factors are involved that may, or 
may not relate to any androgenic effects. Lower levels of androgens may promote 
increased levels of complex binding to the androgen receptor and it is very difficult to 
envisage the changes this may, or may not induce. Despite this, it is reasonable to suggest 
that androgens do, in part, regulate the cytotoxicity of steroidal platinum(II) drugs in the 
cell lines studied. Reports whereby oestrogens regulate cytotoxicity of cisplatin, by 
overexpression of the HMGB-1 protein, possibly shielding cis-GG and cis-AG adducts 
from repair [5641 and platinum(II) complexes interfering with oestrogen levels, [5651 show that 
simply increasing the level of a steroid can have effects using other bio-molecules or 
pathways. There are more reports of hormonal moieties, which may be platinum 
complexes themselves, sensitising cells to platinum(II) drugs [47,564-5661 and, it cannot be 
said that simply removing androgens from the media could result in greater amounts of 
complex being bound to the androgen and, possibly transported to the nucleus causing cell 
death - the effects are more complicated. 
6.4. Conclusion 
The cytotoxic assays have determined that the addition of ethynyltestosterone to an 
aromatic amine bound to a platinum complex of the formula [Pt(NH3)2(L)Cl][NO31 imparts 
cytotoxicity compared to the complex alone, or in the case of complexes containing ET-3- 
Py, to the steroidal ligand. Several of the complexes were more cytotoxic in T47D than 
cisplatin. The cytotoxicity of many of the steroidal complexes is modulated by steroid 
concentration and the removal of other androgens for the AR leads to more active 
complexes. 
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6.5. Materials and Methods 
Tissue culture flasks, 96 well plates, RPMI 1640, DMEM, L-glutamine, trypsin-EDTA, 
HEPES, sodium pyruvate and FCS were obtained from Sigma, UK. Thiazolyl blue 
tetrazoliurn bromide (MTT) and DMSO were from Avocado, UK. 
Cells were grown in RPMI 1640 or DMEM in 10 % FCS supplemented with 1% L- 
glutarnine, 1% HEPES buffer and 1% sodium pyruvate. Cells were routinely cultured in 
the absence of antibiotic and antimycotic. FCS was stripped of steroid using a standard 
protocol and added to the media as normal. [5621 
The MTT assay 15571 was carried out using 96 well plates. Cells were harvested in 
logarithmic growth, 15,000 cells were seeded per well and left overnight to attach. The 
cells were treated, in quadruplicate with 6 difference concentrations of complex dissolved 
in fresh media; the range of concentrations used is dependent on the complex. The cells 
were incubated for 72 hours and 20 gl of thaizolyl blue tetrazolium. bromide (I mg / ml, 0.2 
gm filtered) added. The cell were further incubated for 2 hours for HBL-100 and SK-OV- 
3 and 3 hours for HBL-100. The media was carefully removed by aspiration and the cells 
lysed using lysis buffer (20 pl) and 200 [A of DMSO added to dissolve the cells. 
Absorbance was measured using a 96-well plate reader (Fisher, UK) set at 570 nm. Each 
cell line was investigated beforehand to determine the correct cell numbers to initially seed 
and the required amount of time exposed to thiazolyl blue tetrazolium. bromide to ensure 
sensitivity and accuracy. 
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Chapter Seven - The efficacy of steroidal platinum(II) 
complexes 
Judging the efficacy of platinum(II) complexes as potential targeted cytotoxic drugs 
requires assessing and determining the significance of the information relating to each 
complex. To this end Tables 7.1 - 7.5 contain a summary of all the information, including 
- hydrolysis, binding to model nucleobases, unwinding and bending of DNA, and IC50 
value and factor this reduces with reduced steroids in the cell media. 
The efficacy of the complexes refers to the ability of complexes to affect DNA and cause 
cytotoxicity, both are very important aspects of potential platinum(II) drugs for cancer 
treatment. The non-steroidal complexes in Table 7.2 possess poor efficacy; they exert few 
structural changes and the IC50 values signify the complexes cannot be considered to 
possess cytotoxicity near to that required for an anti-metastatic drug. The binding of non- 
steroidal complexes to DNA likely results in a relatively small mono-functional adduct that 
causing few structural changes to the DNA helix. Previous reports have shown some 
mono-functional adducts can cause relatively large DNA distortions, [5671 including - 
[Pt(NH3)2(L)Cll+ - type complexes with large heterocyclic ligands, 
[568-5701 particularly with 
a cis-geometry; [5711 also afew mono-functional platinum(II) complexes possess impressive 
CytotoXiCity. [3321 The complex [Pt(dien)Cl][CI] can promote a transition from B-DNA to 
another called Z-DNA -a dramatic change -, which is not seen for the non-steroidal 
complexes [5431 nor steroidal complexes [5721 and in the case of the former, these have very 
little effect on the DNA structure in terms of unwinding and bending. Hollis et al . 
[3321 
report similar complexes possessing poor or no cytotoxicity - non-steroidal TC-Py, CC-Py 
and TC-Q fall into this category with two very active complexes. Interestingly, TC-Q is 
more active than the pyridine-containing complexes and this may be a function of the 
larger size of the aromatic ligand forcing slightly greater distortion to the DNA helical 
structure - this has previously been suggested for triamine-type complexes. 
[5713 The fact 
that the complexes are no more active in media stripped of steroids indicates cytotoxicity is 
not modulated by steroid concentration and that the cells are not sensitised to platinum(II) 
drugs due to substantially reduced levels of steroids. In short, the three non-steroidal 
complexes are not candidates for cytotoxic drugs. 
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Table 7.1. Summary for TC-Py, CC-Py andTC-Q 
Hydrolysis Some detected 
7+ Binding to 5'-GMP Reacts with buffer 
ýH3 
N-Pjt-CI N03 / 5'-AMP 
NH3 Gel Electrophoresis Unwinds DNA < 5' 
TC-Py Linear Dichroism A[, D-160nm -31% 
AAbs, 60,,,,, -- 17 % 
Small amount of bending 
I Cl % (HBL-100 198 ýiM / 181 ýLM / 98 pM 
T47D / SK-OV-3 (I. Ittle change without steroids) 
Hydrolysis Some detected 
Binding to 5'-GMP Reacts with buffer 
N 
C1 
-Pjt-NH3 N03 
5'-AMP 
NH3 Gel Elcetrophoresis Unwinds DNA < 5' 
CC-Py Linear Dichroism Al-[)-16N,,, -31% 
AAbS260nrn -21% 
Small amount of bending 
ICFO JIBL-100 210ýtM/ 197ýAM/ 115ýM 
T47D / SK-OV-3 (l, ittle change without steroids) 
Hydrolysis None detected 
Binding to 5'-GMP Reacts with buffer 
N 
C1 
-ý It-NH N03 
/ 5'-AMP 
NH3 Gel Electrophoresis Unwinds DNA < 5' 
Linear Dichroism AID260nin - 26 % 
TC-Q AAbS260nm - 10% 
Small amount of bending 
,0 (HBL-100 / Ice 98 pM / 75 gM / 243 pM 
T47D / SK-OV-3 (I. Ittle change without steroids) 
The results of the various experiments show the presence of an ethnynyl-testosterone 
moiety on a bound aromatic ligand results in complexes substantially altering the structure 
of DNA and possessing cytotoxicity; what were complexes resulting in low levels of 
unwinding and bending of DNA and poor cytotoxicity, have now become very much more 
active because of the addition of an ethynyl-testosterone component. It should be noted 
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that steroidal platinum(II) complexes are, in certain aspects, similar to those without 
steroids; all hydrolyse and appear to the react with nucleobases via direct nucleophilic 
substitution, as opposed to via solvent species (which are also produced). Drawing 
parallels between the interaction of nucleobases and DNA, the results suggest the 
complexes may bind to DNA without the need to hydrolyse; there is support for this from 
the literature regarding triamine complexes, [547,548] however hydrolysis is the rate limiting 
[5731 step between ct-DNA and cis- [Pt(NH3)2(4-methylpyridine)CI] [N031 . Regarding the 
complexes under study, the striking absence and presence of, respectively, parent 
compound and hydrolysed version in the mixture of steroidal metal complex and base is 
very persuasive: it is the parent compound that primarily reacts. Once hydrolysed the 
agarose gels and linear dichroism results show an interaction occurs between DNA and 
bases, with the steroid crucially influencing the degree to which the complex changes the 
DNA structure. The gel and LD results complement each other: gels illustrate DNA 
unwinding, whilst LD shows the helix bends. The nature of a helix is such that to 
accommodate a bend, the helix is required to unwind/wind-up and the presence of the 
steroid increases the ability of the complex to do both, in many cases greater than that of 
cisplatin and other platinurn(II) complexes. The steric bulk of the steroid may require 
greater unwinding / bending of the helix to accommodate the complex and in the case of 
CC complexes, this is a very persuasive argument, given the similarly large unwinding 
angles observed (>- 190) of those complexes. The LD data certainly suggests the presence 
of the ethnynyltestosterone component causes bending of the helix, complementary to the 
gel studies showing unwinding that may be explained by a steroid - helix interaction. The 
nature of the likely interaction between steroidal skeleton and DNA is important and it has 
been known since at least the 1970's that steroid-like molecules can interact with DNA'574- 
5791 using hydrophobic interactions to stabilise kinks [5771 and 3-way DNA junctions [5801 _ 
interactions that directly relate to the steroidal complexes under discussions. Whilst the 
exact interaction between DNA and steroidal skeletons remains elusive and not enough 
data is available to form structure-activity relationships some conclusions can be drawn. 
The steroidal skeleton, in many studies bile acid residues, stabilise terminal A: T pairs (via 
van der Waals interactions) on synthetic oligomers. [5751 _a situation not so relevant in the 
case of steroidal platinum(II) complexes. Of more relevance, perhaps, is those using 
steroidal skeletons substituted with charged polyamincs in the 3 and 17 positions. [5771 
Whilst the charged moieties, perhaps unsurprisingly, interact with the negative 
phosphodiester backbone, there is evidence for a roles for the large hydrophobic surface 
area comprising of most of the steroidal skeleton. Such a situation is not so difficult to 
envisage in the case of steroidal platinum(II) complexes. The steroidal complexes cause 
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large structural changes to the structure of DNA and a hydrophobic interactions between 
the surface of the major groove and steroid may be envisaged and aid stabilising bent 
DNA, similar to HMGB I binding to DNA . 
12661 Although no direct data exists to support 
this theory - it is however one that would be ideally suited to NMR techniques. 
Table 7.2. Summary for steroidal platinum(II) complexes containing ET-3-Py 
Hydrolysis llydrolyses 
Linear ýý1-1)260nm - 53 % 
Dichroism AAbs, 6on,,, - 23 % 
Significant bending 
of the helix 
IC; O (HBL-100 / 27 jiM / 63 pM / 39 
T47D / SK-OV-3 pM. (Little change 
without steroids, 
except in T471) 
(2.63x) 
Binding to 5'- Binds to 5*-(; MP 
GMP /5'-AMP 5'-AMII 
p -NH3 N03 (e, Umvinds DNA 
C1 
Electrophoresis 19' (condenses at 
high loading) 
Pý -Cl N03 
NH3 
Hydrolysis I lydrolyses + 
unidentified signal 
Binding to 5'- Binds to 5'-GMP 
GMP / 5'-AMP 5'-AMII 
Cel Unwinds DNA - 
Electrophoresis 21' 
Linear AI, Dl6OnFn - 61 % 
Dichroism AAbS260nm - 23 % 
Very significant 
bending of'the helix 
ýqo 
(HBL-100 /7 ýM / 16 ýM / 16 ICI 
T47D/SK-OV-3 pM. (Little change 
without steroids) 
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TC-ET-3-Py 
CGET-3-Py 
Table 7.3. Summary for steroidal platinum(II) complexes containing ET-4-Py and ET-3-Q 
Hydrolysis Hydrolyses 
H3N 
-]+ Binding to 51- Binds to 5'-GMP 
Pt ci N03 GMP / 5'-AMP not observed 
N' 
NH3 Gel Unwinds DNA 
Electrophoresis 11 0 
Linear 
Dichroism 
ALD260nm 
- 36 % 
AAbS260nm 
- 33 % 
TC-ET-4-Py Medium bending 
of the helix 
IC50 (HBL-100 / 12 gM / 19 pM 
T47D / SK-OV-3 27 gM. (Little 
change except in 
T47D (2.07x) and 
SK-OV-3 (2.39x) 
Hydrolysis Hydrolyses 
Binding to 5'- Binds to 5'-GMP 
GMP / 5'-AMP 5'-AMP 
Gel Unwinds DNA 
-NH3 N03 Electrophoresis 15' (condenses at 
high loadings) 
Linear ALD260nm - 51 % 
Dichroism AAbS260nrn - 34 % 
Significant 
bending of the 
helix 
IC50 (HBL-100 / 24 ýtkl / 51 ýtkl 
T47D / SK-OV-3 50 gM. (Little 
change without 
steroids) 
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TC-ET-3-Q 
Table 7.4. Summary for steroidal platinum(II) complexes containing ET-4-IQ 
Hydrolysis I lvdrolvses 
Bindint! to 5'- Binds to 5'-GMP 
N 
NH3 
HP-Pý 
cl 
TC-ET-4-IQ 
CMP /5'-AMP not observed 
Cel Unwinds DNA - 4' 
N03 Electrophoresis 
Linear A 1,1) '60nm 42% 
Dichroism AAbs, 6(),,, 18 % 
Significant bending 
of the helix 
IQ 
.; 0 
(HBL-100 28 ýM / 51 pM / 70 
T471) / SK-OV-3 ýLM. (Little change 
without steroids, 
except T471) (2.47x) 
and SK-OV-3 
(9.37x) 
Hydrolysis llydrolyses + 
io N 
cl 
H3N P\t- 
NH3 
CC-ET-4-IQ 
unidentified signal 
Binding to 5- Binds to 5'-(; MP 
GMP / 5'-AMP not observed 
N03 Gel Unwinds DNA -> 
Electrophoresis 21' 
Linear AI, 1)160,,,,, - 64 % 
Dichroism AAbs, 6o,,,, - 13 % 
Very significant 
bending of the helix 
IC1,28 ýM / 33 pM / 26 ,o (HBL-100 / 
T47D / SK-OV-3 pM. Large changes 
in I IBIAOO (6.37x), 
T47D (4.43x) and 
SK-OV-3 (6.11 x) 
-cl H3N - P\' NH3 
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Table 7.5. Summary for steroidal platinum(II) complexes containing ET-6-Q. 
Hydrolysis Hydrolyses 
Binding to 5'- Binds to 5'- 
GMP /5'-AMP GMP 5'- 
NH3 
i3N 
Ft, 
C1 
N03 AMP 
Gel Unwinds DNA 
Electrophoresis - 190 
(condenses at 
high loadings) 
Linear ALD260nm - 54 
Dichroism % 
AAbS260nm - 45 
Medium 
bending of the 
helix 
IC50 (HBL-100 / 26 ýtM / 39 ýtM 
T47D / SK-OV- / 45 gm. 
3 (Little change 
without 
steroids, 
except T47D 
(0.37x) 
1 
Pt, 
NH3 13N 
Hydrolysis Hydrolyses 
unidentified 
signal 
N03 Binding to 5'- Binds to 5'- 
GMP / 5'-AMP GMP / not 
observed 
Gel Unwinds DNA 
Electrophoresis - 190 
(condenses at 
higher 
loadings) 
Linear ALD260nm - 58 
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TC-ET-6-Q 
CC-ET-6-Q 
Dichroism 
AAbS260nm - 24 
Significant 
bending of the 
helix 
IC, o (HBL-100 12 ttM / 14 
T47D / SK-OV- ýtM / 16 gM. 
3 (Little change 
without 
steroids, 
except SK- 
OV-3 (2.34x) 
Broadly speaking, from Tables 7.2 - 7.5, the greater the effect a complex has on the DNA 
structure the lower its IC50 value. The most active complexes, the cis-cationic, affect DNA 
greatly in terms of unwinding (>19') and bending whilst, particularly in the case of CC- 
ET-6-Q, being active in the full range of cell lines studied. At the opposite end of the 
spectrum the three non-stcroidal complexes affect DNA very little, unwinding only a few 
degrees, causing only small bending whilst possessing high IC50 values. This correlation is 
an interesting one and links the effect the complexes have on DNA in terms of global 
changes to its structure with cytotoxicity. Given that DNA is thought the target of 
platinum(II) drugs such a correlation is reasonable and could be a subject of future studies. 
An important result is a substantial reduction in steroid concentration in vitro does not 
sensitise the cells to platinum(II) complexes and than non-steroidal complexes, including 
cisplatin, which do not have their cytotoxicity significantly modulated. However, steroidal 
platinum(II) complexes (Chapter Six) do and this is a direct result of the steroidal skeleton; 
this may be due to reduction in androgens leaving more AR proteins without their usual 
ligands, or it may alter the transportation of the complex. Steroid stripping may remove 
components that bind steroids and increase the bioavailability of the complexes. Further 
testing, including ascertaining relative binding affinities of the complexes for the AR is a 
worthwhile task to undertake. 
The design brief for steroidal metal complexes (Chapter Two) stated the complexes must 
allow good receptor binding, coordination to DNA with a relatively facile synthesis; this is 
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in addition to those qualities required in a potential cytotoxic drug - altering DNA 
structure and possessing good cytotoxicity in a range of cell lines. The steroidal metal 
complexes have fulfilled many of the design briefs. They bind to DNA, causing greater 
unwinding than cisplatin in many cases and the presence of a steroid should mean the 
surface of the adduct exposed to the biological machinery is distinctly different from that 
of cisplatin so as not to possess a similar structure and cross-resistance. They all possess 
good and even excellent cytotoxicity towards a range of cell lines that may be ascribed, 
although not entirely, to the presence of a steroid. 
In short, the presence of a steroidal skeleton, appended to an aromatic planar ligand of a 
platinum(II) complex transforms that complex into one causing greater perturbations to the 
structure of DNA and possessing very much higher cytotoxicity, than complexes without 
the steroidal skeleton. 
227 
Appendix One -Additional Ligand Spectroscopy 
A. 1.1 ET-2-Py 
6' 
5' 
OH 
18 
4' 
. 11,12-l' 
17"ý'rýý21 
3' 
11 1 
3-1 \ 20 
19 14-,, )6 
8 15 
46 
C26H31NO2 
FigureA. 1.1. The mass spectrum of ET-2-Py in the region around ntlz= 391. The 
experimental (top) and theoretical (bottom) isotope distribution patterns are shown. The 
theoretical is ET-2-Py, C26H31NO2- 
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Figure A. 1.2. A COSY spectrum of the aromatic region of ET-2-Py. 
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Figure A. 1.3. The aliphatic region in the 1 H- 13C I IMQC spectrum of ET-2-Py. 
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Figure A. 1.4. The aromatic region in the 1 H- 13 C HMQC spectra of ET-2-Py in CDC13- 
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Figure A. 1.5. The infrared spectrum of ET-2-Py. 
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Figure A. 1.6. The mass spectrum (ESI, +ve) nilz 390.2 peak in ET-3-Py. The experimental 
peak (upper) and theoretical (lower). The theoretical is [H(ET-3-Py)]+. 
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Figure A. 1.7. The IR spectrum of ET-3-Py. 
A. 1.3. ET-4-Py 
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Figure A. 1.8. The mass spectrum (ESI, +ve) of ET-4-Py (upper) and theoretical isotope 
distribution (lower). 
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Figure A. 1.9. The infrared spectrum of ET4-Py. 
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Figure A. 1.10. The COSY spectrum of ET-3-Q in CDC13- 
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FigureA. 1.11. The low field region in the 111_13 C HMQC spectrum of ET-3-Q in CDC13- 
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Figure A. 1.12. The infrared spectrum of ET-3-Q. 
A. M. ET-4-IQ 
6' 8' 
90 5' 
10, 
OH N 
18 21 2' 
., -'12.1" -7 1 13 
1\ 0 
19 14 16 11 ý0-, 9, -, -1 
8 15 
(j5ý 3 46 
C30II33NO2 
236 
4000.0 3600 3200 2800 2400 2000 180D 1600 1400 1200 1000 SW 650.0 
an-I 
HT HIO' 
H8' H5' HT H6' 
m 
8.50 
9.00 
[P 
9.60 8.0 8. ýO 7.50 
PPM 
FigureA. 1.13. The aromatic region in the COSY spectrum for ET-4-IQ in CDC13- 
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Figure A. 1.14. The low field 'H- 13 C HMQC spectrum of ET-4-IQ in CDC13 
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Figure A. 1.15. The aliphatic region in the 111_13 C HMQC spectrum of ET-4-IQ in CDC13. 
Figure A. 1.16. The infrared spectrum of ET4-IQ. 
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Figure A. 1.17. The mass spectrum (ESI, +ve) of ET-6-Q. 
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FigureA. 1.18. The aromatic region in the COSY spectrum of ET-6-Q. 
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Figure A. 1.19. The IR spectrum of ET-6-Q. 
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Appendix Two -Additional trans-cationic complex 
spectroscopy 
A. M. TC-Py 
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Figure A. 2. I. The mass spectrum (ESI, +ve) of TC-Py showing experimental (upper) and 
theoretical (lower). 
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Figure A. 2.2. Comparison of the chemical shifts of free pyridine and TC-Py. 
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Figure A. 2.3. The mass spectrum of TC-Q. 
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Figure A. 2.4. The infrared spectrum of TC-Q. 
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Figure A. 2.5. The COSY spectrum for TC-ET-3-Py in CD30D. 
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Figure A. 2.6. The aromatic region in 111 NMR spectra of ET-3-Py (upper) and TC-ET-3- 
Py(lower) in CD30D. 
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Figure A. 2.7. The infrared spectrum of TC-ET-3-Py. 
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Figure A. 2.8. The ESI mass spectra for TC-ET-4-Py showing the parent ion peak. 
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Figure A. 2.9. The aromatic region of the lH NMR spectrum of ET4-Py and TC-ET-4-Py 
in CD30D. 
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Figure A. 2.1 1. The ESI-MS of TC-ET-3-Q. 
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Figure A. 2.10. The infrared spectrum of TC-ET-4-Py. 
Figure A. 2.12. The actual (upper) and theoretical (lower) isotope pattem of the ntlz-- 704.2 
peak in the spectrum of TC-E-T-3-Q. 
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Figure A. 2.13. The lH NMR COSY spectrum of TC-ET-3-Q. 
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Figure A. 2.14. The 1H NMR spectrum of ET-3-Q (upper) and TC-ET-3-Q (lower) in 
CD30D. 
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Figure A. 2.15. The infrared spectrum of TC-ET-3-Q 
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Figure A. 2.16. Comparison of the aromatic region of the 'HNMR spectrum of crude 
(upper) and pure (lower) TC-ET-4-IQ. 
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FigureA-2-17. The mass spectrum (ESI, + 83.9V) showing the peaks atnLlz= 1107.5and 
1089.5 assigned to [M-H]+ and [M-H20]+, M= [Pt(NH3)2(C301133NO2)21- 
+MS, 0.7-1.0min. subtracted peak start and and 
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Figure A. 2.18. The mass spectrum (ESI, +ve) of purified TC-ET-4-IQ. 
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Figure A. 2.19. The experimental (upper) and theoretical (lower) isotope distribution 
pattems for the mass spectrum (ESI, +ve) of TC-ET-4-IQ. 
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Figure A. 2.20. The aromatic region of the 1H NMR spectrum of ET4-IQ (upper) and TC- 
ET-4-IQ (lower) in CD30D. 
Figure A. 2.21. The infrared spectrum of TC-ET-4-IQ. 
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Figure A. 2.22. The mass spectrum of TC-ET-6-Q (ESI, +ve). 
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Figure A. 2.23. The comparison of the lH NMR spectra of ET-6-Q and TC-ET-6-Q. 
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Figure A. 2.24. The IR spectrum of TC-ET-6-Q. 
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Appendix Three - Additional cis-cationic complex 
Spectroscopy 
A. M. CC-Py 
5' 
Cl 
Tc pt+ 2' ,, NH3 H3N 
[CsHlICIN3][NO31 
344.0 
Figure A. 3. I. The ESI mass spectrum of CC-Py (upper) and the expected isotope 
distribution pattern (lower). 
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Figure A. 3.2. The 1H NMR spectra of pyridine (upper) and CC-Py (lower) in CD30D. 
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Figure A. 3.3. The infrared spectrum of CC-Py. 
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Figure A. 3.4. The 1H NMR spectra of ET-3-Py (upper) and CC-ET-3-Py (lower) in 
CD30D. 
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Figure A. M. The IR spectrum of CC-ET-3-Py. 
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Figure A. 3.6. The 1H NMR spectra of CC-ET-4-IQ showing the crude (upper) spectrum 
and purified (lower) spectrum. Those signals marked double prime represent the 
disubstituted complex in CD30D. 
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Figure A. 3.7. The mass spectrum (ESI, +ve) of CC-ET4-IQ in the nVz = 100 - 
1500 region. 
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Figure A. M. The mass spectrum (ESI, +ve) of CC-ET-4-IQ in the Wz = 700 - 710 region. 
263 
H2' 
H10' 
H8' HT HT H6' 
8.00 
8.50 
0 
9.00 
9.00 8.50 8.00 
Figure A. M. The aromatic region in the COSY spectrum of CC-ET4-IQ in CD30D. 
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Figure A. 3.10. The lH NMR spectra of ET-4-IQ and CC-ET4-IQ in CD30D. 
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Figure A. 3.1 1. The infrared spectrum of CC-ET-4-IQ. 
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Figure A. 3.12. The mass spectrum (ESI, +ve) of crude CC-ET-6-Q. The peaks at nVz 
440 and 554 correspond to [H(ET-6-Q)]+ and [Pt(NI13)2(ET-6-Q)2]2+. 
Figure A. 3.13. The mass spectrum of CC-ET-6-Q (ESI, +ve) of CC-ET-6-Q with 
experimental (upper) and theoretical (lower) isotope distributions of [Pt(NI13)2(ET-6-Q)21- 
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Figure A. 3.15. The mass spectrum of CC-ET-6-Q (upper) and theoretical isotope 
distribution (lower). 
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Figure A. 3.14. The mass spectrum of CC-ET-6-Q (ESI, +ve). 
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Figure A. 3.16. The 1H NMR spectra of CC-ET-6-Q and ET-6-Q in CD30D. 
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Figure A. 3.17. The IR spectrum of CC-ET-6-Q. 
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Appendix Four - Geometry of TC and CC complexes 
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Figure AA 1. A comparison of the lH NMR spectra of TC-Py and CC-Py in CD30D. 
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Figure A. 4.2. A comparison of the 1H NMR spectra of TC-ET-3-Py and CC-ET-3-Py in 
CD30D. 
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Figure A. 4.3. A comparison of the lH NMR spectra of TC-ET-4-IQ and CC-ET-4-IQ in 
CD30D. 
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Figure AAA A comparison of the lH NMR spectra of TC-ET-6-Q and CC-ET-6-Q in 
CD30D. 
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Appendix Five -Additional complexes with DIVISO as a 
ligand: spectroscopic data 
A. 5.1. Trans-Pt(Py)(DMSO)CI2 
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Figure A. M. The infrared spectrum of trans-Pt(Py)(DMSO)CI2- 
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Figure A. 5.2. The infrared spectrum of trans-Pt(Quinoline)(DMSO)CI2- 
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Figure A. 5.3. The COSY aromatic region of trans-Pt(ET-2-Py)(DMSO)CI2- 
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Figure A. 5.4. The HMQC 1 H- 13C correlation spectrum of trans-Pt(ET-2-Py)(DMSO)CI2 
(CD3)2CO- 
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Figure A. 5.6. The infrared sPectrum of trans-Pt(ET-2-Py)(DM SOX12- 
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A. 5.4. Trans-Pt(ET-3-Q)(DMSO)CI2 
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Figure A. 5.7. The aromatic region of the 1H NMR spectrum of trans-Pt(ET-3- 
Q)(DMSO)CI2. Hydrogens labeled for example H2' belong to trans-Pt(ET-3- 
Q)(DMSO)CI2 whilst those labeled, for example, H2" belong to complexes with 2 ET-3-Q 
ligands. 
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Figure A. 5.8. The aromatic region of the COSY spectrum of trans-Pt(ET-3- 
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Figure A. 5.9. A comparison of the aromatic region in the lH NMR spectra of ET-3-Q and 
trans-Pt(ET-3-Q)(DMSO)CI2- 
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Figure A. 5.1 1. The low field chemical shift range in the HMQC spectrum of trans-Pt(ET- 
3-Q)(DMSO)CI2- 
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Figure A. 5.12. The infrared spectrum of trans-Pt(ET-3-Q)(DMSO)CI2. 
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Appendix Six - Additional platinum starting complexes 
spectroscopy 
A. 6.1. Cis-diamminediiodoplatinum(II) 
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Figure A. 6.1. The infrared spectrum of cis-diamminediiodoplatinum(II). 
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Figure A. 6.3. The infrared spectrum of trans-diamminedichloroplatinum(II). 
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Figure A. 6.2. The infrared spectrum of cis-diamminedichloroplatinum(II). 
A. 6.4. Cis-bis(dimethylsulphoxide)dichloroplatinum(II) 
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Figure A. 6.5. The 1H NMR spectrum of cis-bis(dimethylsulphoxide)dichloroplatinum(II). 
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Figure A. 6.4. The infrared spectrum of cis-bis(dimethylsulphoxide)dichloroplatinum(II). 
Appendix Seven - ESI Mass Spectroscopy of Complexes 
illustrating hydrolysis 
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Figure A. 7.1. ESI-MS (+ve) spectra of TC-Py; upper and middle, up to nVz = 500; lower, 
expansion and calculated isotope distribution patterns. 
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Figure A. 7.2. ESI-MS (+ve) spectra of CC-Py up to Wz = 500. 
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Figure A. 7.3. ESI-MS (+ve) spectra of TC-Q up to nVz = 500. 
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Figure A. 7.4. ESI-MS (+ve) spectra of TC-ET-3-Py; left, up to rwz = 1000; right, 
expansion and calculated isotope distribution patterns. 
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Figure A. 7.5. ESI-MS (+ve) spectra of TC-ET4. Py. 
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Figure A. 7.6. ESI-MS (+ve) spectra of TC-ET-3-Q; upper, up to nilz = 1000; lower, 
expansion and calculated isotope patterns. 
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Figure A. 7.7. ESI-MS (+ve) spectra of TC-ET-4-IQ; a) upper, up to nvz = 1000; lower, 
expansion and calculated isotope patterns. 
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Figure A. M. ESI-MS (+ve) spectra of TC-ET-6-Q; left, up to nzlz = 1000; right, 
expansion and calculated isotope patterns. 
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Figure A. 7.9. ESI-MS (+ve) spectra of CC-ET-3-Py; a) upper, up to nvz = 1000; lower, 
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Appendix Eight - ESI mass spectroscopy of complexes 
illustrating nucleophilic substitution 
Figure A. 8.1. ESI-MS (+ve) spectra of TC-Py + 5'-GMP in the range nVz =0- 1000. 
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Figure A. M. ESI-MS (+ve) spectra of TC-Py + 5'-GMP in the range nzlz =0- 500. 
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Figure A. 8.2. ESI-MS (+ve) spectra of CC-Py + 5'-GMP in the range nzlz 0- 500. 
1000; bottom, range from nzlz 1000 - 1500. 
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Figure A. M. ESI-MS (+ve) spectra of TC-ET-3-Py + 51-GMP; top, range from nilz =0- 
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Figure A-8-5. ESI-MS (+ve) spectra of TC-ET-4-Py + 5'-GMP; upper, range from rWz 
500 - 1000; middle, range from Wz = 1000 - 1500; lower, expansion and calculated 
isotope distribution pattern for adduct, around ntlz = 980. 
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1000 Wz = 500 - 1000; middle, range from tWz = 1000 - 1500; lower, expansion and 
calculated isotope distribution pattern for adduct, around nzlz = 1030. 
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Figure A. 8-6. ESI-MS (+ve) spectra of TC-ET-3-Q + 5'-GMP; upper, range from 500- 
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Figure A. 8.9. ESI-MS (+ve) spectra of CC-ET-3-Py + 5'-GMP from tWz = 500 - 1000. 
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Figure A. 8.1 0. ESI-MS (+ve) spectra of CC-ET-3-Py + 5'-AMP, range from nVz = 500 - 
1000. 
299 
1.0 
0.51 
152.3 
11.44P. 
2 
0.0 
1272.6 1360.3 14J7.2 
miz 
Figure A. 8.1 1. ESI-MS (+ve) spectra of CC-ET-4-IQ + 5'-GMP; upper, range from nilz = 
500 - 1000; middle, range from nLIz = 1000 - 15000; lower, expansion and calculated 
isotope distribution pattern for adduct around nilz = 1030. 
300 
400 600 800 1000 
2.0 
1.5 
1.0 
0.5 
600 800 1000 1200 1400 MIZ 
Figure A. 8.12. ESI-MS (+ve) spectra of CC-ET-6-Q + 5'-GMP. Ranging from 1000-1500 
nvz. 
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Appendix Nine - Absorbance spectroscopy, linear 
dichroism and gel electrophoresis 
A. M. Electromagnetic radiation 
Electromagnetic radiation, of which the visible light around us forms a small part, is an 
important technique for biophysical investiga; it consists of electric and magnetic 
components, oscillating - 90' to each other and, to the direction of propogation. 
Electromagnetic radiation may also be characterised in terms of polarisation: e. g. linear 
and circular. The electric field of circularly polarised light remains equal in magnitude but 
rotates around the axis of the propagation direction; the combination of rotation and 
propagation traces out a helix, which may be right handed or left handed depending on the 
direction of rotation of E, the electric field. Linearly polarised light has the electric field, 
E, oscillating in a single plane, at 90' to the direction of propogration. 
A. 9.1.1. Absorption spectroscopy 
Spectroscopy is the investigation into the interactions between electromagnetic radiation 
and matter. The interaction of electromagnetic radiation with matter often results in the 
transfer of energy from the photons of incoming radiation to the molecules the matter is 
composed off; the molecules may scatter the photons, absorb the photons or emit photons, 
or combination of the three in varying proportions. 
There exists a difference of several orders of magnitude between the highest and lowest 
electromagnetic energies; the effect of high energy radiation on matter is vastly different 
from that of low energy, for example molecules may be rotated by microwave radiation 
(wavelengths of 106 _ 109 nm); chemical bonds vibrated by far-infrared radiation (2 x 103 
-2 x 104 nm); electrons are promoted to higher energy levels when irradiated with UV / 
visible light (800 - 170 run); using radiation - very high energy - in the forms of extreme 
UV (10 nm) breaks chemical bonds and, X-rays (10'2 - 104 mn) completely remove 
electrons from atoms. 
In the UV Q. = 170 - 400 nm) and visible (k = 400 - 700 nm) regions of the 
electromagnetic spectrum the energy of the photons is similar to the difference between 
energy levels in the electron containing atomic and molecular orbitals; this can promote 
rearrangement of electron distribution within a molecule. This phenomenon results in an 
absorbance spectrum characteristic of the energy levels and transitions of the molecule 
being studied. The rearrangement of electron density during an electronic transition may 
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be described in terms of a net linear displacement of charge; displacement is described by a 
vector, the transition moment, p, with a defined magnitude (length) and direction 
(polarisation). The direction of this displacement is the polarisation of the transition 
where P' cc A, where A is the absorbance of the transition. 
The intensity of the transition is related to absorbance by A= loglo 
I, 
where A is the 
(10) 
sample absorbance at a defined wavelength, Io is the intensity of light incident on the 
sample and I the intensity of light emerging from the sample. Absorbance may be directly 
related to the concentration of the sample by the Beer-Lambert law which states, A= ECI , 
where c is the concentration of the molecule in question in unit of mol dM-3 and I is the 
length of sample the light travels though in units of centimetres; the molar absorption co- 
efficient, c, is constant for a given substance at a given wavelength in defined conditions; 
the magnitude of c is related to the probability of the transition (P) and the chromophore 
area (a), where v=0.87(l o20 Pa). Deviations from the linear relationship surnmarised by 
the Beer-Lambert law occur: too concentrated a solution may often lead too few photos 
emerging from the sample with resulting poor signal to noise ratio; too high a 
concentration may also lead to deviations due to intermolecular interactions and changes in 
refractive index are not accounted for in the law; scattering is prevented by ensuring no 
particles arc present in the sample. 
Experimentally an electronic transition is not a sharp peak but is broadened as the absorbed 
photons are of slight different energies. Such broadening is due to several factors 
including intermolecular interactions with the solvent, rotational and vibrational transitions 
and the uncertainty principle where the energy of the transition and the lifetime of the 
excited state cannot be known simultaneously. 
AALZ Spectroscopic transitions 
The movement of electrons during an electronic transition may originate from several 
typcs of orbital as shown in Figurc A. 9.1. 
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Figure A. 9. I. Types of UV-vis. spectroscopic transitions seen in organic molecules. 
Absorption originating from 7c - 7r* and a- (Y* transitions typically exhibits intense bands 
(C", > 10 4 mol -1 din 3 CM -1 ) whilst weak bands (E ...... < 10 
2 mol -1 dM 3 CM -1 ) may be 
assigned to n- n* and n- a* transitions. Many bands from a- a* transitions are 
predominately found at wavelengths below 200 nm in the vacuum-UV whilst 7E - 7E* and n 
- 7E* transitions are found above 200 nm. 
Metallo-organic entities have additional transitions as a consequence of the presence of 
metals and their bonding to the organic component. Transition metal metallo-organic 
complexes here exhibitd -> d transitions due to partially filled d-orbitals; metal centred 
transitions from 7E to a orbitals (7Em - am* for example) and metal-to-ligand (MLCT) and / 
or ligand-to-metal (LMCT) charge transfer transitions, for example from the 7E orbitals of 
the metal to those of the ligand; the movement of charge between ligands and / or between 
the ligand and metal centre lead to charge transfer (CT) transitions. 
A. 9.1.3. DNA transitions 
DNA solutions are colourless, exhibit absorbance below 300 rim (", - 260 nm) arising 
from the nucleobases; specifically the a- n* electronic transitions of the purine and 
pyrimidine bases give rise to a characteristic absorbance centred on 260 nm. The 
concentration of duplex DNA solutions may be calculated using the Beer-Lambert law as E 
is known for several duplex DNA's; for example, duplex calf thymus DNA E258nn = 6600 
mol -1 dM 3 CM -1. 
A. 9.2. Linear dichroism spectroscopy 
Linear dichrosim (LD) is the difference in absorption between light, linearly polarised 
parallel and perpendicular to a defined orientation axis at a giben wavelength; it may be 
used to investigate DNA-molecule interactions as the DNA helix may be aligned in 
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Figure A. 9. I. Types of UV-vis. spectroscopic transitions seen in organic molecules. 
Absorption originating from a- 7E* and a- cr* transitions typically exhibits intense bands 
(Emax > 10 4 mol " dM 3 cm ") whilst weak bands (c .. a., < 102 mol -1 dM 
3 cm -1) may be 
assigned to n- 7c* and n- a* transitions. Many bands from (; - cr* transitions are 
predominately found at wavelengths below 200 mn in the vacuum-UV whilst 7c - n* and n 
-, x transitions are found above 200 nm. 
Metallo-organic entities have additional transitions as a consequence of the presence of 
metals and their bonding to the organic component. Transition metal metallo-organic 
complexes here exhibit d -> d transitions due to partially filled d-orbitals; metal centred 
transitions from a to a orbitals Orm - crm* for example) and metal-to-ligand (MLCT) and / 
or ligand-to-metal (LMCT) charge transfer transitions, for example from the 7r orbitals of 
the metal to those of the ligand; the movement of charge between ligands and / or between 
the ligand and metal centre lead to charge transfer (CT) transitions. 
A. 9.1.3. DNA transitions 
DNA solutions are colourless, exhibit absorbance below 300 nrn Q,,,,, - 260 nm) arising 
from the nucleobases; specifically the 7c - ir* electronic transitions of the purine and 
pyrimidine bases give rise to a characteristic absorbance centred on 260 nm. The 
concentration of duplex DNA solutions may be calculated using the Beer-Lambert law as C 
is known for several duplex DNA's; for example, duplex calf thymus DNA E258nm = 6600 
mol " dM 3 CM -1. 
A. M. Linear dichroism spectroscopy 
Linear dichrosim (LD) is the difference in absorption between light, linearly polarised 
parallel and perpendicular to a defined orientation axis at a giben wavelength; it may be 
used to investigate DNA-molecule interactions as the DNA helix may be aligned in 
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specific orientation using a variety of techniques. Mathematically, LD is defined 
as LD = A# - A. L, where A// is absorption of linearly polarised light parallel to the 
orientation axis and A_L is absorption of linearly polarized light perpendicular to the same 
orientation axis. A consequence of the directional component of the electronic transition 
of the orientated chromphore is differential absorption of parallel and perpendicular 
linearly polarised light of oriented samples resulting in an LD spectrum. For a transition 
whose transition moment is aligned at exactly 90 degrees to the orientation axis (assuming 
uniaxial orientation), LD at X... is 
AIi. 
e. LD < 0, a negative signal; the LD is exactly 2 
zero if the transition moment is at the magic angle, 54.7', to the orientation axis; whilst it 
is positive for transitions whose transition moment lies at angles >54.7* to the orientation 
axis. In the case of DNA, transition moments of the 7c - a* transition of the nucleobases are 
at the angle of -90' to the orientation axis of DNA, so that LD spectroscopy is able to 
probe the roll and tilt of the bases relative to the orientation axis. 
Furthermore, quantitative information may be gained from the reduced linear dichroism 
(LD'): LD r= 
LD 
= 
All - A. L =3 S(3 cos 2a- 1), where A is the average absorption over AA2 
all possible orientations, i. e. the isotropic absorption; S defines the efficiency of 
macroscopic orientation, Le. S=I for perfect orientation; the angle between the orientation 
axis and transition moment or the transition in question is cc. The magnitude of the LD " is 
constant across the absorption band of a single transition; therefore, LD' can identify 
different electronic transitions that are perhaps not so apparent using absorption 
spectroscopy. A change in LD"suggests another electronic transition. In an ideal 
situation, sections of constantLD'will be clearly seen; however, for transitions whose 
absorption envelope overlap, sections of constant LD" are more difficult to identify; in this 
situation a change of LD" is may be interpreted as entering another absorption envelope. 
Orientation of chromophores is achieved in many ways: long polymers, such as ct-DNA 
(>1000 base pairs), ' are orientated using shear flow; smaller chromophores require 
different techniques that possess a greater ability to orientate, such as stretching a film 
loaded with analyte. 
A. 9. ZI. Stretchedpolymerfilm linear dichroism spectroscopy 
Polymers, such as polyvinyl alcohol (PVA) or polyethylene (PE) may absorb small 
molecules onto their surface and into their matrix. The small molecules then align when 
305 
the film is stretched; the alignment is along the long axis of the molecule in the direction of 
the stretch (Figure A. 9.2). Small molecules may either be cast within the film (such as 
with polyvinyl alcohol) or the solution added to the film and the solvent allowed to 
evaporate (such as polyethylene) before or after the film is stretched to align the molecules. 
The orientation power of film LD is superior compared to other techniques for small 
molecules but no method, except perhaps crystallisation, produces a perfectly orientated 
sample and orientation of samples must be considered to be a distribution around the 
orientation direction; the distribution results as individual molecules are not all exactly 
alined with the orientation axis. 
N 
N 
IN 
6141 
N-r 
polyethylene stretched film 
Ir 
Ný Ný 
NNN& 
Nzý C. 0 Cl, ONý C 
No" N 
stretch direction 
Figure A. 9.2. Pictorial representation of the orientation of quinoline using a polyethylene 
film. 
A mathematical description of the degree of orientation of a molecule in a matrix used the 
three vectors S, _., 
Syy and S,,,. The orientation factor, S, defines the efficiency of 
macroscopic orientation, which may be split into three vectors relating to the efficiency of 
macroscopic orientation along the x, y, and z axes. They are a measure of the degree to 
which molecules aligns within a matrix (often polyethylene in film LD). The orientation 
triangle (Figure A. 9.3. ) defines the possible combinations of the orientation parameters Syy 
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and S,,, and illustrates several different molecules and the degree to which they align; long 
thin molecules tend to align better and magnitude of S. and S, tend to be high. 
SYY 
0.25 
-0 
0 
Sý 
Ic 9 ýb szz Qoz 
0---HO 
-O. S 
Figure A. 9.3. The orientation triangle. The orientation parameters ($, dS )for ,,, an ,y 
molecules orientated in stretched PE. 15811 The z-axes are horizontal. 
LD spectra obtained using the stretched film method can yield valuable information; 
polarised absorbance and transition moments may be derived for example. LDr may be 
LD(A) S. "C' 
(A) + SYYE, (A) + S. E., (A) ftulher defined was as LD "(A) = A(A) =36, (A) + cy (A) + E., (A) I 
where A is 
the absorbance of an un-orientated sample and e., (A) etc. are the extinction coefficients. 
The subscripts x, y and z indicate the axis to which incident light is parallel too; S is the 
degree to which the molecule is orientated in the direction indicated by its subscript. 
For disk shaped molecules used in this thesis, i. e. quinoline and isoquinoline, for 
transitions whose direction lies solely in the x, y or z axis, the reduced linear dichroism is 
given by: LD* (z) = 3S.; LD " (y) = 3S.; LD(x) = 3S, In quinoline x, y, and z are 
defined by symmetry - the z axis follows the long axis of the molecule. Identification of 
pure z-polarised and pure y-polarised transitions may be achieved by observing the large 
positive LD'(for z-polarised transitions) and lower or negativeLD" (for y-polarised 
transitions); from this the orientation parameters, SzzandSW are calculated. Once 
calculated, SZZandSyyare used to determine Az (A) and AY (A); these represent the 
absorbance of the sample if the incident radiation is polarized along, respectively, the z and 
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y axes. Symmetry rules predict planar aromatic molecules must have in plane z -+ ;r* 
transitions: using our coordinate system C., (A) =0 and we may 
write LD = SzzA, (A)+ SYYAY(A), which once solved for A, and AY, determines the 
absorbance of z- and y-polarised light, respectively. Towards the goal of establishing the 
transition moments for each absorbance band in planar aromatic molecules, absorbance of 
x-polarised light is ignored as the transition are all in plane, hence 
LD" (A) =3S. 
E, (A) + syycy (A)+ S. S. (A) 
6, (A) + cy (A) + C., (A) 
S 
zz 
+ Syy 
S. Cz (A) + SOCY (A) 
reduces to LD(A) =36, (A) + ey (A) 
3C 
z+I 
Cy 
e, LDr A) -3S 2 which, after further rearrangement: 
16 
.= 
LDr(A)-3S 
,- Cos 
2a= Cot2 a where a 
y sin a 
angle that defines the transition moment that causes absorption at a given wavelength 
relative to the orientation axis. [5811 
A. 9. ZZ Flow LD 
Orientation of long polymers such as DNA requires a lesser orientation force compared to 
small molecules. In flow LD, long molecules are orientated by placing a solution between 
two cylindrical surfaces rotating relative to each other which orientates DNA biaxially, 
although the helical nature of DNA means that orientation is considered to be uniaxial. 
A Couette flow cell (Figure A. 9.4) is capable of sufficient orientation of DNA (>1000 
bases pairs). In this work, the flow cell used consists of a fixed outer cylinder with a 
rotating inner cylinder with a small annular gap between the two surfaces causing a viscous 
drag and alignment of DNA; greater orientation of the DNA strands is achieved by 
increasing the speed of the cylinders relative to each-other, but not so high to avoid 
turbulent flow, that gives rise to air bubbles and artefacts in the LD spectrum. 
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Figure A. 9.4. The design of a couette flow cell 
Reduction of volumes, important when using biological samples, has lead to the design of 
micro-volume couette cell and based on the same principle as the larger design. A quartz 
cylindrical cell (-5 mm OD, -3 mm ID) rotates and an inserted stationary rod (-2.5 mm 
OD) causing a 0.25 mm annular gap between the cell and rod resulting in orientation of 
DNA . 
15821 Most of the data reported in this work is collected with a micro-volume Couette 
cell. 
A. 9.2.3. Linear dichroism of DNA - molecule conjugates 
LD is a powerful tool in determining the binding orientation of a molecule to DNA with 
the provision that the molecule is spectroscopically active, whose transitions are assigned 
and, preferably do not overlap with the n- 7r* transitions of the nuclear bases. An LD 
signal from a transition assigned to the binding molecule signifies that the molecule is 
bound to DNA in a specific orientation; coupled with further knowledge regarding the 
transition moment and the orientation of the molecule may be determined and, although the 
exact location of binding cannot be assigned, it provides clues to possible sites of binding. 
A. 9.3. Supercoiled DNA and gel electrophoresis 
It is possible for DNA duplexes to exist in other conformations: one of the most important 
is supercoiled, where the duplex twists around itself and, depending on the direction of 
twisting, DNA may form right-handed (negatively supercoiled) or left-handed (positively 
supercoiled) topologies; examples of supercoiled DNA are shown in Figure A. M. 
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Figure A. M. Examples of relaxed (centre) and increasingly supercoiled DNA: 
increasingly negative supercoiling (far left) and increasingly positive supercoiling (far 
right). 
Negative supercoiling causes a torsional stress to the DNA favouring unwinding of the 
duplex, whereas positive supercoiling favours winding up of the duplex. Conformational 
changes to the duplex affects the degree of supercoiling and visa versa, which can result 
from interactions with bound molecules. Many differenct methods of analysis are 
employed to investigate this interaction; one of the most common uses gel electrophoresis 
- the movement of charged particles through a porous medium such as a gel - that 
separates on the basis of size. The DNA's shown in Figure A. 9.5 are all different sizes, 
supercoiled DNA is smaller than relaxed for example and will travel through gels at 
different speeds. If for some reason the supercoiling is reduced the bands in the gels 
eventually slows to that of the relaxed form; this fact can be used to characterized the 
degree to which a platinum(II) complex may unwind the helix. Using the mathematical 
properties of supercoiling, electrophoresis can quantify unwinding according to the 
18a 
equation: 0=, where 0= the unwinding angle, a= superhelicity constant and rb(, ) the 
rb(c) 
ratio where supercoiled and relaxed DNA co-migrate. [5831 The superhelicity contant is a 
quantitative measure of supercoiled - it is the average number of superhelical turns per 10 
base pairs. 
Electrophoresis is derived from the Latin electrum and Greek i1xCKT POI) (meaning amber, 
the rubbing of). The medium for electrophoretic separation of DNA is agarose, a linear 
galactan. hydrocolloid from agar, and is the standard medium of size-based separation of 
DNA fragments using electrophoresis. Gels are cast by melting agarose in the present of 
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buffer - Tris Acetate EDTA (TAE) or Tris Borate EDTA (TBE) - by pouring into a 
casting tray and cooling beneath the gelling point (approx 32'C) thus allowing hardening 
and the formation of a gel matrix. The agarose concentration varies from 0.3 %-2% w/v, 
depending on the size of the DNA fragments to be separated. Once DNA is loaded into 
wells cast into the gel, the casting tray and gel are submerged in buffer solution and the 
DNA samples, complete with the tracking dyes xylene cyanol and bromophenol blue, are 
added. The speed of migration of bromophenol blue and the DNA plasmid pBR322 are 
similar for example, allowing the location of DNA to be pin-pointed. Since the DNA 
cannot be directly visualised, the gel is finally soaked in a solution of ethidium bromide 
which contains a planar aromatic group that intercalates between DNA base pairs in the 
helix; once bound the fluorescence of ethidium, bromide increases and irradiation of the gel 
at 254 nin is absorbed and light is emitted at 590 run. 
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Appendix Ten - UV / visible spectroscopy of ligands and 
complexes 
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Figure A. 10.1. Absorption spectroscopy of various I igands and complexes at 
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Appendix Eleven - Calculation of the transition moments 
of quinoline and isoquinoline 
A. 11.1. Film linear dichroism of quinline and isoquinoline 
This appendix describes the calculation of the transition moments of quinoline and 
isoquinoline using film LD spectrum collected as outlined in § 5.7. Representative film 
LD, absorbance and reduced LD spectra of quinoline and isoquinoline are shown in Figures 
A. 11.1 and A. 11.2. The origin of the absorbance is clear from the molecular structure of 
quinoline and its isomer: ; r--*; r* and n-. >; r transitions; although n--+; r* transitions are likely 
to be weak. In the wavelengths studied, quinoline and isoquinoline display only positive 
linear dichroism and the reduced LD signal is also positive; however, around 280 nm the 
LD" approaches zero. The sign of the LD" means the orientation factors, Szz and Syy, are 
both positive and on the orientation triangle (Figure 5.11) quinoline and isoquinoline are - 
not surprisingly - associated with disc shaped molecules rather than rods. Calculation of 
the transition moments followed the method of Rodger and Norden; E5811 briefly, the 
following was assumed 1) 3Sýý = LD'(max); 2) 3Sýy = LD "(min); 3) disk shaped planar 
aromatic molecules must have transition moments parallel or perpendicular to the 
molecular plane. For quinoline, the peak at 314.5 mn was assumed to be of pure z- 
polarisation; hence, S. = 0.03 93 ; assuming the trough at 280 nm is of pure y-polarisation 
leads to S. = 0.0071. Similar calculations for isoquinoline assume the following: LY at 
227.2 mn is purely z-polarised and that at 282.6 nm, y-polarised; this results in 
Szz = 0.0441 and SYY = 0.0093. Using the fact that the orientation factors sum to zero, it 
follows that for quinoline, S.,, = 0.0464 and isoquinoline, S. = 0.0534; this is exactly as 
expected for disk shaped molecules and it is concluded that the polarisation assignments 
are correct. The relatively small magnitudes of these values reflect the poor alignment of 
such molecules; this correlates with the large loading of analyte required to obtain a 
reasonable LD spectra in addition to the problem that longer wavelength coefficients are 
very much greater than those of shorter wavelengths. 
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FigureA. 11.1. The film LD, absorbance and LD' spectra of quinoline using PE film. 
Lines represent minimum, maximum or flat regions of LD". 
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Figure A. 11.2. a) The LD, absorbance and LD" of isoquinoline on PE film. b) expansion of 
the LD" spectrum; lines represent minimum, maximum or flat regions of LD'. 
The isotropic spectrum of quinoline in Figure A. 11.1 displays 6 bands, at 206,226,230, 
275,3 10 and 314 nm and no absorption (likely to arise from n -> 7r * transitions) is 
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present above 325 nm. TheLD'of quinoline is complicated; it increases from 195 rim. 
(magnitude - 0.03) to a maximiurn at 240 run (magnitude - 0.075) before decreasing to a 
minima at 275 nm (magnitude - 0.02); it then increases to a maxima at 314 run before 
decreasing, leveling off around 320 mn before decreasing further. There exists several 
abrupt and several more subtle changes to the magnitude of the LD': an indication of the 
present of a transition. Bands 1,11 and III in Figure A. 11.2 appear to consist of transitions 
at 206,214,230 and 240 rim. Between band III and IV, changes are very subtle; 
transitions at 248 and 275 mn can be identified and can account for the absorption 
envelope of band IV. Band IV appears to include transitions at 289 and 296 ran; the latter 
forms part of band V in addition to transitions at 302 nm and 309 nm (the 309 nm 
transition may actually be two). The final band, VI, consists of two transitions at 312 and 
320 run. In total 12 separate transitions are suggested to exist for quinoline in 
the LD " spectrum. Some of the small changes in the LD " may be attributed to vibrational 
structure of electronic transitions, particularly as the differences between apparent band 
positions above 289 rim are 6-7 nm; this may account for features labeled as individual 
transitions, it may be suggested that instead of 12 transitions in the UV / visible spectrum 
of quinoline there are very much fewer, and these occur at 314,305,276,248,240,230, 
225,214 and 206 nm. It is proposed that these are true electronic transitions present in the 
isotropic absorbance spectrum of quinoline and to the author's best knowledge this 
information does not exist in the literature. 
Isoquinoline (Figure A. 11.2. ) possesses an even more complicated spectrum than 
quinoline, with particular reference to longer wavelengths. A total of five bands arc 
observed between 195 and 325 nm; no absorption is observed at longer wavelengths. The 
magnitude of the LD " increases from - 0.02 (at 195 nm) to a maximiurn - 0.13 (at 227run); 
theLD"then decreases, to minima of -0.03 (at 256 rum) before increasing again to a 
maximum magnitude at 308 run. At longer wavelengths theLD' fluctuates, before 
decreasing in magnitude to minima at 320 nm. Band I appears to consist of three 
transitions, <196,198 and 210 nm; the latter also contributes towards band 11, in addition 
to a transition at 227 nm. At least three transitions appear to contribute to towards band 
111, at 237,248 and 265 nm. Towards higher wavelengths the fluctuation of the LD' 
introduce difficulties, with II separate changes in magnitudes suggesting II individual 
transitions; a rather high number. In a similar way to that of quinolinc, some of the small 
changes observed in the reduced LD spectrum may be due to vibrational structure present 
on electronic transitions; this reduces the number of transitions though present in 
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isoquinoline to those occurring at 198,210,217,227,237,248,265,300,313 and 320 nrn. 
The small change present at 248 nrn may be considered as a vibrational component but is 
required to fully account for the isotropic absorbance in the region. At longer wavelengths 
three transitions are proposed centred at 300,313 and 320, taking into account the 
variations in the reduced LD spectrum. A summary of apparent band positions is given in 
Table A. 11.1. 
'rable A. 11.1. Suggested transitions in the isotopic spectra of quinoline and isoquinoline. 
Band positions, nm 
III IV V vi Vil Vill Ix x 
Quinoline 206 214 225 230 240 248 276 305 314 320 
Isoquinoline 198 210 217 227 237 248 265 300 313 
From the values for S-- and SYY a polarized absorption spectra may calculated, as described 
in Appendix Nine, which quantifies the absorbance of z- and y-polarised light. 
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Figure A. 11.3. Polarised absorption spectrum of quinoline. 
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Figure A. 11.4. Polarised absorption spectrum of isoquinoline. Insert: expansion in the 
region 220 - 325 nm. 
In determining z and y components of the spectra of quinoline and isoquinoline, the effect 
of small incremental changes in Szz and S YY on the component spectra was assessed, three 
times, in line with the Trial and Error Method; [5841 the resulting calculated component 
spectra were all very similar and the original estimates for S-, and S,, were used. All the 
features present in the absorbance, LD and LD' spectra are also present in Figures A. 11.3 
and A. 11.4; this suggests the component spectra may be considered to accurately reflect 
the transitions present in quinoline and isoquinoline. The magnitudes of A- and AY are less 
than three times the isotropic absorbance (isotropic 
absorbance, A ........ P,, =I 
(Aý, + AY +A, )). A summary of the component spectra may be 3 
found in Table A. 11.2. Transition moments are calculated using formulae found in 
Appendix Nine; these angles arc relative to the z-axis, therefore two solutions exist: those 
measured clockwise and counter-clockwise from the z-axis; Table A. 11.2 gives the 
solutions clockwise from the z-axis. 
320 
Table A. 11.2. Polarisation in the absorbance spectra of quinoline and isoquinoline (based 
on 2 independent experiments). 
Quinoline Isoquinoline 
Band position TM angle Band position TM angle 
206 64 or 116: h 3 198 65 or 115 A: 5 
214 56 or 124 ±3 210 30 or 150 ±2 
225 51 or 129 ±2 217 36 or 144 ±2 
230 48 or 132 13 227 0 
240 39 or 141 ±3 237 23 or 157 ±3 
248 43 or 137± 1 248 35 or 145 ±1 
276 79 or I]] ±4 265 56 or 124 ±4 
305 31 or 149 ±3 300 54 or 126 ±3 
314 3 or 177 3 313 62 or 118 ±3 
320 22 or 158 1 320 71 or 109 ±3 
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Appendix Twelve - UV / visible flow linear dichroism 
spectroscopy of steroidal metal complexes 
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Figure A. 12.1. The LD (A) and absorbance spectra (B) of TC-Py and ct-DNA; the change 
of LD versus DNA: complex ratio (C). Experimental repeat. 
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Figure A. 12.2. The LD (A) and absorbance spectra (B) of CC-Py and ct-DNA; the change 
of LD versus DNA: complex ratio (C). Experimental repeat. 
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Figure A. 12.3. The LD (A) and absorbance spectra (B) of TC-Q and ct-DNA; the change 
of LD versus DNA : complex ratio (C). Experimental repeat. 
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Figure A. 12.4. The reduced LD spectra (A) of TC-Q treated ct-DNA and repeat (B). 
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Figure A. 12.5. The LD (A) and absorbance spectra (B) of TC-ET-3-Py and ct-DNA; the 
change of LD versus DNA: complex ratio (C). Experimental repeat. 
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Figure A. 12.6. The LD (A) and absorbance spectra (B) of TC-ET-4-Py and ct-DNA; the 
change of LD versus DNA: complex ratio (C). Experiment One. 
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Figure A. 12.7. The LD (A) and absorbance spectra (B) of TC-ET-4-Py and ct-DNA; the 
change of LD versus DNA : complex ratio (C). Experiment Two. 
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Figure A. 12.8. The LD (A) and absorbance spectra (B) of CC-ET-3-Py and ct-DNA; the 
change of LD versus DNA: complex ratio (C). Fxperiment One. 
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Figure A. 12.9. The LD (A) and absorbance spectra (B) of CC-ET-3-Py and ct-DNA; the 
change of LD versus DNA: complex ratio (C). Experiment Two. 
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Figure A. 12.10. The LD (A) and absorbance spectra (B) of TC-ET-3 -Q and ct- DNA, the 
change of LD versus DNA : complex ratio (C) and the reduced LD (D). Experimental 
repeat. 
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Figure A. 12.11. The LD (A) and absorbance spectra (B) of TC-Py and ct-DNA; the change 
of LD versus DNA: complex ratio (C). Experiment One. 
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Figure A. 12.12. The LD (A) and absorbance spectra (B) of TC-ET-6-Q and ct-DNA; the 
change of LD versus DNA: complex ratio (C). Experiment Two. 
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Figure A. 12.13. The LD (A) and absorbance spectra (B) of CC-ET-6-Q and ct-DNA, the 
change of LD versus DNA : complex ratio (C) and the reduced LD (D). Experiment One. 
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Figure A. 12.14. The LD (A) and absorbance spectra (B) of CC-ET-6-Q and ct-DNA, the 
change of LD versus DNA: complex ratio (C) and the reduced LD (D). ExperimentTwo. 
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